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Abstract
The cytochrome P450 enzyme, CYP101B1 from Novosphingobhium aromaticivorans
can catalyse the highly efficient and regioselective oxidation of norisoprenoids. How-
ever, it has lower affinity towards hydrophobic substrates. Site-saturation mutagenesis
of its Histidine85 (H85) residue was carried out as the equivalent tyrosine residue in
the sequence of the closely related P450cam enzyme (CYP101A1 from a Pseudomonas
species) provides hydrophilic interactions with camphor. Mutagenesis of the H85
residue to a phenylalanine residue (H85F) has been reported to increase the enzyme’s
affinity towards small hydrophobic molecules. Eleven mutants that differ at position
85 were successfully produced and these were incorporated into two separate plasmid
vectors for enzyme purification and whole-cell studies. Whole-cell oxidation of the
CYP101B1 mutants with various substrates that include norisoprenoids, terpenoids,
and hydrophobic molecules of varying sizes were carried out to screen if the mutants
have activity towards these substrates. A number of the mutants such as H85V, H85S,
H85G and H85I displayed increased product formation and altered product selectivity
but most were not as effective as the WT or the H85F mutant in oxidising hydrophobic
molecules.
Purification of both the H85A and H85G mutants was also carried out and ferrous-
CO assays showed they were functional P450 enzymes. In vitro studies with these two
mutants demonstrated they have poorer binding affinity and oxidation activity towards
phenylcyclohexane when compared to the WT enzyme and the H85F variant.
A mutant library of rationally designed P450cam variants which have been created to
increase the affinity and oxidation activity towards the monoterpene, α-pinene, was
tested with other monoterpenoids and related compounds. The mutations in this
library were incorporated at residues in the active site. The library was screened using
a whole-cell system with five substrates of similar size and chemical functionality to
camphor and pinene. These were fenchone, fenchyl acetate, isophorone, 1,8-cineole
and 1,4-cineole. The screening of these mutants displayed higher selectivity for the
oxidations of these substrates compared to the WT. The metabolites were produced in
larger quantities for isolation and identification. Fenchone and fenchyl acetate oxidation
by different mutants generated a mixture of the C5, C6 and C7 hydroxylation products
with the exo face being preferred. Isophorone oxidation by the mutants F87W-Y96F-
L244A-V247L (WFAL) and F87W-Y96F-L244A (WFA) gave selective formation of
(4R)-hydroxyisophorone. This product is valuable as a flavouring agent. Several of
the mutants also selectively oxidised 1,8- and 1,4-cineole at different C-H bonds. A
iii
desaturation product was observed at the isopropyl group during 1,4-cineole oxidation.
Concurrent studies of isophorone and cineole oxidation by mutants of another enzyme
(P450BM3) also gave selective transformation of both substrates with high yields in
whole-cell turnover systems. The whole-cell oxidation of isophorone and cineole by
these P450cam and P450BM3 mutants were compared to determine if oxidation activity
of the two enzymes were similar. For the isophorone turnovers, the P450cam mutants
resulted in greater product yields over the P450BM3 mutants, whereby most if not
all substrate added was converted to product. In contrast, cineole oxidation by the
P450BM3 mutants gave higher yields over the P450cam mutants.
As well as oxidising norisoprenoids, CYP101B1 displayed efficient and selective ox-
idation of monoterpenoid acetates. P450BM3 mutants have also been developed to
oxidise terpenes and norisoprenoids. A selection of flavour and fragrance compounds
with structures similar to norisoprenoids and monoterpenoid acetates were screened
both in vitro and in vivo with CYP101B1 and P450BM3-A74G/F87V/L188Q (GVQ).
CYP101B1 displayed selective oxidation towards norisoprenoids such as δ- and α-
damascone. P450BM3-GVQ also showed selective oxidation for acetate compounds such
as cuminyl acetate and verdyl acetate. Larger scale turnovers with these two P450
enzymes were carried out and the metabolites were identified. CYP101B1 oxidises
norisoprenoids at the ring C3/C4 position and this was preserved in the oxidation of
δ- and α-damascone. α-Damascone oxidation by CYP101B1 formed both C3 hydroxy
diastereomers and a further oxidation product at the same position. δ-Damascone
oxidation occurred across its ring C3/C4 alkene to form the epoxide. P450BM3-GVQ
oxidised both cuminyl and verdyl acetate at regions distant from the acetate group.
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P450 enzymes are a ubiquitous class of enzymes that exist in all domains of life.
They are a superfamily of heme monooxygenases and were first discovered in 1958
by Garfinkel1 and Klingenberg2 within pig and rat liver microsomes, respectively. The
genomes of species from across all domains in the tree of life contain more than 300,000
cytochrome P450 sequences that further highlights the abundance of P450s in living
organisms.3
The term P450 was coined after its red pigmentation (P) and the distinctive 450 nm
absorption peak generated when the enzyme is reduced and carbon monoxide is added
(450).4 The large number of P450 enzymes has warranted the development of nomen-
clature to study and categorise them. The members in this superfamily of enzymes
are first grouped into a specific family and then subfamily. Family members share ≥
40 % amino acid sequence similarity and subfamily members share ≥ 55 % similarity.5
P450 enzymes are designated by the prefix CYP, that indicates it is a P450 enzyme,
followed by its family number. For example, CYP1 - CYP9 are mammalian P450
families, CYP71 - CYP99 are for plant-based P450s and CYP101 to CYP281 are for
the bacterial families.3 Following the family number, its subfamily is denoted by the
subsequent letter and number.5 For example, CYP101A1 from Pseudomonas putida,6
is a member of family 101 and is the first member identified for subfamily A of this
family.
1.2 Structure and Catalytic Cycle of P450s
P450 enzymes are involved in a large number of biological oxidative transformations
that include, but are not limited to, steroid synthesis and xenobiotic metabolism in
eukaryotic organisms. P450 enzymes are responsible for 75 % of all phase 1 metabolism
of known human pharmaceuticals.7,8 These enzymes are monooxygenases that insert a
single oxygen atom from atmospheric dioxygen into an inert C-H bond (Equation 1).
This occurs often in a regio- and stereospecific manner.
R-H + O2 + H
+ + NAD(P)H→ R-OH + H2O + NAD(P)+ (1)
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P450 enzymes contain an iron protoporphyrin IX (heme) centre that is bound covalently
to the rest of the enzyme via a proximal cysteine thiolate ligand.9,10 The bound thiolate
ligand is critical for enzymatic activity and contributes to the unique Soret absorption
peak of the CO-reduced enzyme (450 nm).10,11 The distal side of the heme centre has an
iron bound water ligand that is generally observed in substrate free crystal structures
of the enzyme superfamily.9
The distal water ligand bound to the ferric centre represents the resting state of the
P450 enzyme (I) (Figure 1). In most instances, the binding of a substrate causes the
water ligand to dissociate and initiates the catalytic cycle. This step is accompanied
by a shift in the iron complex from low spin (LS) to high spin (HS) (II). The transfer
of the first electron sourced from NADPH or NADH to the iron centre can then occur
to produce the ferrous form of the enzyme (III). The binding of molecular oxygen to
the free distal site forms the ferrous-dioxy complex (IV).9
Figure 1: The P450 Catalytic Cycle.
Figure 2: Radical Rebound Mechanism of P450s.
The transfer of a second electron to complex IV forms the ferric-peroxy anion complex
(V) . Protonation of complex V forms the ferric hydroperoxo-complex (VI). This sets
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the stage for the dioxygen bond to undergo heterolytic cleavage to form the ferryl-oxo
porphyrin-cation radical (VII).12 This highly reactive species is known as Compound
I and is the reactive intermediate which undergoes a radical rebound mechanism to
introduce a single oxygen atom within the substrate (Figure 2).8 The oxidised substrate
then dissociates from the enzyme (VIII) and a water molecule binds to the iron centre
to reform the ferric resting state (I). It has been observed that this catalytic cycle is
largely conserved for all members of this superfamily.13 Specific substrate selectivity
and chemical activity of individual P450s arises from the sequential and structural
differences in regions around the active site.14
As seen in Figure 1, the catalytic cycle requires the transfer of electrons that are
sourced from NADH or NADPH using electron transfer systems.15 These systems con-
sist of electron transfer proteins and the characterised proteins have been divided into
ten classes.16 For example, class I systems which are associated with mitochondrial and
bacterial P450s possess two separate redox protein partners.15 These are an iron-sulfur
containing ferredoxin and a flavin containing reductase (FAD). The electron is first re-
ceived by the reductase, subsequently transferred to the ferredoxin and is finally trans-
ferred again to the target P450.17 P450s that belong to the Class I grouping include
CYP101A1 (P450cam) and CYP101B1 from Novosphingobium aromaticivorans.
18,19
Class II systems are commonly found in eukaryotes such as P4501A1 in rats. This
uses a single membrane-bound NADPH-cytochrome P450 with both FAD and flavin
mononucleotide (FMN) domains.16 Class III systems are similar to class I systems but
has a flavodoxin protein similar to FMN instead of the iron-sulfur ferredoxin.16 P450cin
(CYP176A1) from Citrobacter braakii utilises this system.20 Class VIII systems are
catalytically self-sufficient enzymes where the P450 is fused to a reductase, which has
FAD and FMN domains. CYP102A1 (P450BM3) from Bacillus megaterium belongs to
Class VIII, which are similar to the class II eukaryiotic systems, using both FAD and
FMN domains.16,21,22
1.3 Utility of P450s for Biocatalytic Synthesis
The ability of P450 enzymes to selectively oxidise a single C-H bond, often in a regio-
and stereospecific manner, has drawn significant interest amongst synthetic chemists.
Conventional chemistry employs harsh or toxic reactants to achieve the same trans-
formations but in low product yields and with undesirable side-products.23 The P450
enzymes however can catalyse their reactions under mild ambient conditions utilising
molecular oxygen which is abundant, inexpensive and non-toxic to the environment.24
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The field of bioremediation could also make use of P450s, whereby pollutants generated
by industrial processes are metabolised and degraded by these enzymes to provide a
safe method for their disposal into the environment.25–27 The other application that
has generated significant interest is using P450 enzymes for the biocatalytic production
of fine chemicals.28–32
One limitation of using enzymes is that the wild-type (WT) form may have little or no
affinity and activity towards their non-physiological substrates. This is an impediment
to their use for compound oxidation to yield desirable products. To address this issue,
protein engineering of P450 enzymes has been carried out to improve their activity
towards non-physiological substrates.
1.4 P450cam Mutagenesis and Biocatalytic Studies
P450cam from the bacterium Pseudomonas putida catalyses the conversion of camphor
to 5-exo-hydroxycamphor in a regio-and stereospecific manner (Figure 3).33,34 This is
the first step in the utilisation of camphor as an energy source by this bacterium.33,34
The enzyme has been successfully expressed in E.coli and was the first bacterial P450
enzyme isolated recombinantly for in vitro study.35,36 The enzyme has also been crys-
tallised in many forms and provided a wealth of information as a model system in
determining the general mechanism of P450 catalysis.37–39 P450cam utilises a Class I
electron transfer system with a FAD containing putidaredoxin reductase (PdR) and a
[2Fe-2S] putidaredoxin ferredoxin (Pdx) as its electron transfer partners.16
Figure 3: Conversion of camphor to 5-exo-hydroxycamphor by P450cam.
The available crystallographic data (PDB ID: 3WRH) on P450cam made it an attractive
target for protein engineering studies for use in biocatalytic transformations.40–42 The
active site residues of P450cam have been identified from these crystal structures (Figure
4).43–46 The active site structure of camphor bound P450cam shows that the Tyr96
(Y96) residue forms a hydrogen bond with the camphor carbonyl group.40 The Phe87
(F87), Leu244 (L244) and Ile395 (I395) residues provide hydrophobic contact with the
substrate while Val247 (V247) interacts with the ring carbon methyl group.46,47 These
hydrophillic and hydrophobic residues interact with the substrate and maintain its
orientation to allow stereospecific 5-exo oxidation.
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Figure 4: Active site of Cytochrome P450cam with bound camphor (yellow) (PDB ID: 3WRH).
Residues of interest in this work are highlighted in cyan.43
Tricistronic plasmids (pCWSGB and pSGB) that express P450cam and its electron
transfer co-factor proteins have been constructed to yield a functional whole cell in
vivo oxidation system.44,46 The in vivo system expressing WT-P450cam can catalyti-
cally convert 4 mM of camphor to 5-exo-hydroxycamphor within 4 h using E.coli cells
indicating enzyme activity was successfully reconstituted.44 The system was also re-
ported to be active for at least 48 h if additional aliquots of carbon and nitrogen sources
were added.44
Mutagenesis of the enzyme by site-directed rational design was carried out to enable
the oxidation of (+)-α-pinene (Figure 5). (+)-α-Pinene is a bicyclic 3.1.1 monoterpene
compound that is structurally related to camphor, though lacking a carbonyl group.
P450cam was mutated at the Y96 residue to a Phe residue (Y96F) to remove the polar
phenol group and improve (+)-α-pinene binding by compensating its lack of a carbonyl
group.46 The F87 and V247 residues were also mutated to a Trp residue (F87W) and
a Leu residue (V247L) respectively as a way to “fill in” the leftover space caused by
the absent carbonyl group and the different ring methyl position to improve enzyme-
substrate complementarity.46 F87L and F87A mutants were also made as a way to
investigate the effect of side-chain volume. Finally, the Leu244 residue was mutated to
an alanine residue (L244A) to create additional space to further orient (+)-α-pinene
to resemble the orientation of camphor in the WT enzyme.46 A library of P450cam
enzymes consisting of different combination of mutants at the F87, Y96, V247, L244
and I395 residues (Chapter 4, Table 10) were tested for the oxidation of (+)-α-pinene.
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The mutants in the library all displayed> 70 % conversion to high spin (HS) heme when
bound to (+)-α-pinene.46 Variants that possess an altered F87 residue when combined
with V247L and L244A displayed improved oxidation activity and coupling efficiency
over the WT enzyme (Figure 5).46 This indicates that mutagenesis by rational design
of the enzyme was successful in improving the oxidation of (+)-α-pinene.
Figure 5: (+)-α-Pinene oxidation products by WT and a P450cam mutant, F87W/Y96F/L244A
(WFA). The remaining products consists of cis/trans (+)-α-pinene epoxides (WT = 4 %, WFA
= 2 %), other monooxygenenated and further oxidation products (WT = 51 %, WFA = 5 %).
WT-P450cam oxidises (+)-α-pinene to form (+)-cis-verbenol, an important flavouring
precursor material, as the major product (31 %, Figure 5). It also formed other oxida-
tion products (> 51 %), indicating poor selectivity. Amongst the mutants tested, the
F87W-Y96F-L244A (WFA) mutant displayed the most selective oxidation of (+)-α-
pinene. This generated (+)-cis-verbenol in higher yield (86 %), (+)-verbenone (5 %),
(+)-myrtenol (2 %) and other oxidation metabolites as minor products (7 %) (Figure
5).46
Verbenol, verbenone and myrtenol are all naturally occuring plant fragrances and
flavourings. Verbenone and myrtenol are important components in rosemary oil and
berry fruits, respectively.48,49 Verbenone and verbenol can also function as pheromones
for pine bark beetles and thus have potential for use as pesticides.50 Myrtenol has also
been reported to display anti-inflammatory activity, indicating possible future phar-
maceutical applications.51
The Y96F-V247L mutant of P450cam also selectively oxidises S -limonene. This mutant
has improved binding with 40 % HS (versus 20 % in WT) and a product formation rate
of 187 min−1 (versus 0.2 min−1 in WT).45 The mutant generates both (S )-Isopiperitenol
(70 %) and (−)-trans-carveol (16 %) (Figure 6) with a limonene epoxide as the minor
product (14 %). (S )-isopiperitenol is the precursor compound for the production of
menthol, an important component of Mentha plants, which is responsible for their
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minty smell and flavour.48,52 Carveol is a flavouring agent found in orange peel and has
also shown chemoprevention properties in mammary carcinogenesis.53,54
Figure 6: S -Limonene oxidation products by a P450cam mutant. The remaining product is limonene
ring epoxide (14 %).
P450cam mutants have also been used to enhance the activity of the enzyme towards
other hydrophobic substrates. Oxidation of ethylbenzene by P450cam was greatly en-
hanced with the Y96F-V247L mutant. The product formation rate was 40-fold higher
than that of the WT with 1-phenylethanol being generated as the sole product.44
Ethane, n-butane and propane have all been oxidised to their alcohol derivatives by
different mutants of P450cam which decrease the size of the active site.
55
There are likely many substrates which could be oxidised by variants of P450cam. The
mutant libraries generated for P450cam provide a convenient method to carry out screen-
ing for substrate oxidation to generate alternate synthetic pathways for other highly
valuable compounds.
1.5 CYP101 enzymes from N. aromaticivorans.
Microorganisms that can degrade a wide range of compounds are potential sources
of new enzymes for biocatalysis. The oligotrophic bacterium Novosphingobium aro-
maticivorans DSM12444 can degrade a wide range of polyaromatic hydrocarbons, ter-
penoids and linear alkanes.56,57 The genome of the bacterium consists of its chromoso-
mal DNA and two circular plasmids. Within the genome, there are a high proportion
of genes encoding for oxygenase enzymes.56,58,59
Sixteen cytochrome P450s were identified across the chromosomal DNA and one of the
plasmids.57 The large number of P450 genes within N. aromaticivorans likely allows
it to metabolize a wide variety of environmental xenobiotic compounds and enable it
to survive in conditions that offer little support for life.58 The P450s of this bacterium
belong to 10 different families.57 There are four members of the CYP101 family and
one CYP111 family enzyme which use a common class I electron transfer system.
This consists of a FAD containing ferredoxin reductase, ArR and a [2Fe-2S] ferredoxin
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(Arx).19 These five enzymes (CYP101B1, CYP101C1, CYP101D2, CYP111A2) were
produced with the electron transfer partners in E.coli using DUET vectors,19,57 to
generate a whole-cell oxidation system.19 This enabled the production of hydroxylated
metabolites which could be scaled up to a gram-per-litre scale, indicating its viability
for use in large scale biocatalysis.19
Initial studies with CYP101B1 showed that it can oxidise camphor to form 5-exo-
hydroxycamphor alongside the formation of four other products (Figure 7a).19,57 The
whole-cell oxidation system containing this enzyme also generated the blue pigment in-
digo from the P450 catalyzed oxidation of indole (Figure 7b).19,60 CYP101B1 did how-
ever show higher activity and selectivity when oxidising the norisoprenoid, β-ionone
(Figure 7c) to form 3-hydroxy-β-ionone (90 %) and one minor product, 4-hydroxy-β-
ionone (10 %).19 In addition, CYP101B1 showed a high binding affinity for β-ionone
(≥ 95 % HS, Kd = 0.23 µM) and a fast product formation rate (1010 min−1). This
suggests that the physiological substrate of CYP101B1 could be a norisoprenoid com-
pound.61 The diverse structures of camphor, β-ionone and indole (Figure 7) suggest




Figure 7: Oxidation of (a) camphor and (b) indole by CYP101B1 and (c) β-ionone oxidation by
CYP101B1 and CYP101C1.
8
Further screening of CYP101B1 was carried out with a variety of other terpenoid and
aromatic compounds.61 The enzyme displayed high binding affinity for other noriso-
prenoids such as α-ionone (≥ 95 % HS, Kd = 0.26 µM) and β-damascone (≥ 80 %
HS, Kd = 8.3 µM).61 The hydroxylation of α-ionone was regioselective, producing
both trans- and cis-3-hydroxy-α-ionone in an approximate 2:1 ratio (Figure 8a).61 Ox-
idation of β-damascone by CYP101B1 displayed similar regioselectivity to β-ionone,
generating 3-hydroxy-β-damascone (86 %) and 4-hydroxy-β-damascone (11 %) (Figure
8b), with lower activity.61 A third minor product (< 4%) generated was not isolated
in high enough yield for characterisation.
(a)
(b)
Figure 8: Oxidation of (a) α-ionone and (b) β-damascone by CYP101B1. For β-damascone, a minor
metabolite (< 4 %) was not isolated in high enough yield for characterisation.
(a)
(b)
Figure 9: Oxidation of (a) phenycyclohexane and (b) p-cymene by CYP101B1.
When screened with aromatic substrates, CYP101B1 was found to be capable of ox-
idising both phenylcyclohexane and p-cymene (Figure 9).61 Phenylcyclohexane ox-
idation by the enzyme was regioselective and generated a single product, trans-4-
phenylcyclohexane (Figure 9a).61 p-Cymene oxidation by CYP101B1 gave a mixture
of p-α-α-trimethyl benzyl alcohol (25 %) and isopropylbenzyl alcohol (75 %) (Figure
9b).61 Both induced small spin-state shifts and moderate NADH turnover rates when
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compared to norisoprenoids, indicating that they were not as effective as substrates for
CYP101B1.61
CYP101C1, also from N. aromaticivorans, is a homologue of P450cam (CYP101A1)
and CYP101B1.62 The enzyme uses the same Class I electron transfer system as
CYP101B1.63 It displayed no observeable binding or activity with camphor.57,62 Sub-
strates that are able to bind and be oxidised by CYP101C1 include α-ionone, β-ionone
and β-damascone, but all induce low spin-state shifts (≤ 20 % HS).62 Despite this,
CYP101C1 can effectively hydroxylate norisoprenoids, where for example β-ionone ox-
idation produces 3-hydroxy-β-ionone (25 %) and 4-hydroxy-β-ionone (75 %) (Figure
7c).62 In contrast, the major product for CYP101B1 is of the C4 oxidation (90 %).
α-Ionone oxidation by CYP101C1 resulted in three products.62 As with CYP101B1,
this substrate was oxidised exclusively at the C3 position forming both cis- and trans-
3-hydroxy-α-ionone alongside 3-oxo-α-ionone (Figure 10).62
Figure 10: Oxidation of α-ionone by CYP101C1. A minor oxidation product (< 2 %) was not isolated
in high enough yield for characterisation.
CYP101B1 and CYP101C1 oxidise norisoprenoids exclusively on the C3 and C4 po-
sitions within the aliphatic ring. This implies that the norisoprenoids interact with
the enzymes’ active site in such a way that it is held with the ring above the heme
group for oxidation. The lower spin-state shift with β-damascone and CYP101B1 sug-
gests that the position of the alkene and ketone groups on the butenone side chain
are somewhat important for substrate-enzyme binding interactions.61 The location of
the cyclic alkene bond within the ionones and damascones does play a role in the re-
gioselectivity of both CYP101 enzymes. As both enzymes oxidise all norisoprenoids
at the C3-position, it is the C3 hydrogens within these substrates that are closest to
the heme iron.61 The oxidation at the C4 position in both β-substrates indicates that
the more reactive allylic C4 hydrogens are also close enough to the heme to be oxi-
dised in competition with the C3 hydrogens.61 The alkene in α-ionone is not oxidised
and is presumably too far away for efficient epoxidation.61 The different selectivities
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of CYP101B1 and CYP101C1 with β-ionone could lead to pathways for the selective
oxidation of related flavour and fragrance compounds.
1.6 P450BM3 Mutagenesis and Biocatalytic Studies
P450BM3 was discovered by Fulco et al. in 1974, where it was first identified as a fatty
acid hydroxylating enzyme from Bacillus megaterium.64 It exhibited high substrate
oxidation activity in the presence of oxygen and NADPH without any other protein
partners.64 This enzyme was capable of exclusively hydroxylating pentadecanoic acid
at sub-terminal positions, while also accepting hydroxylated fatty acids, fatty alco-
hols/amides, and ω-oxo fatty acids as substrates.64–71
The enzyme is a single 119 kDa polypeptide that possesses two distinct domains,
which are firstly a P450 haem domain (55 kDa) fused to a reductase domain with
flavin containing FAD and FMN groups (65 kDa).21,23 This is a class VIII type elec-
tron transfer system that allows P450BM3 to be catalytically self-sufficient, as opposed
to requiring separate partner proteins to receive electrons such as in class I systems
(P450cam and CYP101B1).
16,21,22 The self-sufficent nature of P450BM3 provides biocat-
alytic P450 monooxygenase activity without the need to co-expresss separate protein
partners. The heme domain of P450BM3 has been structurally characterised, enabling
the identification of the active site residues involved in substrate binding (Figure 11,
PDB ID: 1FAG).72,73
Figure 11: Active site of Cytochrome P450BM3 with palmitoleic acid. Residues of interest in this work
are highlighted in cyan (PDB ID: 1FAG).73
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Mutagenesis studies targeting improved activity towards flavour and fragrance
molecules have been carried out with P450BM3.
74 WT-P450BM3 is capable of oxidis-
ing β-ionone although it exhibits an extremely poor turnover rate of < 1 min−1 and no
spin-state shift.74 Site-directed mutagenesis of P450BM3 was carried out to accommo-
date the bulkier structure of β-ionone compared to fatty acids and move it closer to the
heme. Position 87 of the enzyme was the first target for mutagenesis and it contains
a Phe residue that sits directly above the heme and is involved with controlling the
enzyme’s regio- and enantioselectivity.75,76
Single mutants at the Phe87 position were tested and it was found that smaller glycine,
valine and alanine residues displayed significantly higher oxidation activity towards β-
ionone compared to the WT enzyme.74 The single product arising from the oxidations
observed was 4-hydroxy-β-ionone (Figure 12a) and the F87V mutant exhibited the
highest product formation rate (115 min−1) among the single mutants.
Further mutagenesis was then carried out at the Arg47 and Tyr51 residues, both which
are located at the substrate access channel. Arg47 and Tyr51 were substituted to more
hydrophobic substrates of leucine and phenylalanine respectively to allow easier entry
of β-ionone into the active site. The R47L and Y51F mutant when coupled with the
F87V mutant displayed a significant increase in product formation rate (268 min−1)
compared to the WT.74 This indicates that mutagenesis of P450BM3 is also a viable
way to develop biocatalysts for the oxidation of norisoprenoids such as β-ionone.
(a)
(b)
Figure 12: Oxidation of (a) β-ionone and (b) (+)-valencene by P450BM3. For valencene oxidation,
the remaining minor metabolites (6 %) were unidentified.
In a separate study, the target molecule, (+)-valencene, which is a sesquiterpenoid
that is found in orange oil, was oxidised to the ketone derivative, nootkatone, a highly
sought after fragrance molecule derived from grapefruit (Figure 12b).77–79
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WT-P450BM3 showed low NADPH oxidation activity (40 min
−1) and little to no change
in spin-state when (+)-valencene was added.79 Products formed from the oxidation of
(+)-valencene with WT-P450BM3 did not contain nootkatone at all but a mixture of
five products. One of these was identified as nootkatol (Figure 12b).79 Nootkatone
was succesfully produced when mutations at the Phe87 and Ile263 residues (F87A and
I263A) were introduced (Figure 11). The major product was nootkatol and other minor
epoxide products (< 10 %).79 A significant improvement in P450BM3’s production of
nootkatone was achieved by screening a mutant library containing mutant variants
at the Phe87 and Ala328 residues (Figure 11).23 Three variants containing the A328I
mutant and different Phe87 mutant variants were the best, resulting in a high ratio
of nootkatone against other metabolites. The F87A-A328I mutant produced the most
nootkatone (26 %, Figure 12b).80
P450BM3 mutants have also been developed to enhance the enzyme’s activity for
non-natural substrate oxidation while maintaining the WT-enzyme’s regioselectiv-
ity.81 These mutants were coined as rate-accelerator variants. These variants include
A191T-N239H-I259V-A276T-L353I (KT2), R47L-Y51F-I401P (RLYFIP) and R47L-
Y51F-H171L-Q307H-N319Y (R19).81–84 These mutations are all located outside of the
substrate binding pocket. These enzymes are believed to be in a more catalytically
ready conformation in the substrate-free form. Substrate induced changes are less im-
portant in activating the electron transfer steps and lead to the oxidation of non-natural
substrates at increased rates.81 The R47L-Y51F mutation is also hypothesized to fa-
cilitate easier access of small hydrophobic molecules.26 Substrates that have displayed
increased activity with these variants include aromatic compounds such as propylben-
zene and napthalene.82,85
These mutagenesis studies indicate that P450BM3 is a suitable enzyme system for the
production of high value compounds. In particular, terpene derivative compounds.
1.7 Producing High Value Compounds with P450s
The creation of new perfume and flavouring agents relies not only on the discovery of
new odorous molecules but also the modification of the chemical structures of existing
commercial products.86,87 The second line of research is of interest as the relation-
ship between chemical structure and odor is often unpredictable, whereby molecules
with similar structures can possess dissimilar scents and odor thresholds.88 The al-
cohol functionality is a prevalent functional group present in flavour and fragrances,
making P450 enzymes an ideal method for modifying existing compounds to generate
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hydroxylated derivatives with hopefully new olfactory properties.89 For example, 3-
hydroxy-α-ionone possesses a tobacco-like odor that is unlike the floral scent possessed
by its parent molecule, α-ionone.90
Apcarotenoids or norisoprenoids are derived from the selective oxidative cleavage of
carotenoids that are catalysed by carotenoid cleavage dioxygenases.91 The ionone
and damascone C13 norisoprenoids (Figure 13) in particular are highly important
carotenoid-derived compounds studied within the food and fragrance industry due to
their pleasant aromas (Table 1) and low odor thresholds.92 For example, carotenoid-
derived compounds have found wide use in personal care products such as shampoos,
body lotions and deodorants.93,94
Figure 13: The general structures of damascones and ionones.
Table 1: Norisoprenoids of interest alongside descriptions of their odours.
Norisoprenoid Occurrence Odour
β-Ionone Carrots, Rose,Blackberries Floral with fruity and berry notes
α-Ionone Blackcurrant, Blackberries Violet and scent with, raspberry notes
β-Damascone Osmanthus, Rose, Papaya Fruity and floral scent
α-Damascone Rose Rose petals with apple and fruity notes.
Another class of compounds that are of interest are the terpenoids. This class of com-
pounds, which includes their oxygenated derivatives, are produced mainly within herbs
and higher plants have been used as flavourants and fragrances for centuries, making
them possible targets for P450 oxidations to develop new fragrances.23,95 Terpenoids
have also drawn considerable interest commercially in the prevention and treatment
of diseases and use as natural pesticides and antimicrobial agents.95 Enzymatic enan-
tioselective pathways for the production of hydroxylated derivatives can also provide
new sources of chiral intermediates or auxiliaries.96 Oxidised derivatives of carotenoid
and terpenoid compounds have also found use in chemical syntheses as precursors and




The ability of P450cam and P450BM3 variants in oxidising terpenes, terpenoids and
norisoprenoids displays a potential for these mutants in oxidising other similar
molecules. Small mutant libraries for P450cam and P450BM3 have been previously
made.46,84 Selected variants will be screened with a range of terpenes, terpenoids and
norisoprenoids to study if new oxidation pathways towards high value hydroxy com-
pounds can be discovered.
CYP101B1 from Novosphingobium aromaticivorans has been shown to be a potential
biocatalyst for norisoprenoid oxidation. Therefore, it is a viable target for additional
substrate screening. A range of different carbonyl containing substrates such as tricyclic
and aromatic acetates will be screened with CYP101B1 to investigate if any significant
catalytic turnover activity is observed and if new products are formed. Reactions with
interesting oxidation patterns or high yield as determined with GC-MS and/or HPLC
analysis will be scaled up and the products isolated for characterisation.
Mutants of CYP101B1 will be generated with the aim of improving its activity with
hydrophobic substrates. Protein sequence alignment of CYP101B1 with P450cam
showed that the 96 residue in the latter was equivalent to the His85 (H85) residue
in CYP101B1.61 The Y96 residue is responsible for the hydrogen bonding interac-
tion with camphor in P450cam (Figure 4) and it is hypothesized that the H85 residue in
CYP101B1 may play a similar role and interacts with the carbonyl group of the noriso-
prenoids. As such it is a suitable target for mutagenesis studies.47,61 Site-saturation
mutagenesis will be carried out on the H85 residue and the variants will be cloned into
plasmid systems to enable in vitro and in vivo screening. Following that, variants with
increased activity towards aromatic substrates of different sizes and hydrophobicities




General reagents, HPLC solvents, organic substrates and derivatisation agents were
purchased from Sigma-Aldrich, VWR, Fluorochem, Acros Organics, Tokyo Chemical
Industry or Matrix Scientific. Antibiotics, isopropyl β-D-thiogalactopyranoside (IPTG)
and dithiothreitol (DTT) were purchased from Astral Scientific. A racemic mixture
of (4R)/(4S )-hydroxyisophorone was provided by Shaghayegh Dezvarei and A/Prof
Stephen Bell of the University of Adelaide using methods previously described.99 The









UV/Vis spectra and activity assays were recorded at 30 ± 0.5 ◦C on a Varian Cary 60
spectrophotometer. NMR spectra were obtained using an Agilent DD2 spectrometer
operating at 500 MHz for 1H or 126 MHz for 13C NMR or on a Varian Inova-600 spec-
trometer operating at 600 MHz for 1H or 151 MHz for 13C NMR. Optical rotations of
enantiomeric products were measured using an Anton-Paar MCP 100 Modular Circular
Polarimeter.
2.2 Enzymes and Molecular Biology
T4 DNA ligase was purchased from Lucigen and restriction enzymes for molecular
biology were from New England Biolabs. General DNA, microbiological experiments
and protein purification were carried out by standard methods as described below.100
Proteins were stored in Tris (50 mM, pH 7.4) containing 50% v/v glycerol at -20 ◦C
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and desalted before use with a PD-10 column (GE Healthcare). DNA for WT-P450cam
and P450BM3 along with their mutants and whole-cell oxidation systems have been
purchased previously.44–46,82 The media solutions used for cell growths are listed in
Table 2.
Table 2: Growth media constituents.
Medium Constituents (L−1)
LB tryptone (10 g), yeast extract (5 g), NaCl (10 g)
SOC tryptone (20 g), yeast extract (5 g), MgCl2 (1 g),
NaCl (0.5 g), KCl (0.2 g), glucose (0.2% w/v)
Trace Elements Na2EDTA(20.1 g), FeCl3.6H2O (16.7 g), CaCl2.H2O (0.74 g),
CoCl2.6H2O (0.25 g), ZnSO4.7H2O (0.18 g),
MnSO4.4H2O (0.132 g), CuSO4.5H2O (0.10 g)
EMM K2HPO4 (7 g), KH2PO4 (3 g), (NH4)2SO4 (1 g),
Na3Citrate (0.5 g), MgSO4 (0.1 g), 20% glucose (20 mL)
2.2.1 Protein Engineering of CYP101B1
DNA encoding for WT CYP101B1 + Arx in pRSFDUET and WT CYP101B1 in
pET22 were available.101 The gene for CYP101B1 in both vectors was inserted in
between the NdeI (5’) and KpnI /HindIII (3’) restriction sites. The gene contained a
SalI restriction site at base pair 373 - 378.
A gBlock fragment library for CYP101B1 was purchased from Integrated DNA Tech-
nologies which included a nnC triplet codon (n is a random base) incorporated at the
His85 position. The nnC codon was used to generate a library of mutants. The gBlock









Figure 14: Sequence of the gBlock fragment of CYP101B1 with the nnC codon at the H85 residue
(in bold), a NdeI restriction site at the 5’ terminus and a SalI restriction site at 3’ terminus (both
underlined).
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Digestion of the gBlock fragment library and vectors pRSFDUET-Arx and pET22
containing CYP101B1 was first carried out. The digests were prepared using a mixture
of the DNA (1 - 1.5 µg) with NdeI and SalI restriction enzymes (30 units, 1.5 µL)
in 10X NEB-Cutsmart® buffer in a volume of 20 µL for the DNA vectors and 50 µL
for the gBlock fragment. The digests were incubated at 37 ◦C for 2 h. Agarose gel
electrophoresis was used to purify the required DNA fragment from the digests (Section
2.3). The DNA fragments were excised, whereby the digested vector and cut gBlock
fragment were purified with the EZ-10 Spin Column Plasmid DNA Minipreps Kit from
Bio Basic Inc.
The mutant gene library (12.5 µL) was then ligated into the digested vectors (12.5 µL)
between the NdeI and SalI restriction sites using T4 DNA ligase (400 units, 1 µL) in
10X T4 DNA Ligase Reaction Buffer (4.5 µL) and H2O (19 µL). The ligation mixture
was incubated at room temperature for 12 h.
The newly ligated DNA vectors were then transformed into competent DH5α E.coli
cells (35 µL) and incubated at 0 ◦C for 60 min. This was followed by heat shock at
42 ◦C for 50 s. After 2 min incubation at 0 ◦C, SOC media (150 µL) was added to
the cells and the resulting culture shaken at 37 ◦C and 120 rpm for 1 h. The cells
were then grown on LB plates containing either 100 µg mL−1 ampicillin or 30 µg mL−1
kanamycin for the pET22 and pRSFDUET vectors, respectively.
Single colonies were harvested from the plates and used to inoculate a culture of LB
(16 mL) with the appropriate antibiotic. The DNA plasmid vectors were purified from
the cell pellet of these cultures using the EZ-10 Spin Column Plasmid DNA Minipreps
Kit from Bio Basic Inc (2 purification preps for each growth). To confirm if gene
fragments were successfully ligated into the desired vectors, the plasmids were digested
with NdeI /KpnI restriction enzymes and analytical agarose gel electrophoresis was
carried out to confirm if the insert is of the correct size (Section 2.3). To identify the
codon at position 85, the plasmids (900 - 1000 ng in 9 µL) were then sequenced by the
Adelaide Genome Research Facility using the T7 promoter primer (3 µL) for pET22
and the DuetUP2 primer (3 µL) for pRSFDUET.
Mutants which were identified in either vector pET22 or pRSFDUET but not the other
were first digested with NdeI and KpnI for cloning into the other vector. Purified
fragments were then ligated into desired vectors using T4 DNA ligase and were sub-
sequently transformed into competent DH5α E.coli cells. The plasmids were purified
and sequenced as described above.
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2.3 Agarose Gel Electrophoresis
A 0.8 % w/v agarose gel was prepared by dissolving 0.4 g of agarose in 50 mL of TAE
buffer (40 mM Tris, 1 mM EDTA). This was dissolved by heating in a microwave at
10 - 30 sec intervals. The solution was then cooled to 50 ◦C and 0.5 µL of ethidium
bromide solution (10 mg mL−1) was added. The gel was then cast and left to set for 2 h
before being immersed in TAE buffer (250 mL) containing 1.5 µL of ethidium bromide
(10 mg mL−1).
DNA from restriction digests (15 µL) was mixed with 80 % glycerol (4 µL) and loaded
into separate lanes of the gel alongside a molecular weight DNA ladder. The gels were
run at 60 V for 1.5 h. The DNA bands were then viewed under UV light and the
desired fragments were excised and purified (Section 2.2.1).
Analytical gel electrophoresis was also carried out using the gels that were prepared as
above. Gel loading buffer (4 µL of 6 x buffer) was added to the DNA samples before
loading into the gels. Gels were run at 100 V for 0.5 h and visualised under UV light.
2.4 Enzyme Purification
2.4.1 Purification of CYP101B1 mutants
The CYP101B1 mutants which were cloned into the pET22 vector (Section 2.2.1) were
transformed into BL21(DE3) competent cells and grown on a LB plate containing
ampicillin (100 mg L−1). A single colony from the plate was used to inoculate 750 mL
of LB in a 2 L shake flask with ampicillin (100 mg L−1) and trace elements (2.25 mL).
The culture was allowed to grow at 37 ◦C and 100 rpm overnight within a shaking-
incubator. The incubation temperature was then lowered to 18 ◦C for 30 min. Benzyl
alcohol (0.02 % v/v) and EtOH (2 % v/v) were then added. The culture was allowed to
shake for a further 30 min and IPTG (0.1 mM) was added to induce protein expression.
The culture was grown for a further 48 h to 72 h and then centrifuged (5000 g, 20 min)
to collect the cell pellet. The pellet was re-suspended in 200 mL of Buffer T (50 mM
Tris, pH 7.4, 1 mM DTT). Sonication was used to lyse the re-suspended cells using
an Autotune CV334 Ultrasonic Processor equipped with a standard probe (136 mm
x 13 mm; Sonics and Materials, US) using 40 x 20 s pulses with 40 s intervals. Cell
debris was then removed using centrifugation (18000 g, 30 min, 4 ◦C). The protein
containing supernatant was loaded on to a DEAE Sepharose column (XK50, 200 mm
x 40 mm; GE Healthcare) and eluted using a linear salt gradient from 100 mM to
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400 mM KCl in Buffer T at a flow rate of 6 mL min−1. Red coloured fractions were
combined and concentrated using ultrafiltration (10 kDa exclusion membrane). The
concentrated protein was desalted using a Sephadex G-25 medium grain column (250
mm x 40 mm; GE Healthcare) and Buffer T.
The protein once desalted was concentrated again to a volume of 15 mL and loaded on
to a Source-Q ion-exchange column (XK26, 80 mm x 30 mm; GE Healthcare) using an
AKTA pure and eluted using a linear salt gradient from 0 mM to 250 mM KCl in Buffer
T. Fractions with A417/A280 > 2 were combined and concentrated using ultrafiltration.
The protein concentration was determined using ε417= 113 mM
−1 cm−1.19
2.4.2 Purification of ArR and Arx
ArR was supplied by Md Raihan Sarkar which was generated and purified using meth-
ods previously described.61,101
pETDUET containing the Arx gene was transformed into BL21(DE3) competent cells
and grown on a LB plate containing ampicillin (100 mg L−1). A single colony from the
plate was used to inoculate 8 × 750 mL of LB in 2 L flasks containing 100 mg L−1 of
ampicillin and trace elements solution (2.25 mL). The cultures were allowed to grow
at 37 ◦C and 120 rpm for 8 h. The incubation temperature was lowered to 18 ◦C and
left for 30 mins before benzyl alcohol (0.02 % v/v) and EtOH (2 % v/v) were added.
The culture was left to shake for 30 mins and IPTG (0.1 mM) was added to induce
protein expression. The culture was then allowed to incubate for 16 h at 18 ◦C and
90 rpm. The cells were harvested by centrifugation (5000 g, 20 min) and re-suspended
in Buffer T (300 mL) that also contained glycerol (10 %), β-mercaptoethanol (3 mL)
and Tween (1 mL). The re-suspended cells were mixed with lysozyme (300 mg) and
stirred for 30 mins at 0 ◦C. The cells were then lysed using sonication as per Section
2.4.1 and cell debris removed via centrifugation (18000 g, 30 min, 4 ◦C).
The supernatant was loaded on to a DEAE Sepharose column (XK50, 200 mm x 40
mm; GE Healthcare) and eluted using a linear salt gradient from 200 mM to 400 mM
KCl in Buffer T at a flow rate of 6 mL min−1. Brown coloured fractions were combined
and concentrated using ultrafiltration (10 kDa exclusion membrane). The concentrated
protein was desalted using a Sephadex G-25 Medium grain column (250 mm x 40 mm;
GE Healthcare). The protein once desalted was concentrated again to a volume of
15 mL and loaded onto a Source-Q ion-exchange column (XK26, 80 mm x 30 mm;
GE Healthcare) using an AKTA pure and eluted using a linear salt gradient from 0
mM to 250 mM KCl in Buffer T. Fractions with A316/A280 > 0.6 were combined and
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concentrated using ultrafiltration. Protein concentration was determined using ε316=
12.5 mM−1 cm−1.19
2.5 P450 Carbon Monoxide Assays
2.5.1 CO Assay of CYP101B1 mutants
The P450 enyme was desalted and diluted with 50 mM Tris to ≈ 1 µM. Its absorbance
spectrum was recorded (700 nm - 250 nm) and used to baseline the UV/visible spec-
trometer. Sodium dithionite (< 1 mg) was then added to the enzyme and its spectrum
was used to baseline the instrument again. Carbon monoxide (CO) was bubbled gently
through the solution and its absorbance recorded to generate the ferrous-CO bound
spectrum.102
2.5.2 Quantification of P450 enzymes
A 100 mL growth of E.coli cells containing proteins (after induction) was centrifuged
(4000 g, 15 min) and re-suspended in Tris Buffer (30 mL, 50 mM, pH 7.4). The
re-suspended cells were sonicated as per Section 2.4.1 with 5 × 5 s pulses at 10 s
intervals. The supernatant (500 µL) was used to measure a CO difference spectrum
(Section 2.5.1) to obtain the absorbance at 450 nm. The concentration of P450 enzyme
contained within 100 mL of overnight culture was calculated using ε450= 91000 M
−1
cm−1.102,103
2.6 Enzyme-Substrate Binding Assays
The purified P450 enzymes were diluted with Tris Buffer (50 mM, pH 7.4) to ≈ 1 µM
and their absorbance was recorded using a UV-visible spectrophotometer (700 nm -
250 nm). The substrate (0.5 µL, 100 mM stock in EtOH) was mixed with the enzyme
(500 µL) and the spectrum was recorded again. Further 0.5 µL aliquots of substrate
were added until the spectrum showed no further observable change. The shift from
low spin (LS, 420 nm) to high spin (HS, 390 nm) was then recorded. The percentage of
HS enzyme was determined by comparing the enzyme’s absorbance spectrum to that
of a set of existing spectra generated by the HS and LS forms of P450cam (camphor-
bound/free) (Figure 15).
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Figure 15: Spin-state diagram for P450cam in camphor free/bound diagrams from 0 % to 100 %.
Dissociation contants (Kd) were measured to determine the affinity of a substrate
binding to the enzyme. The enzyme was diluted to ≈ 2 µM using Tris Buffer (50
mM, pH 7.4) and this enzyme was used to baseline the UV/visible spectrophotometer.
Aliquots of substrate (1 - 2 µL, 1 mM) were added to the enzyme (2.5 mL) and the
difference spectrum after each addition was recorded. After cumulative addition of
10 µL of 1 mM substrate, 1 - 2 uL of 10 mM substrate (up to 10 µL) and then 100
mM substrate were added until the peak to trough difference in absorbance showed no
observable change.
The difference in peak to trough absorbance was fitted against the substrate concen-





where ∆A is the peak-trough difference, ∆Amax is the maximum peak-trough difference
and [S ] is the substrate concentration.
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2.7 Enzyme Activity Assays
2.7.1 In Vivo Activity Assays
For the P450cam, P450cin and P450BM3 systems, the plasmids listed in Table 3 contain-
ing the genes encoding these enzymes or their mutants were transformed into compe-
tent BL21(DE3) cells and grown on LB plates containing ampicillin (100 µg mL−1) or
kanamycin (30 µg mL−1) depending on the vector used.46,82,104
The pRSFDUET vector containing WT-CYP101B1 or its mutants and pETDUET
containing Arx and ArR (Table 3) were both transformed into competent BL21(DE3)
cells and grown on LB plates containing both ampicillin (100 µg mL−1) and kanamycin
(30 µg mL−1).61
Table 3: Plasmids with P450 in vivo systems used.
Plasmid Genes Contained Antibiotic
pCWSGB++ P450cam mutants, Pd, PdR
46 Amp
pSGBF WT-P450cam, Pd, PdR
46 Amp
pRSFDUET WT CYP101B1 or its mutants, Arx61 Kan








A single colony from the plates was used to inoculate 500 mL of LB containing the ap-
propriate antibiotic and 1.5 mL trace elements solution. The culture was then allowed
to grow at 37 ◦C and 120 rpm for 6 h, which was followed by lowering the incubation
temperature to 18 ◦C for 30 min. Benzyl alcohol (0.02 % v/v) and EtOH (2 % v/v)
were then added to the culture. The culture was left for 30 min and protein expression
was then induced by adding IPTG (0.1 mM). The culture was then left for 16 h at 18
◦C and 90 rpm. The cells were harvested via centrifugation (5000 g, 15 min) and the
wet weight of the cells harvested was recorded.
Small scale turnovers were carried out by re-suspending the harvested cells in 500 mL
of EMM and splitting this into either 2 mL, 25 mL or 50 mL aliquots. Substrate (2
mM) was added to the growths and the reactions were then shaken at 180 rpm and 30
◦C. A 1 mL aliquot was taken from 25 mL and 50 mL reactions at 3 h and 18 h for
analysis. For the 2 mL aliquots, only a 1 mL aliquot was taken at 18 h for analysis.
23
Large scale turnovers were carried out by dividing the re-suspended cells into 200 mL
aliquots (EMM) in 2 L baffled shake flasks. Substrate (1 mM) was added to each
reaction and the reactions were then shaken at 150 rpm and 30 ◦C. Further substrate
additions were made at 4 h (1 mM) and 6 h (2 mM). At 6 h, glucose (1 % v/v) and
phosphate buffered saline (PBS, 2.5 % v/v) were added and the turnover reaction was
left to shake for a further 18 h. The supernatant of the turnover reaction was collected
by centrifugation (5000 g, 20 min, 4 ◦C) to remove cell debris before extractions.
2.7.2 In Vitro Activity Assays
In vitro NADH activity assays with purified CYP101B1 were carried out by preparing
a 1.2 mL mixture of the enzyme (0.5 µM), Arx (5 µM), ArR (0.5 µM), bovine liver
catalase (12 µL of 10 mg mL−1 stock in glycerol) and oxygenated Tris Buffer (50 mM,
pH 7.4). The mixture was equilibrated at 30 ◦C for 1 min and NADH (≈ 320 µM,
A340 ≈ 2.0) was added from a 20 mg mL−1 stock. The reaction was monitored at 340
nm using a UV-vis spectrophotometer (Figure 16a). Substrate (1 mM, 100 mM stock
in EtOH) was added after 1 min. The gradient of the plot of A340nm against time was
used to calculate the rate of NADH consumption using ε340nm = 6.22 mM
−1 (Figure
16a). All in vitro activity assays were measured in triplicate.
(a) (b)
Figure 16: (a) In vitro NADH assay measured and (b) calibration curve for cuminyl acetate.
Table 4: Calibration factors for different substrates and any associated oxidation products. All cali-









For P450BM3 turnovers, the 1.2 mL turnovers consisted of the enzyme (0.2 µM), bovine
liver catalase (12 µL of 10 mg mL−1 stock in glycerol), oxygenated Tris buffer (50 mM,
pH 7.4) and 1 mM substrate (100 mM stock in EtOH). The mixture was equilibrated
at 30 ◦C for 1 min and NADPH (≈ 320 µM, A320 ≈ 2.0) was added. The reaction was
monitored and the rate of NADPH consumption was calculated as above.
In vivo and in vitro turnovers were analysed via GC-MS. A 990 µL aliquot of the
turnover was taken and p-cresol was added as an internal standard (10 µL, 20 mM in
EtOH). The mixture was extracted with ethyl acetate (400 µL, EtOAc) and separated
by centrifugation. Extracts were analysed via GC-MS/GC-BID analysis.
The concentration of product in an in vivo and in vitro turnover sample was determined
by quantifying the samples against a calibration curve of a known product standard
in EtOAc containing the internal standard measured using GC-MS (Figure 16b). If
authentic product standards were not available, an isomer or the starting material was
used. The concentration of the product in the turnover was divided by the concentra-
tion of NADH used to give the coupling efficiency.
The coupling efficiency is defined as the percentage of NADH/NADPH used to suc-
cessfully oxidise the substrate to generate product. The product formation rate was
calculated by multiplying the coupling efficiency by the NADH consumption rate to
give the product formation rate.
2.8 Analysis and Identification of Enzymatic Metabolites
Gas chromatography-mass spectrometry (GC-MS) analysis was performed using man-
ual injection on a Shimadzu GC-17A equipped with a QP5050A GC-MS detector and
DB-5 MS fused silica column (30 m x 0.25 mm, 0.25 µm). The injector was held at
250 ◦C and the interface at 280 ◦C. High throughput GC-MS analysis was carried out
with a Shimadzu GC-2010 equipped with a QP2010S GC-MS detector, AOC-20i au-
toinjector, AOC-20s autosampler and DB-5 MS fused silica column (30 m x 0.25 mm,
0.25 µm). Injection volume used was 1 µL with He as the carrier gas.
For GC-MS analysis with aromatic, norisoprenoid and acetate compounds, the oven
temperature was held at 100 ◦C for 3 min, increased at 14 ◦C min−1 up to 240 ◦C and
held at this temperature for 5 min. For terpenes or terpenoid compounds, the oven
temperature was held at 80 ◦C for 3 min, increased at 10 ◦C min−1 up to 200 ◦C and
was held at this temperature for 5 min.
GC analysis was performed on a Shimadzu TRACERA with a BID detector and Su-
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pelcoWax column (30 m x 0.25 mm, 0.25 µm). The injector was held at 250 ◦C and
the interface at 280 ◦C. For chiral GC analysis, a β-DEX column was used and both
the injector and detector were held at 230 ◦C.
For chiral GC-analysis of the cineole metabolites, the dried samples (2 mg) were de-
rivitised by dissolving them in dichloromethane (500 µL) followed by the addition of
trifluoroacetic anhydride (5 µL, TFAA). The mixture was incubated for 2 h at room
temperature. Solvent and other volatiles were removed under a stream of nitrogen and
the remaining residue re-dissolved in EtOAc (500 µL). The GC oven method used for
TFAA-derivitised cineole products was as follows: the oven temperature was held at 60
◦C for 3 min, increased at 5 ◦C min−1 up to 140 ◦C and was held at this temperature
for 5 min. The temperature was then increased by 29 ◦C min−1 to 200 ◦C and this was
held for 1 min.
Other chiral products were also analysed via GC or chiral HPLC. The GC method used
was as follows: the oven temperature was held at 80 ◦C for 3 minutes, then increased
at 5 ◦C min−1 to 200 ◦C and held for 3 minutes. The injector and detector temperature
were both held at 230 ◦C.
All high performance liquid chromatography (HPLC) analysis was carried out on a
Shimadzu system equipped with a DGU-20A5R degasser, 2 × LC-20AR pumps, SIL-
20AC HT autosampler, SPD-M20A photodiode array detector and a CT0-20AC column
oven with an Ascentis Si HPLC column (25 cm × 4.6 mm × 5 µm; Sigma-Aldrich).
Preparative HPLC was performed using an Ascentis Si HPLC column (25 cm × 10 mm
× 5 µm; Sigma-Aldrich). Samples were injected at volumes of 1 - 5 µL and observed at
254 nm. For chiral HPLC analysis, a CHIRALPAK IG column (150 mm × 4.6 mm ×
5 µm; Daicel Chemical Industries Ltd.) attached to a CHIRALPAK IG guard column
(4 mm × 5 mm × 5 µm; Daicel Chemical Industries Ltd.) was used instead. For chiral
HPLC analysis, the chiral compound was eluted in isocratic mode with 5 % IPA in
hexane at 0.5 mL min−1 for 38 min.
The supernatant from larger scale turnovers containing oxidation products were ex-
tracted into EtOAc (3 × 100 mL), washed with brine (100 mL) and dried with MgSO4
followed by solvent removal under reduced pressure. Products were purified on silica
with a gradient from 80:20 to 50:50 hexane to EtOAc with a 2.5 % increase every 100
mL. When this was not successful, products were purified using preparative HPLC.
They were eluted at 4 mL min−1 using a 5 % isocratic run of IPA in hexane for 5
mins before appplying a gradient from 5 % to 10 % for 20 mins. The identities of the
products were determined via GC-MS and/or NMR analysis. All NMR samples were
dissolved in 600 µL of CDCl3.
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3 Site-Saturation Mutagenesis of CYP101B1
3.1 Introduction
CYP101B1 is able to oxidise norisoprenoids such as β- and α-ionone with high regios-
electivity for the C3 position with fast product formation rates (> 1000 min−1). In
addition, these substrates bind to the enzymes with high affinity (≥ 95 % HS, K d < 0.30
µM).57,61 The butenone side chain on the ionones is thought to be involved in substrate
binding (Figure 17). β-Damascone (Figure 17), which has differing alkene and ketone
positions on the butenone, showed lower binding affinity (≤ 90 % HS, K d ≥ 7 µM),
however the regioselectivity of the oxidation is comparable to β-ionone.101 Isophorone
(Figure 17), which has a ring system similar to the ionones but missing the butenone
side chain, displayed only a 40 % shift to the high spin form and slow NADH oxidation
rate (75 min−1).101 Isophorone oxidation by CYP101B1 was unselective, generating 3
metabolites in low yield.
Figure 17: Structures of β-ionone, β-damascone and isophorone. The butenone side chain in β-ionone
is highlighted in red.
Terpenoid substrates functionalised with an ester directing group, which mimics the
butenone side chain of the norisoprenoids, have also been oxidised with high efficiency
and regioselectivity by CYP101B1.101 As an example, isobornyl acetate showed a 100-
fold increase in binding affinity and was oxidised with a nearly 40-fold increase in
product formation rate compared to isoborneol. It was also hydroxylated exclusively
at the 5-exo position (Figure 18), whereas isoborneol was oxidised to three products
in low yield.101 The ester moiety is thought to act as a directing group to anchor the
substrate in the active site of the enzyme. These oxidations demonstrate the utility
of CYP101B1 in oxidising a wide range of high value compounds that are commonly
used as flavourings and fragrances.
Figure 18: Regioselective oxidation of isobornyl acetate by CYP101B1.
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The oxidation of hydrophobic substrates by CYP101B1 was less impressive. Phenylcy-
clohexane and p-cymene oxidations by the enzyme induced moderate (141 min−1) to
poor (25.3 min−1) product formation rates.61 It has also been reported that CYP101B1
was also capable of oxidising alkyl substituted naphthalene and biphenyl molecules with
slower product formation rates than that of phenylcyclohexane (< 80 min−1). These
substrates also bind with lower binding affinities (≤ 55 % HS, Kd = 17 - 135 µM).106
The aforementioned studies demonstrate the broad substrate range associated with
CYP101B1. The aim of this study is to improve the activity of CYP101B1 towards
hydrophobic substrates.
Sequence alignment of the CYP101 enzymes: CYP101B1, CYP101D1, CYP101D2 and
CYP101A1 (P450cam) show there are several equivalent residues within the active sites
of these enzymes.61 A residue of interest within CYP101B1 was the H85 residue which
is equivalent to tyrosine residues in P450cam (Y96), CYP101D1 (Y98) and CYP101D2
(Y96).61 These tyrosines are conserved in the structures of P450cam and CYP101D1,
where they provide the only hydrophilic interaction with camphor as a substrate.40
CYP101D1 and CYP101D2 have been structurally characterised by X-ray crystallog-
raphy.107,108 CYP101D1 is the closest homolog of CYP101B1 in the Protein Data Bank
(PDB) and its camphor-bound structure (PDB ID: 3LXI) was used to model the struc-
ture of CYP101B1 using Swiss Model.109 The modelled active site is shown below
(Figure 19).
(a) (b)
Figure 19: (a) Crystal structure of CYP101D1 with bound camphor (PDB ID: 3LXI).63 (b) Mod-
elled structure of CYP101B1 using Swiss Model that shows the possible location of the H85 residue
(highlighted in orange).109
P450cam has been used as a model system to demonstrate how mutations of active site
residues allow the enzyme to oxidise non-physiological substrates.110–112 For example,
the Y96 residue of P450cam, which interacts with the carbonyl group of camphor via
a hydrogen bond interaction, has been mutated to both alanine (Y96A) and pheny-
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lalanine (Y96F). These two mutants showed increased binding affinity and oxidation
rates towards phenycyclohexane when compared to the WT-enzyme.110–112 The same
mutations of the equivalent tyrosine residue of CYP101D2 also increased the affinity
of this enzyme towards hydrophobic substrates.113
The H85 residue of CYP101B1 has been previously mutated to a phenylalanine (H85F).
This change decreased the binding affinity and activity of CYP101B1 for β-ionone. The
H85F mutant also showed improved affinity and activity towards certain hydrophobic
substrates, such as acenapthene which showed poor activity with WT-CYP101B1.
The binding affinity for this substrate was improved nearly six-fold with the H85F
mutant.114
The mutagenesis of the H85 residue and subsequent change in enzyme activity showed
that the residue plays a role in substrate binding and is likely to be within the active
site of CYP101B1. This position is therefore a suitable target for site-saturation mu-
tagenesis. This involves replacing the H85 residue within CYP101B1 with a range of
other possible amino acid residues. The mutants generated in this library will then be
screened for activity with hydrophobic non-natural substrates. It is hypothesised that
changing the steric bulk and hydrophobicity of the H85 residue should allow CYP101B1
to accommodate different substrates.
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3.2 Results
Site-saturation mutagenesis was achieved using a gene fragment (gBlock) with a nnC
triplet codon (n is a random base) incorporated at the H85 position. The nnC codon
would allow the introduction of all possible amino acids with codons ending with cy-
tosine at this position. For example, when the GGC codon is present, position 85
within CYP101B1 would now contain a glycine residue and this mutant is now termed
the H85G mutant. A total of 14 possible mutants can be produced with this gBlock
fragment. The following table lists all the possible mutants that can be generated with
the gBlock gene fragment and the mutants that were successfully produced (Table 5).
Table 5: All possible mutants that can be produced using the gBlock fragment with a nnC codon
at the H85 residue. Mutants that were successfully produced and identfied were denoted with ’Y’
and mutants that were not produced were denoted with ’N’. The CAC codon which was generated

















The gBlock fragment was cloned into vectors pET22 and pRSFDUET (Chapter 2,
Section 2.2.1). Vector pET22 was used for enzyme production and purification for in
vitro studies, while vector pRSFDUET which has the Arx gene was used in whole-cell
studies with a pETDUET vector containing the ferredoxin reductase, ArR (Chapter 2,
Section 2.7.1). The mutants H85P, H85L and H85C were not able to be produced. A
total of 11 mutants were generated using this method (Table 5). To confirm whether
expression could be achieved, each H85 mutant enzyme within vector pET22 in Table
5 was produced using E.coli cells. In all cases, the cell pellets produced were red in
appearance, indicating that functional P450s were being generated.
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3.2.1 Whole-Cell Studies of CYP101B1 Mutants
The mutants contained in vector pRSFDUET along with the ferredoxin, Arx were
co-expressed with a pETDUET vector that contains the ferredoxin reductase, ArR.
This generates all three enzymes of the CYP101B1 systems in a single E.coli cell and
enables whole-cell oxidation. These mutant whole-cell systems were then used for in
vivo screening with various substrates (Figure 20).
The substrates screened include β-ionone as a control to determine if the mutants al-
tered the oxidation activity. Small and bulky hydrophobic molecules with poor affinity
and activity with WT-CYP101B1 were also screened to assess if the mutants have
improved oxidation activity. Norisoprenoid and terpenoid compounds such as pseu-
doionone and 1,8-cineole, were chosen to assess if the mutants improved metabolite
yield over the WT enzyme or changed the selectivity of oxidation. The WT enzyme
was also screened concurrently with the mutants as a control. Any metabolites previ-
ously shown to be generated by the WT enzyme were used to identify products from
the mutant.101,104,106,114
Figure 20: Substrates used for whole-cell in vivo screening of CYP101B1 mutants.
The total metabolite yield for β-ionone oxidation with the mutants was lower com-
pared to the WT enzyme. However, the mutants H85G, H85V and H85A all shifted
the selectivity of product formation towards the 4-hydroxy metabolite (Figure 21).
H85G, H85V and H85A were all mutants containing small hydrophobic residues and
these variants favoured oxidation of the more reactive allylic C-H bonds.114 The al-
tered levels of product formation and change in selectivity provided evidence that the





Figure 21: (a) The oxidation of β-ionone by CYP101B1 mutants. (b) GC-BID analysis of CYP101B1
mutant whole-cell turnovers include the WT (red), mutants H85G (black), H85A (blue) and H85V
(green). The remaining mutants that were tested produced lower metabolite yield than the WT. For
clarity, the chromatograms were offset along the y-axis.
Phenylcyclohexane is a bulky hydrophobic substrate, and when oxidised by WT-
CYP101B1, the sole product was trans-4-phenylcyclohexanol (Figure 22).61 The same
product was formed for each of the H85 mutants screened with phenylcyclohexane.
Figure 22: (a) The oxidation of phenylcyclohexane by CYP101B1 mutants. (b) GC-BID analysis of
CYP101B1 mutant whole-cell turnovers include the WT (red), mutants H85A (blue), H85V (green)
and H85F (pink). For clarity, the chromatograms were offset along the y-axis. Impurities were marked
with *.
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The product formation levels for all mutants observed were lower than the WT enzyme,
even for mutants with smaller residues such as glycine, alanine and valine, which were
expected to accommodate the bulkier substrate by virtue of having larger active sites
(Figure 22). Potential impurities were also present within the turnovers with phenyl-
cyclohexane but were not identified.
In this study, the metabolites arising from turnovers with isobutylbenzene, n-
propylbenzene and p-cymene and the mutants matched those of the WT-enzyme.61,114
For all three substrates, the H85F variant generated more product than the WT-enzyme
and the other mutants (Figure 23, 24 and 25). This agreed with previous in vitro stud-
ies of the H85F variant which showed that this mutant increased the binding affinity
and oxidation activity of CYP101B1 towards these three substrates.115
(a)
(b)
Figure 23: (a) The oxidation of n-propyl benzene by CYP101B1 mutants. (b) GC-BID analysis of
CYP101B1 mutant whole-cell turnovers with n-propylbenzene. 1-Phenylpropan-2-ol is labelled as #.
For clarity, the chromatograms were offset along both axes.
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Figure 24: The oxidation of isobutylbenzene by CYP101B1 mutants. GC-MS analysis of the whole
cell turnovers of the WT (red) and mutants H85F (pink) and H85V (green). Ratio of the sole product
to internal standard (IS): 1.92 (WT), 4.63 (H85F), 1.02 (H85V). For clarity, the chromatograms have
been offset along the x -axis.
(a)
(b)
Figure 25: (a) The oxidation of p-cymene by CYP101B1 mutants. Product distribution was deter-
mined via GC-MS analysis. (b) GC-MS analysis of the whole cell turnovers of the mutants including
the WT (red), mutants H85F (pink) and H85V (green). For clarity, the chromatograms have been
offset along the y-axis.
Amongst the new variants tested, the n-propylbenzene turnovers had seven variants
that displayed similar levels of product formation with the WT enzyme (Figure 23).
Mutant H85V showed the highest product formation with isobutylbenzene and p-
cymene, though the levels were lower than the H85F variant (Figure 24 and 25). The
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p-cymene turnovers did display altered product selectivity with the mutants, forming
more isopropylbenzyl alcohol, which was less favoured by the WT enzyme (Figure 25).
CYP101B1 oxidises both isomers regioselectively at the alkene furthest from the car-
bonyl group to yield two epoxide products (cis/trans, Figure 26).101 All mutants
screened formed the same epoxide products as the WT-enzyme and potential impurities
were also present (Figure 26).
(a)
(b)
Figure 26: (a) The oxidation of pseudoionone isomers by CYP101B1. (b) GC-MS analysis of
CYP101B1 mutant whole-cell turnovers with pseudoionone include the WT (red), mutants H85S
(purple), H85G (black) and H85F (pink). For clarity, the chromatograms have been offset along the
y-axis. Impurities were marked with *.
Amongst the mutants screened with pseudoionone, H85F generated similar amounts of
product compared to the WT-enzyme. The amount of product generated by the mu-
tants H85S and H85G was approximately two-fold higher (Figure 26). WT-CYP101B1
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and H85F favoured the formation of the trans isomer. Mutants H85G and H85S seems
to have shifted the selectivity of CYP101B1 to favour the oxidation of the cis isomer
instead. There were also impurities present with the pseudoionone turnovers that were
not identified (Figure 26b).
1,8-Cineole oxidation by WT-CYP101B1 forms multiple products that have been previ-
ously identified as 5-keto-, 5-α-, 6-α-, 6-β- and 5-β-hydroxy-1,8-cineole (Figure 27a).104
The H85F and H85I mutants generated the highest amount of product and also dis-
played changes in product selectivity over the WT (Figure 27b). The WT enzyme
displayed high selectivity towards towards both 5-keto- and 5-α-hydroxy-1,8-cineole
(> 99 %), but the selectivity towards the 5-keto metabolite was decreased with the
H85I and H85F mutants (Table 6). The minor metabolites, 6-α-, 6-β- and 5-β-hydroxy-
1,8-cineole, which were only produced in small quantities by the WT, were formed in
higher yield by these mutant enzymes (Figure 27b, Table 6).
(a)
(b)
Figure 27: (a) Products of 1,8-cineole oxidation by CYP101B1. (b) GC-MS analysis of CYP101B1
mutant whole-cell turnovers with 1,8-cineole which include the WT (red), H85I (gray) and H85F
(pink).
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Table 6: Percentage distribution (%) of 1,8-cineole oxidation products by CYP101B1 and its mutants
are listed. See Figure 27 for abbreviations.
5-keto 6-β 6α 5α 5β
WT 34 < 1 < 1 66 < 1
H85I 11 12 < 1 73 4
H85F 3 51 14 29 3
Initial whole-cell screening of the new CYP101B1 mutants thus showed that altering
the H85 residue did not improve or alter the in vivo activity of the enzyme with a broad
range of substrates. This was in spite of equivalent mutations in other CYP101 family
enzymes with higher activity with hydrophobic substrates. Further in vitro analysis of
the new mutants would be needed to confirm the activity of the mutant enzymes.
3.2.2 In Vitro Studies of CYP101B1 Mutants.
This lack of improvement in enzyme activity by the mutant enzymes suggested that
the alterations of the H85 residue did not significantly affect the binding and oxidation
of CYP101B1. To test this hypothesis, the CYP101B1 mutants H85A and H85G were
produced and purified for more detailed in vitro investigation (Section 2.4.1).
Mutant H85F and WT-CYP101B1 have been studied previously and have low affinities
towards sterically bulky substrates like biphenyls and phenylcyclohexane.61,106 It was
hypothesised that the mutants with less bulky residues such as alanine and glycine
would introduce more space within the active site to accommodate these substrates.
A similar study employing P450cam was successful in increasing the enzyme’s affinity
towards bulkier substrates such as phenylcyclohexane and naphthalene.110,111 Both
proteins were purified and the ferrous-CO assay of each variants showed they were
functional P450s (Figure 28).102
(a) (b)
Figure 28: CO-Assay of CYP101B1 (a) H85A and (b) H85G. The enzyme ferric (black, λmax = 417
nm), ferrous (blue, λmax = 414 nm) and ferrous-CO bound forms (red, λmax = 450 nm) are shown.
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WT-CYP101B1 induced a high spin-state shift with both α and β-ionone (> 95 % HS,
Table 7).61 Spin-state shift studies with the H85A and H85G mutants were carried out
firstly with these two substrates. The H85A mutant with both ionones displayed large
type I spin-state shifts (90 % HS, Figure 29) which were only marginally lower than
those observed with the WT enzyme.61 The spin-state shifts observed for H85G were
even lower with β-ionone inducing a 60 % HS shift and α-ionone only inducing a shift
to 40 % HS (Figure 30).
(a) (b)
Figure 29: Spin-state shifts of H85A-CYP101B1 with (a) β-ionone and (b) α-ionone.
(a) (b)
Figure 30: Spin-state shifts of H85G-CYP101B1 with (a) β-ionone and (b) α-ionone.
The dissociation constants for the mutants towards β-ionone were determined to be
100 ± 20 µM and 231 ± 32 µM for H85A and H85G respectively (Figure 31, Table 7).
The binding affinity of the WT enzyme with β-ionone was significantly higher (0.23
µM, Table 7). The lower spin-state shifts and weaker dissociation constants observed
for both variants indicated that the active site mutants lowered the binding preference




Figure 31: Dissociation constant analyses of β-ionone with (a) H85A-CYP101B1 and (b) H85G-
CYP101B1. Peak to trough used to measure Kd was from A420-A600 as β-ionone absorbed strongly
below 400 nm.
Table 7: Substrate binding and in vitro turnover data for CYP101B1 mutants with different substrates.
The data are given as mean ± S.D. with n ≥ 3. Rates are given as nmol.nmolP450−1.min−1.
Mutant Substrate % HS K d (µM) NADH PFR Coupling
WT61
β-Ionone ≥ 95 0.23 ± 0.1 1600 ± 100 1010 ± 60 63
α-Ionone ≥ 95 0.26 ± 0.04 1380 ± 140 660 ± 60 48
Phenylcyclohexane 20 7.8 ± 0.9 293 ± 9.0 141 ± 17 48
H85A
β-Iononea 90 100 ± 20 760 ± 7 302 ± 13 40 ± 2
α-Ionone 90 -b 740 ± 16 187 ± 54 25 ± 7
Phenylcyclohexane 20 15 ± 2 106 ± 5.0 22 ± 1 21 ± 1
H85G
β-Iononea 60 231 ± 32 569 ± 24 185 ± 10 33 ± 1
α-Ionone 40 -b 294 ± 57 22 ± 7 7 ± 3
Phenylcyclohexane -c 25 ± 6 24 ± 4.0 -d -d
aPeak to trough used to measure Kd was from A420-A600 as β-ionone absorbed strongly below 400
nm. bNot measured. cNo spin-state shift observed. dNo product formation.
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The two mutants were then assayed with phenylcyclohexane to determine if the mutants
were better able to accommodate this hydrophobic molecule as hypothesised. The
H85A mutant only induced a 20 % HS shift (Figure 32a, Table 7) that was similar
to the WT.61 Addition of phenylcyclohexane to the H85G mutant did not display a
significant change in spin-state (Figure 32b, Table 7). The dissociation constants of
the mutants (Figure 33) with phenylcyclohexane were measured and found to be 15
± 2 µM and 25 ± 6 µM for H85A and H85G respectively, which showed that both
mutants had weaker binding affinity than the WT (7.8 µM, Table 7).61
(a) (b)
Figure 32: Spin-state shifts of (a) H85A-CYP101B1 (b) H85G-CYP101B1 with phenylcyclohexane.
(a)
(b)
Figure 33: Dissociation constant analysis of phenycylohexane with (a) H85A-CYP101B1 and (b)
H85G-CYP101B1.
The NADH oxidation and product formation rates for both mutants were determined
with phenylcyclohexane and β- and α-ionone to measure the catalytic activity of the
two mutants towards each substrate (Table 7). The products of each turnover were
identified by comparison to the WT-turnover as per the whole-cell screening studies.61
Products were calibrated against the substrate and this was then used to estimate the
concentration of the product peak using GC-MS analysis.
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The rates of NADH oxidation with β-ionone were 760 and 569 nmol.nmolP450
−1.min−1
(henceforth abbrieviated as min−1) for the H85A and H85G mutant, respectively. These
were more than 2-fold slower than that of the WT-enzyme. This result was also
consistent with the lower spin-state shifts and binding affinities observed for both
mutants with β-ionone. The reduced coupling efficiencies for H85A and H85G (40 %
and 33 % respectively) were a result of lower levels of products compared to the WT
(Table 7). The product distribution, as determined by GC-MS analysis of the mutant
turnovers displayed altered product selectivity by favouring the 4-hydroxy metabolite.
This change in selectivity was consistent with the whole-cell oxidation turnovers of the
H85A and H85G mutant systems with β-ionone (Figure 21). This was also observed
with the H85F variant, where 4-hydroxy-β-ionone was the major product.19,57,114
Figure 34: GC-MS analysis of the in vitro turnovers of WT-CYP101B1 (red) with β-ionone in com-
parison to mutants H85A (blue) and H85G (black) with β-ionone. For clarity, the chromatograms
have been offset along the x - and y- axes.
The oxidation activity of both mutants with α-ionone showed similar trends as β-
ionone. The NADH oxidation activity of both mutants was more than 5-fold slower
than the WT-enzyme, and low coupling efficiencies (≤ 30 %) resulted in a significant
decrease in the product formation rates (< 200 min−1, Table 7). Both mutant turnovers
generated cis- and trans-3-hydroxy-α-ionone alongside small quantities of 3-oxo-α-
ionone (Figure 35). The mutants did not change the product selectivity in comparison




Figure 35: GC-MS analysis of the in vitro turnovers of WT-CYP101B1 (red) with α-ionone in com-
parison to mutants H85A (blue) and H85G (black) with α-ionone. For clarity, the chromatograms
have been offset along the x and y axes.
More surprisingly, the hydrophobic substrate, phenylcyclohexane also displayed low
oxidation activity with both mutants (Table 7). The H85A and H85G mutants both
displayed slower NADH oxidation rates compared to the WT (293 min−1), with the
H85G mutant being reduced by more than 10-fold (24 min−1). The H85A mutant
displayed low coupling efficiency (21 %) that resulted in a reduced product formation
rate (22 min−1). trans-4-Phenylcyclohexane was the sole product (Figure 36).
Figure 36: GC-MS analysis of the in vitro turnovers of WT-CYP101B1 (red) in comparison to mutant
H85A (blue) with phenylcyclohexane. For clarity, the chromatograms have been offset along the x -
and y- axes.
The H85G variant did not generate any product formation from monooxygenase ac-
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tivity. The weaker binding affinity and slower oxidation activity for both mutants
indicates that additional active site volume to accommodate phenylcyclohexane may
not have been introduced as initially hypothesized.
3.2.2.1 Spin-State Shift Studies with Mutants H85A and H85G
To further investigate the substrate range of these variants of CYP101B1, spin-state
shifts of the H85A and H85G mutants were measured with a wider variety of hydropho-
bic, terpenoid and norisoprenoid substrates. The highest spin-state shift induced for
both mutants was with β-damascone which was 80 % HS for H85A and 50 % HS for
H85G respectively (Figure 37). These were on par or lower than the spin-state observed
with the WT (80 %).
(a) (b)
Figure 37: Spin-state shift studies of β-damascone with CYP101B1 mutants (a) H85A and (b) H85G.
Terpenoids such as 1,8-cineole, cis-jasmone, fenchyl acetate, isobornyl acetate, and
nopol, induced spin-states that were less than 10 % HS for the H85G mutant (Appendix
A1). This contrasted the higher spin-state shifts observed for WT-CYP101B1 with
these substrates (45 - 95 % HS).101 Spin-state shifts of these substrates with H85A
were not measured.
A selection of cycloalkanes were also assayed with both mutants. The H85A mutant
with cyclodecane displayed the highest spin-state shift (60 % HS), this was followed
by cyclooctane (50 % HS) and then cyclododecane (40 % HS, Figure 38). Spin-state
shift data for the WT and H85F mutant enzyme with cycloalkanes were also collected
for comparison (Table 8). The spin-state of cyclodecane and cyclooctane were greater
with the H85F variant (¿ 50 %).
It is worth noting that both the H85A and H85F mutants had higher spin-state shifts
induced by cyclodecane and cyclooctane than the WT-enzyme. It appears that hy-
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drophobic methyl and phenylalanine residues at the H85 position enhanced the bind-
ing of CYP101B1 towards the cycloalkanes. The H85G variant with cyclodecane and
cyclododecane had poor spin-state shifts (≤ 10 % HS, Appendix A2), suggesting that
smalller residues did not give the same effect. We also note that the larger substrate
cyclododecane induced lower spin-state shifts with the H85A variant than cyclodecane
or cyclooctane (Table 8).
Table 8: Spin-state shift data for CYP101B1 and its mutants, H85A and H85F, with cycloalkanes.











a Data provided by Raihan Sarkar of the University of Adelaide.
(a) (b)
(c)
Figure 38: Spin-state shift studies of CYP101B1-H85A with (a) cyclodecane, (b) cyclooctane and (c)
cyclododecane.
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Additional in vitro studies of both mutants with a selection of hydrophobic substrates
all consistently gave spin-state shifts lower than 30 % HS irrespective of the substrate
size (Appendix A3, A4 and A5). This is a strong indication of poor enzyme-substrate
fit and it was likely that the mutants had weak binding affinity with hydrophobic
substrates.
3.3 Discussion
We were able to generate eleven mutant forms of CYP101B1 at the H85 position. Ten
of the mutants were new variants including Gly, Ala, Thr, Asp, Val, Arg, Tyr, Asn,
Ser and Ile residues at position 85 in CYP101B1. The screening using in vivo systems
showed that some of the mutants had increased product formation and changes in the
product selectivity (Figure 21, 26 and 27). However, the majority were less effective
than the WT enzyme or the previouly studied H85F variant at oxidising hydrophobic
substrates.61,114 The higher product formation of H85F with n-propylbenzene, isobutyl-
benzene and p-cymene was expected, as the mutant showed improved enzyme activity
and binding affinity with these three substrates in vitro (Figure 23, 24 and 25).114
The lack of significant improvement to the enzyme activity of the other mutants with
the substrates screened were unexpected. The changes in enzyme activity and selec-
tivity of the mutants with β-ionone is strong evidence that the H85 residue is within
the active site or the access channel. It also suggests that this residue has a role in
substrate binding. However, the high spin-state shift and enzyme activity induced by
β-ionone with the H85A mutant infer that the H85 residue is not the only significant
residue involved in substrate binding (Figure 29).
The in vitro studies on mutants of CYP101B1 suggests that mutating to smaller
residues (alanine and glycine) did not lead to the expected increase in binding affin-
ity or activity with larger hydrophobic substrates. In contrast, P450cam was able to
oxidise larger molecules such as diphenylmethane upon the introduction of the Y96A
mutant.112 An important observation is that the Y96A variant of CYP101D2 from
N. aromaticivorans did not improve the activity towards larger substrates either.113
Therefore, the enzymes of the CYP101 family from different bacteria seem to display
different behaviour upon mutagenesis of equivalent residues. This suggests that these
mutations may have an effect on the conformation of these enzymes. The introduction
of the mutants may have caused altered interactions between residues within the active
site and of those surrounding it, which changes the architecture of the substrate bind-
ing pocket and thus affect substrate binding. Crystal structures of CYP101B1 would
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be a useful tool in probing the conformation of the enzyme’s active site for further
study.
There are other residues of interest within the CYP101B1 active site that could be
mutated to accommodate larger hydrophobic molecules, including Q234 and I237 that
are equivalent to residues L244 and V247 in P450cam (Figure 39).
61 The L244 and
V247 residues when mutated were able to increase the activity of P450cam towards non-
natural substrates such as valencene and phenylcyclohexane.79,116,117 However, a similar
attempt at mutating equivalent residues within CYP101D2 to increase its binding
affinity towards camphor was not successful.113
(a) (b)
Figure 39: (a) Crystal structure of P450cam with bound camphor (PDB ID: 3WRH). (b) Modelled
structure of CYP101B1 using Swiss Model. The L244 and V247 residues of P450cam and the equivalent
residues of Q234 and I237 in CYP101B1 are highlighted in orange.
This work provided evidence that P450 evolutionary function and substrate preference
does not solely depend on the identity of residues within the first sphere of the active
site and their interactions with the substrate. There are likely other unknown factors
as well that determine how the identity of the residues affect the overall conformation
and subsequently the activity of P450 enzymes.
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4 Oxidation of Terpenoids by P450 Mutants
4.1 Introduction
Monoterpenoids are a class of terpenes that are important constituents of plant essential
oils.118 Monoterpenoids consists of a 10 carbon backbone made up of 2 isoprene units.119
These compounds have found widespread use as flavours, fragrances and pheromones
with applications in pesticides, herbicides and as pharmaceutical ingredients.120–122
Oxygenated monoterpenes are highly sought after intermediates within commercial
industries.123 The parent monoterpenes can be easily extracted in large quantities from
their natural sources but the oxidised variants of these terpenes often exist in lower
quantities.48 P450 catalysed regio- and enantioselective oxyfunctionalisations of these
compounds have therefore garnered widespread attention as an important research
field123 New regio- and enantioselective oxidation of existing terpenoids could lead
to new fragrances and flavouring compounds with unique sensorial properties.88,124
Flavouring and fragrance compounds used in commercial products that are generated
using chemical synthesis methods also need to be labelled as “nature-identical” under
US and European legislation, but the same compounds produced using enzymatic
processes can be labelled as “natural” and are more strongly preferred by consumers.125
The distinct marketing advantage given to products labelled as “natural” has driven
significant development for biotechnological processes that also include P450 research
into developing novel methods to produce these compounds.125
The monoterpenoid, camphor (Figure 40), is the natural physiological substrate of
P450cam that stereoselectively hydroxylates this substrate at the 5-exo position.
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P450cam therefore serves as a good starting point to develop biocatalysts for the oxida-
tion of terpenes and terpenoids. Mutagenesis of P450cam has generated variants that
are capable of oxidising terpene compounds such as α-pinene.46,74 The aim of this study
involves utilising a library of P450cam mutants that have been previously developed for
terpene oxidation. This library will be screened against a selection of terpenoids and
other similar compounds to selectively generate metabolites (Table 9 and Figure 40).
Table 9: Norisoprenoids of interest alongside descriptions of their odours.
Compound Odour
Fenchyl Acetate Sweet and pine-like scent
Fenchone Sweet and camphor-like scent
1,8-Cineole, 1,4-Cineole Citrus and eucalyptus scent
Isophorone Sharp and sweet-green camphor-like scent
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Figure 40: Target substrates used for screening by the library of P450cam mutants.
Fenchone and fenchyl acetate (Figure 40) are both constituents of essential oils from
Foeniculum vulgare, otherwise known as the common fennel.126 Fennel oils have ex-
hibited antioxidant and antimicrobial activity and the biotransformation of these two
terpenoids could lead to compounds with new biological profiles.126
1,8-Cineole is a monoterpenoid that is known trivially as eucalyptol and as the name
suggests, the major component of eucalyptus oil.96 Its isomer, 1,4-cineole (Figure 40),
has a similar natural occurrence in many of the same species but often in much lower
quantities.127 The two cineoles are rather chemically inert and require the use of highly
reactive reagents to hydroxylate them, often leading to racemic products. The meso
symmetry of the cineoles allows a single hydroxylation to form at least two chiral
centres.96 These hydroxylated derivatives can be used as chiral auxiliaries in organic
syntheses or as synthetic intermediates for herbicides and antimicrobial agents.96,127,128
Isophorone is cyclic ketone with a structure similar to the other terpenoids used
in Figure 40. It is an important precursor compound for the synthesis of 4-
hydroxyisophorone.129 This compound is an important aroma molecule within saf-
fron,130,131 and a flavouring agent within tobacco products.132 It also has applications
within the synthesis of pharmaceuticals and natural dye pigments.133,134
Variants of P450BM3 have also demonstrated the ability to catalyse selective and high
yielding oxidation of isophorone and both cineole isomers.105,135 Therefore, a second
aim of this study is to compare P450cam variants to those of P450BM3 using whole-cell
systems to determine if one enzyme system is more efficient than the other in oxidising
these substrates.
It is evident that the oxyfunctionalised derivatives of these compounds have many com-
mercial applications and potential new synthetic pathways towards these compounds
would be highly valued. Here, we will screen these terpenoids as substrates against
the library of P450cam mutants in vivo. Mutants that display high levels of prod-
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uct formation will be scaled up accordingly for product isolation and identification.
This will potentially provide new biocatalytic pathways towards the synthesis of useful
compounds derived from these monoterpenoids.
4.2 Results
Rationally designed mutants of P450cam have been found to increase the enzyme’s ac-
tivity towards (+)-α-pinene while also exhibiting good activity and selectivity towards
terpenoid based substrates such as limonene.45,46 This library of variants consisted of
active site mutations at the F87, Y96, L244, V247 and I395 positions (Figure 41, Table
10).45,46
Figure 41: Active site of Cytochrome P450cam with bound camphor (PDB ID: 3WRH). Residues of
interest in this work are highlighted in cyan.43
Table 10: A list of P450cam mutants tested with monoterpenoid substrates alongside the WT-enzyme.








These mutants are therefore suitable for screening with substrates that are of a similar
size to (+)-α-pinene.136 The genes encoding the mutants have been previously cloned
into a whole-cell oxidation system alongside the physiological electron transfer partners
of P450cam, Pdx and PdR.
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This library of mutants (Table 10) was transformed into BL21(DE3) competent E.coli
cells and was screened with fenchone, fenchyl acetate, 1,8-cineole, 1,4-cineole and
isophorone (Figure 40) to determine if any of the mutants were able to selectively oxi-
dise these substrates with high levels of product formation. WT-P450cam was screened
concurrently with the mutants as a control for comparison. The screening results were
analysed with both GC-MS and GC-BID analysis. Mutants that displayed selective
oxidations with high yields of product were then scaled up accordingly (200 mL) for
product purification and identification.
4.2.1 Fenchone and Fenchyl Acetate Oxidation by P450cam Mutants
Fenchone and fenchyl acetate both possess a bicyclic-2.2.1 structure that is also present
in camphor, the natural substrate for P450cam. Fenchone and camphor both possess a
C2 ring carbonyl. This has been substituted with an acetate moiety in fenchyl acetate.
The most significant structural difference between these two substrates and camphor
is that the methyl groups within fenchone and fenchyl acetate are located on the C3
carbon instead of the C7 bridge position (Figure 42).
Figure 42: Structures of Fenchone and Fenchyl Acetate in comparison to camphor.
The initial whole-cell oxidation results with fenchyl acetate showed the WT displayed
higher levels of product formation compared to the majority of the mutants (Figure
43). The oxidation of fenchyl acetate by WT-P450cam formed three products. Two of
the products formed were not fully resolved by GC. The only mutant that exceeded the
metabolite formation of the WT was the Y96A variant and this mutant also altered




Figure 43: (a) Product distribution of fenchyl acetate oxidation by P450cam variants and (b) GC
analysis of the whole-cell turnovers of fenchyl acetate with WT-P450cam (red) and mutant Y96A-
P450cam (blue). The three products present within both turnovers and were identified as 6-exo-
hydroxyfenchyl acetate (6-exo-FA, tR = 10.75 min), 5-exo-hydroxyfenchyl acetate (5-exo-FA, tR =
10.9 min), (7S )-hydroxyfenchyl acetate (7S -FA, tR = 11.3 min). It is noted that the product peaks
are not resolved completely via GC analysis and therefore the quantifications is an estimate. For
clarity, the chromatograms have been offset along the y- axes.
A larger scale whole-cell turnover of WT-P450cam and variant Y96A was carried out
to generate the metabolites for characterisation. These were extracted and purified by
silica chromatography. The major metabolite for the Y96A turnover was identified via
1H NMR and MS analysis as 5-exo-hydroxyfenchyl acetate (tR = 10.9 min, Figure 43).
Both the NMR and MS spectra were in agreement with previously reported data (Ap-
pendix B1).101 The C-H-OH signal (δH = 4.18 ppm, endo-H5) displayed a doublet cou-
pling pattern with J = 6.7 Hz (Figure 44). Coupling constants of this magnitude have
also been observed in the endo-endo coupling between the C5 hydrogen to the adjacent
C6 hydrogen in the related hydroxylated monoterpenoid, 5-exo-hydroxycamphor.137
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Figure 44: Expansion of the 4.4 - 2.2 ppm region within the 1H NMR spectrum of 5-exo-hydroxyfenchyl
acetate. The endo-H5 signal (4.18 ppm) had a coupling constant of 6.7 Hz that is indicative of endo-
endo coupling to the adjacent H6 hydrogen.
A second minor metabolite from the P450cam-Y96A turnover was isolated and identified
as (7S )-hydroxyfenchyl acetate (tR = 11.3 min, Figure 43) based on NMR analysis.
This less abundant product displayed an additional 1H signal at δH = 3.86 ppm that
indicated a CH2 site was hydroxylated to produce a C-H-OH signal (H7, Figure 45a).
This signal displayed no endo-endo/endo-exo coupling that is characteristic of C5 or C6
hydroxylation as observed with the 5-exo metabolite.138,139 This leaves the C7 position
as the likely oxidation site. The orientation of the hydroxy group was confirmed through
1H-1H ROESY analysis (Figure 45b), whereby a through-space correlation was seen
between the remaining H7 signal with the exo methyl group (H9) that indicates the
hydroxylation occurred on the C7-C6-C5 face.
(a)
(b)
Figure 45: NMR data for (7S )-hydroxyfenchyl acetate that shows (a) an expansion of the 1H NMR
data showing the C-H-OH signal (H7, 3.86 ppm) and (b) 1H-1H ROESY NMR data showing a through
space correlation between H7 with the exo methyl group (H9).
Purification of the three metabolites from the WT enzyme turnover was attempted.
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The turnover yielded the same (7S )-hydroxyfenchyl acetate product as observed with
the Y96A variant. The other two metabolites were isolated as a mixture (Figure 46).
One of these metabolites was confirmed as 5-exo-hydroxyfenchyl acetate and the third
product could then be assigned as 6-exo-hydroxyfenchyl acetate from NMR analysis of
the other signals of this mixture (Figure 46).
Figure 46: 1H NMR spectrum of the isolated mixture from WT-P450cam with fenchyl acetate that
contains 6-exo- and 5-exo-hydroxyfenchyl acetate. The NMR of the mixture was overlaid with the 1H
NMR spectrum of 5-exo hydroxyfenchyl acetate. Signals belonging to be the 6-exo-hydroxyfenchyl
acetate were labelled in the NMR spectrum of the mixture.
The third product had an additional 1H signal at δH = 4.03 ppm upon oxidation that
is once again characteristic of a hydroxylation at a CH2 site (Figure 47a). This signal
displayed a dd coupling with J = 7.1 and 3.5 Hz. The magnitude of the coupling
constants for this signal is indicative of endo-endo and endo-exo coupling of the C-H-
OH signal to the neighbouring CH2 group. These coupling constants can only arise
from oxidation at either the C5 or C6 position as observed with 5-exo- and 6-endo-
hydroxycamphor.137
1H - 13C HSQC NMR was used to assign the hydrogen signals within the mixture
where possible to their respective carbons. 1H - 13C HMBC analysis (Figure 47b) of
the mixture shows a correlation between the hydroxylated (C-OH) carbon and the CH3
methyl hydrogens at the C10 carbon, which places the likeliest hydroxylation site at
the C6 position. The lack of any significant W-coupling observed within the C-H-OH
signal and the exo-H2 signal placed the orientation of the hydroxy group in the exo




Figure 47: NMR data for the 5-exo and 6-exohydroxyfenchyl acetate mixture that shows (a) an
expansion of the 1H NMR data showing the C-H-OH signals for both compounds and (b) 1H -
13C HMBC NMR data showing a correlation between the C6 and a CH3 group (H10) of 6-exo-
hydroxyfenchyl acetate.
GC-MS co-elution experiments with the purified fenchyl acetate oxidation products
and the enzyme turnover confirmed the presence of the products within the whole-cell
turnovers (Figure 48). However, the 5-exo/6-exo-hydroxyfenchyl acetate mixture was
not resolved with GC-MS.
(a) (b)
Figure 48: GC-MS co-elution experiments of fenchyl acetate turnovers using (a) Y96A-P450cam (blue)
and (b) WT-P450cam (red). The co-elution was carried out with purified 5-exo-hydroxyfenchyl acetate
(dashed, tR = 6.55 min), the 5-exo-/6-exo-hydroxyfenchyl acetate mixture (grey, tR = 6.55 min),
purified (7S )-hydroxyfenchyl acetate (black, tR = 6.72 min).
The oxidation of fenchone by the WT enzyme displayed low levels of formation of
4 different products that were detectable by both GC and GC-MS analysis (Figure
49). Of the 14 mutants screened, mutant Y96F generated identical metabolites to the





Figure 49: (a) Product distribution of fenchone oxidation by P450cam-Y96F and the WT enzyme.
(b) GC-BID analysis of the in vivo turnovers of fenchone with WT (red) and Y96F (pink). Products
identified were 6-exo-hydroxyfenchone (tR = 16.3 min), 6-endo-hydroxyfenchone (tR = 17.0 min),
5-exo-hydroxyfenchone (tR = 17.25 min), (7S )-hydroxyfenchone (tR = 18.1 min). For clarity, the
chromatograms have been offset along the y- axes.
A larger scale turnover of the Y96F variant with fenchone was carried out to isolate
enough of each metabolite for characterisation. Silica chromatography of the turnover
extract isolated one metabolite which NMR matched that of 5-exo-hydroxyfenchone
(Figure 50).101
Figure 50: 1H-NMR data 5-exo-hydroxyfenchone.
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The other three oxidation products could not be separated from each other. Compar-
ison of the GC-MS (Appendix B8) and NMR data (Figure 51 and Appendix B7) of
the mixture with those of hydroxyfenchone metabolites in the literature indicated the
presence of both 6-exo- and 6-endo-hydroxyfenchone. The MS and NMR data matched
those previously reported in the literature.140 These two products were identified via
their C-H-OH peaks : 4.09 ppm for 6-endo and 3.62 ppm for 6-exo; alongside the three
methyl peaks: 1.16, 1.12 and 1.10 ppm for 6-endo and 1.14, 1.06 and 0.96 ppm for
6-exo.140
The fourth product showed a C-H-OH signal (δH = 4.05 ppm, Figure 51a) with no
distinct coupling pattern similar to that observed for the equivalent NMR signal within
(7S )-hydroxyfenchyl acetate (δH = 3.86 ppm, Figure 45a). This metabolite was there-
fore assigned as (7S )-hydroxyfenchone. In addition, there does not appear to be any
evidence of carbonyl reduction within the turnover of Y96F with fenchone.
(a)
(b)
Figure 51: Selected signals within the NMR data for a mixture of fenchone oxidation products isolated
that shows (a) an expansion of the 1H NMR data showing the C-H-OH signals and (b) methyl hydrogen
signals for 6-exo-, 6-endo and (7S )-hydroxyfenchone.
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The presence of all 4 products within the turnover of Y96F-P450cam with fenchone was
confirmed via GC-MS co-elution experiments as shown in Figure 52.
Figure 52: GC-MS analysis of purified 5-exo-hydroxyfenchone (dashed), the 6-endo-/6-exo-/(7S )-
hydroxyfenchone mixture (black) and the Y96F-P450cam turnover with fenchone (blue).
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4.2.2 Biocatalytic Oxidation of Isophorone by P450cam Mutants
Isophorone is an α, β-unsaturated cyclic ketone. It lacks the bicyclic structure of
camphor and contains an additional alkene double bond. It has a similar size and
chemical functionality to camphor which makes it a suitable target for screening with
the P450cam mutant library (Table 10).
GC analysis of the WT turnover with isophorone showed the formation of two metabo-
lites (Figure 53). One of these metabolites was produced in significant excess by sev-
eral of the mutants. Amongst the variants screened, the mutants F87W/Y96F/V247L
(WFL) and F87W/Y96F/L244A/V247L (WFAL) showed increased product formation
and selectivity for this metabolite over the WT enzyme (Figure 53). The other mutants
tested all showed lower formations of product and were also less selective.
Figure 53: Oxidation products of isophorone by P450cam mutants alongside chiral GC analysis of the
whole-cell screening of isophorone with WT (red), F87W-Y96F-V247L (WFL, green), F87W-Y96F-
L244A-V247L (WFAL, blue) and Y96F-V47L (cyan). The chromatograms were offset along the x
and y axes for clarity. Note the enantiomers of 4-hydroxyisophorone were not separated using this
method.
A large scale whole-cell oxidation of isophorone (Figure 56a) with the WFL variant
was carried out to isolate the two products formed. The products were purified using
silica chromatography. The major product isolated and identified via NMR was 4-
hydroxyisophorone (35 mg; Appendix B9). The minor product was characterised as
7-hydroxyisophorone (12 mg; Appendix B12) (Figure 53).
1H NMR data for 4-hydroxyisophorone (Figure 54a) matched previously reported lit-
erature NMR data (Table 11).141 The oxidation site for the major metabolite was
identified by the presence of a 1H hydrogen signal at 4.03 ppm that is an indication
of a hydrogen attached to a hydroxylated carbon (C-H-OH), which suggests a CH2
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group was oxidised. Isophorone possesses two CH2 groups at the C4 and C6 position.
HMBC NMR analysis of the C-H-OH signal (4.03 ppm) found it had correlations with
the three methyl carbons (C7, C8, C9) and the two alkene carbons (C2, C3). This
places the oxidation site at the C4 position which is the only position equidistant to
the three methyl and alkene carbons.
(a)
(b)
Figure 54: (a) 1H NMR data and (b) expansion of the HMBC NMR analysis of 4-hydroxyisophorone
that shows the correlations of the C-H-OH signal.
Table 11: Comparison of Experimental NMR data of 4-hydroxyisophorone to the literature.141





H6 2.21 (J = 16.3 Hz) 2.21 (J = 16 Hz)




The oxidation site of the minor metabolite was identified at the C7 position via 1H
NMR analysis (Figure 55). The NMR spectrum showed a loss of one methyl signal
alongside the presence of a 2H signal at 4.22 ppm that indicates a methyl group was
oxidised. The two remaining methyl groups were equivalent as indicated by a large 6H
signal at 1.05 ppm. This suggests that the C9 and C8 carbons were not oxidised and
therefore the C7 carbon was hydroxylated to generate 7-hydroxyisophorone.
Figure 55: 1H NMR of 7-hydroxyisophorone. The H9/H8 signal (1.06 ppm) had an integration of 6
which indicates symmetry was present.
The oxidation of isophorone to 4-hydroxyisophorone can generate a pair of enantiomers.
Chiral GC analysis of the mutant enzyme-catalysed reactions only showed the forma-
tion of a single peak (Figure 53). A racemic mixture of 4-hydroxyisophorone was
generated via the reduction of 4-ketoisophorone with NaBH4 using a previously de-
scribed method.99 This racemic sample was also observed as a single peak by chiral
GC, suggesting the enantiomers are not resolved. Chiral HPLC analysis (Figure 56b)
of the enzymatic product and the racemic mixture of 4-hydroxyisophorone both dis-
played two peaks. However, the enzymatic product had one enantiomer produced in
much greater excess over the other (99 % e.e, Figure 56b). This indicated that the
enzyme-catalysed reactions were enantioselective.
(a) (b)
Figure 56: (a) GC-MS analysis of the large scale whole-cell turnover of WFL-P450cam with isophorone
and (b) chiral HPLC analysis showing the region of the purified 4-hydroxyisophorone (red) with the
racemic product (black). (R)-4-hydroxyisophorone was produced with 99 % e.e.
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While this work was being undertaken, a separate research group also showed that
P450cam mutants stereoselectively generated (R)-4-hydroxyisophorone.
142 The pure 4-
hydroxyisophorone from the whole-cell turnovers of our study had a specific rotation
of [α]D
20= +113.2 (c= 1.00, MeOH) which agreed with the rotation data of the pure
(R)-enantiomer previously reported in the literature. This enabled the assignment of
the enantiomer.129,133,142
4.2.2.1 Comparisons between P450cam and P450BM3 Isophorone Oxidation
In a separate investigation, our group has shown that mutants of P450BM3 are also
capable of oxidising isophorone to form (R)-4-hydroxyisophorone as the major prod-
uct.135 The formation of other minor metabolites such as 7-hydroxyisophorone and
4-ketoisophorone was also observed with the P450BM3 variants.
135 The self-sufficient
nature of P450BM3 provides easy production and its high enzyme activity makes it a
prime candidate for biocatalytic reactions. The P450cam system requires co-expression
of electron transfer proteins within the whole-cell oxidation systems but also displayed
high oxidation activity.19,44,143
P450cam’s class I system and P450BM3’s class VIII system cannot be compared directly
due to the disparate natures of their electron transfer systems (FMN vs ferredoxins),
co-factor requirements (NADPH vs NADH) and different plasmid systems used (pET28
vs pCWori). However, we wished to assess if both systems, under the same growth
and turnover conditions, would give rise to similar levels of product formation. Two
P450BM3 mutants which displayed selective and high levels of product formation with
isophorone were assessed; A74G/F87V/L188Q (GVQ) and R47L-Y51F-F87A-I401P
(RLYFFAIP).
The P450cam variant, WFAL, was compared with the RYLFFAIP and GVQ variants of
P450BM3 via whole-cell oxidations in E.coli BL21(DE3) cells. The two enzyme systems
both produced similar amounts of cell biomass (13 - 14 gram cell wet weight per litre
of culture, Appendix B1). The P450 concentration detected for the P450BM3 variants
(88 - 183 nM) were significantly higher than those of the P450cam mutants (25 - 54 nM,
Appendix B1).
After the whole-cell reactions were carried out for 7 hours, the RLYFFAIP and the
GVQ variants of P450BM3 displayed similar levels of product formation (∼ 650 ± 100
µM, Figure 57 and 58a). However, the GVQ variant formed other metabolites in small
amounts. These minor metabolites include 7-hydroxyisophorone, isophorone oxide, 4-
ketoisophorone epoxide and levodione.135 These remaining metabolites were not formed
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in significant quantities with the WFAL-P450cam mutant (Figure 57).
135
Figure 57: GC-MS analysis of the whole-cell turnover of WFAL-P450cam (blue) and GVQ-P450BM3
(red) with isophorone. Peaks shown are isophorone (tR = 6.25 min), 4-hydroxyisophorone (tR = 9.25
min), 7-hydroxyisophorone (tR = 10.6 min). Minor metabolites include isophorone oxide (IPO, tR =
5.8 min), 4-ketoisophorone epoxide (ket ox, tR = 6.4 min), 4-ketoisophorone (KIP, tR = 6.7 min) and
levodione (tR = 7.1 min). Impurities are marked with *.
The WFAL-P450cam variant generated more product than any of the P450BM3 mutants
at 7 hours (∼ 950 ± 10 µM). After leaving the samples for a further 13 hours, only the
P450cam variant was able to convert the majority of the added substrate (4 mM total)
to product (Figure 58b). Both P450BM3 mutants displayed lower amounts of product
formed after 13 hours (∼ 1200 µM) when compared to the P450cam system. Overall,
the P450cam systems provided higher conversions (2.8 - 4 mM of 4-hydroxyisophorone)
to product over the P450BM3 systems (Figure 57 and 58).
(a) RLYFFAIP (b) WFAL
Figure 58: GC-BID analysis of the in vivo turnover of (a) WFAL-P450cam and (b) RLYFFAIP-
P450BM3 with isophorone at 7h (gray) and 20h (black). For WFAL-P450cam, it is apparent that
majority of the substrate (4 mM) was consumed after 20 h to show an increase in product levels at 7
h (∼ 970 µM) to 20 h (> 2.5 mM). The isophorone substrate (tR = 5.8 min), internal standard (IS)
(tR = 12.8) min and 4-hydroxyisophorone tR = 15.83 min) are shown. The chromatograms have been
slightly offset along the x - and y-axes for clarity.
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4.2.3 The Oxidation of Cineoles by P450cam Mutants
1,8-Cineole and 1,4-cineole possess bicyclic-2.2.2 and 2.2.1 structures, respectively, that
are largely similar in size and shape to (+)-camphor. The two cineoles possess an
ether oxygen rather than the carbonyl group found in camphor. For the cineoles, the
established literature numbering system for both structures is shown in Figure 59.96
(a) (b)
Figure 59: Chemical numbering and stereochemical nomenclature of (a) 1,8-cineole and (b) 1,4-cineole.
In order to discuss the stereochemistry of the products formed, the descriptors α and β will be used.
The α descriptor is used to define substituents that sit below the plane that passes through the C2,
C3, C5 and C6 centres, while β is employed for substituents that sit above this plane. The structure
of both cineoles are meso and achiral, whereby any functionalisation at either methylene bridge will
generate three new stereogenic centres at the C1, C4 and hydroxylated carbon. Therefore, if a carbon
after hydroxylation generates the R-C1 isomer, it is defined as a pro-R carbon and a carbon that
produces the S -C1 isomer is a pro-S carbon.
Previous studies on the oxidation of cineoles by P450s include the enantiospecific
hydroxylation of 1,8-cineole by CYP176A1 (P450cin) to form (1R)-6-β-hydroxy-1,8-
cineole. Wild-type P450cam has also been used to oxidise 1,8-cineole, albeit less selec-
tively to form (1S )-6-α-, 5-α- and 5-β-hydroxy-1,8-cineole.104 The latter two products
are primarily formed as the (1S ) enantiomer and the products were made in a 18:68:14
ratio. WT-P450cam and P450cin were screened alongside the P450cam variants.
The P450cam mutant variants were initially screened for 1,8- and 1,4-cineole oxidation
using the whole-cell systems with analysis by chiral GC. The variants which displayed
high yield and selective formation of products were scaled up accordingly and their
metabolites extracted and isolated. Products were identified via MS fragmentation
pattern data from previous studies and with comparison to metabolite product stan-
dards of the WT-turnover for the 1,8-cineole products.104
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4.2.3.1 1,8-Cineole Oxidation by P450cam Mutants
The products formed from the WT control include 6-α-, 5-α- and 5-β-hydroxy-1,8-
cineole (Figure 60) and the MS fragmentation data matched those previously reported
(Appendix B16).104 It would be expected that the (S )-enantioselectivity is also pre-
served with these metabolites formed. Several of the P450cam mutants displayed altered
product distribution for 1,8-cineole oxidation when compared to WT. The metabolites
formed were the same as those in the WT. For example, compared to the WT enzyme,
the mutant F87V/Y96F/L244A (VFA) showed increased formation of 6-α-hydroxy-1,8-
cineole which was the major product (90 %), while 5-α and 5-β hydroxylation products
were formed in lower amounts at 8 % and 2% respectively (Figure 60 and 61).
Mutant F87W/Y96F/L244A/V247L (WFAL) had a preference towards 5-α-hydroxy-
1,8-cineole (85 %). The other metabolites formed were the 5-β- and 6-α-hydroxy
products (Figure 60 and 61). The F87W/Y96F/L244A mutant (WFA) showed an
even stronger preference for 5α hydroxylation (90 %) and only the 5β metabolite was
produced as the minor product (Figure 60 and 61). However, the product formation
level was almost 10-fold lower for the WFA mutant when compared to the WFAL
variant (Figure 61). In previous studies with WT-P450cam, enantioselective GC was not
able to determine the optical purity of the 5-hydroxy-1,8-cineoles formed. Oxidation
of the 5-hydroxy variants to 5-ketocineole produced the (1S ) enantiomer in 86 % e.e.,
this could also be the enantiomer of the products from the 5-α/5-β hydroxylations for
the mutants but this needs to be determined.104
Figure 60: Product distribution of 1,8-cineole in vivo turnovers by WT-P450cam mutants. Products
from P450cin and P450BM3 turnovers are given for comparison.
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Figure 61: GCMS analysis of 1,8-cineole in vivo turnovers by WT-P450cam (red), variants WFAL
(blue), VFA (purple), WFA (black) and P450cin (gray). Products shown are (1R)-6-β-hydroxy-1,8-
cineole (6β, tR = 7.5 min), 6-α-hydroxy-1,8-cineole (6α, tR = 7.7 min), 5-α-hydroxy-1,8-cineole (5α,
tR = 7.9 min), 5-β-hydroxy-1,8-cineole (5β, tR = 8.2 min). For clarity, the chromatograms were offset
along the x - and y-axes.
The screening of only a small library of P450cam mutants has allowed for the selective
oxidation of different C-H bonds within 1,8-cineole to favour a specific product, i.e.
the VFA mutant favours the 6-α- derivative, while WFAL mutant favours the 5-α-
derivative instead.
4.2.3.2 1,4-Cineole Oxidation by P450cam Mutants
Screening of the P450cam mutant library with 1,4-cineole was carried out alongside WT-
P450cin. P450cin was able to oxidise 1,8-cineole in a stereoselective manner (Figure 60),
but its oxidation of 1,4 cineole generated multiple products. These were analysed by
GC and GC-MS (Figure 62). The MS fragmentation patterns of the major prod-
ucts (Appendix B17) formed were consistent with previously published MS data of
8-hydroxy-, 2-β- and 3-β-hydroxy-1,4-cineole.144–147 The former two metabolites were
the major products formed with WT-P450cin. The P450cin turnover also showed low
amounts of an additional product (A) observed under GC-MS with a retention time
close to that of the substrate (1,4-cineole, tR = 4.15 min; Product A, tR = 4.2 min).
The MS spectrum of A when compared to the 1,4-cineole substrate (m/z = 154.3)
was consistent with a desaturation product being two mass units lower (m/z = 152.1,
Appendix B17g).
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Figure 62: GC-MS analysis of 1,4-cineole (black) and 1,8-cineole (red) in vivo oxidation by P450cin.
Substrates and products are labelled as follows: 1,4-cineole (1,4, tR = 4.1 min), 8-hydroxy-1,4-cineole
(8-hydroxy, tR = 6.0 min), 3-β-hydroxy-1,4-cineole (3-β, tR = 6.85 min), 2-β-hydroxy-1,4-cineole (2-β,
tR = 7.15 min), 1,4-cineole desaturation product (A, tR = 4.15). 1,8-cineole (1,8, tR = 4.3 min) and
its oxidation product, 6-β-hydroxy-1,8-cineole (6-β, tR = 7.5 min) were present as impurities.
The 1,4-cineole sample used was always contaminated with small amounts of 1,8-cineole
(Figure 62). Colleagues at the University of Queensland had access to a wide range
of hydroxy-cineole metabolites from other studies with P450cin mutants. The extracts
from the larger scale turnovers were sent to them for further characterisation. This
enabled facile confirmation of metabolites arising from 1,4-cineole oxidation as opposed
to those from the 1,8-cineole contaminant (Figure 62).
1,4-Cineole oxidation by WT-P450cam (Figure 63b) resulted in a low yield of metabo-
lites. The major product formed appears to be the 8-hydroxy metabolite and the
remaining products were identified as 3-α- and 2-α-hydroxy-1,4-cineole. A number of
the P450cam mutants displayed improved product yields and higher regioselectivity in
the oxidation of 1,4-cineole (Figure 63b). The variant WFA displayed a strong pref-
erence for oxidation at the 3-α- position (90 %) and similar levels of regioselectivity
was also observed with the WFAL mutant. The 3-α- product from the WFA turnover
was crystallised, which confirmed the relative configuration of the product and deter-
mined the absolute configuration as (1S ).105 The remaining products from the WFA
and WFAL turnovers (Figure 63b) were identified by their MS fragmentation patterns
(Appendix B17). These were confirmed either via their NMR spectra and/or GC-





Figure 63: (a) Product distribution and (b) GCMS analysis of 1,4-cineole turnovers by WT-P450cam
(red), variants LF (purple), WFA (green), WFAL (blue). Products identified include: 8-hydroxy-1,4-
cineole (8-hydroxy, tR = 6.0 min), 3-β-hydroxy-1,4-cineole (3-β, tR = 6.85 min), 2-β-hydroxy-1,4-
cineole (2-β, tR = 7.15 min), 3-α-hydroxy-1,4-cineole (3-α, tR = 7.3 min), 2-α-hydroxy-1,4-cineole
(2-α, tR = 7.65 min), 9-hydroxy-1,4-cineole (9-hydroxy, tR = 8.25 min). The 1,4-cineole desaturation
product was labelled as A (tR = 4.15 min). All 1,4-cineole samples have small amounts of 1,8-cineole
and impurities and products arising from 1,8-cineole oxidation are marked with *. For clarity, the
chromatograms were offset along the x - and y-axes.
The mutant F87L/Y96F (LF) favoured hydroxylation on the isopropyl moiety to give
rise to 8-hydroxy-1,4-cineole (85 %) with product formation levels of this product
far exceeding those observed with WT-P450cam by approximately 10-fold (Figure 63).
Minor products observed include 2-β-, 2-α- and 9-hydroxy-1,4-cineole (Figure 63). The
LF variant also generated increased levels of the desaturation product A at 4.15 min.
There appeared to be a trend in the increase of product A with the increasing levels
of 8-hydroxy-1,4-cineole amongst the mutants tested (Figure 63). The desaturation
product A likely has an alkene between the C8 and C9 carbons of the isopropyl moiety
of 1,4-cineole and hence has been assigned as such (Figure 63a).
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4.2.3.3 Comparison between Different Bacterial P450 systems for Cineole
Oxidation
Separate investigations into the use of P450BM3 mutants for the selective oxidation
of the two cineoles identified several mutant enzyme systems that can oxidise both
substrates in a regioselective manner.105 For 1,8-cineole oxidation, mutants GVQ and
R47L-Y51F-A74G-F87V-L188Q (RLYFGVQ) were able to oxidise 1,8-cineole selec-
tively to form 6-α-hydroxy-1,8-cineole (Figure 60). For 1,4-cineole oxidation, mutant
RLYFFAIP was selective for 3-β-hydroxy-1,4-cineole (Figure 63a).105 A comparison
between both P450 in vivo systems was carried out to compare the relative amounts of
product formed between the most selective cineole oxidation systems. P450 mutants
of both systems relevant to cineole oxidation were transformed into E. coli BL21(DE3)
cells. All systems generated similar levels of cell biomass (13 - 17 gram of cell wet
weight per litre of cell culture, Table B1). The P450cam systems again displayed lower
levels of the P450 (10 - 98 nM) compared to the P450BM3 mutants (86 - 108 nM).
In contrast to the isophorone oxidations, the P450BM3 mutants displayed higher levels
of product formation for both cineoles. GVQ and RLYFGVQ were able to produce
2.26 mM ± 0.4 mM of 6-α-hydroxy-1,8-cineole after 16 h from the addition of 4 mM
of 1,8-cineole (Figure 64a and 64b).
(a) P450BM3-GVQ (b) P450BM3-RLYFGVQ
(c) P450cam-VFA (d) P450cam-WFA
Figure 64: Whole cell turnovers of (a) P450BM3-GVQ and (b) RLYFGVQ, (c) P450cam-VFA and (d)
WFA with 1,8-cineole at 6 h (black) and 16 h (grey). Products observed include 6-α-hydroxy-1,8-
cineole (6α, tR = 8.01 min), 5-α-hydroxy-1,8-cineole (5α, tR = 8.4 min) and 5-β-hydroxy-1,8-cineole
(5β, tR = 8.52 min). For clarity, the chromatograms were offset along the x - and y-axes.
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1,8-Cineole oxidation by the VFA mutant also produced 1.0 ± 0.4 mM of 6-α-hydroxy-
1,8-cineole but the WFA variant gave even lower yields of 5-α-hydroxy-1,8-cineole (Fig-
ure 64c and 64d). For the 1,4-cineole turnovers, the RLYFFAIP mutant generated high
amounts of 3-α-hydroxy-1,4-cineole (2.0 ± 0.1 mM) under the same conditions (Fig-
ure 65a). The yields for the P450cam systems were consistently lower than P450BM3
for both cineoles (Figure 64 and 65) and appeared to be in agreement with the lower
amounts of P450 detected for this system. Mutant WFA was still capable of generating
approximately 1.0 ± 0.4 mM of 3-α-hydroxy-1,4-cineole (Figure 65c). The LF variant
only produced 470 µM of 8-hydroxy-1,4-cineole alongside the 2-α-hydroxy metabolite
(Figure 65b). Unknown oxidation products were also present for mutants RLYFFAIP
($, m/z = 170.15, Appendix B18) and LF (#, m/z = 168.15, Appendix B18).
(a) P450BM3-RLYFFAIP (b) P450cam-LF
(c) P450cam-WFA (d) P450cin
Figure 65: Whole cell turnovers of (a) P450BM3-RLYFFAIP, (b) P450cam-LF and (c) WFA, (d) P450cin
with 1,4-cineole at 6 h (black) and 16 h (grey). Unknown oxidation products were labelled as # and $.
Products observed include 8-hydroxy-1,4-cineole (8-hydroxy, tR = 6.4 min), 2-α-hydroxy-1,4-cineole
(2α, tR = 7.8 min), 2-β-hydroxy-1,4-cineole (2β, tR = 7.5 min) and 3-α-hydroxy-1,4-cineole (3α, tR
= 7.6 min). For clarity, the chromatograms were offset along the x - and y-axes.
The P450BM3 mutant systems overall provided better biocatalytic conversions of the
cineoles compared to the P450cam systems in these whole-cell turnovers. In spite of this,
the WT-P450cam system was able to unselectively convert 1,8-cineole (4 mM total) to its
three hydroxy products at levels similar to the P450BM3 mutants (> 2.0 mM) (Figure
69
66). The higher yields of WT-P450cam and the high in vivo product formation for
isophorone with P450cam systems tested previously, suggests that further optimisation
of the systems could be used for larger scale production of these metabolites in a
selective manner. Further investigation into the in vitro activity and binding properties
of the P450cam variants would also provide insights into how these systems could be
improved.
Figure 66: Whole-cell turnover of WT-P450cam with 1,8-cineole, where the samples were taken at
6 h (bottom) and 16 h (top). It can be seen after 16 h, a majority of the substrate was converted
to products. Products identified include 6-α-hydroxy-1,8-cineole (6α, tR = 8.01 min), 5-α-hydroxy-
1,8-cineole (5α, tR = 8.4 min) and 5-β-hydroxy-1,8-cineole (5β, tR = 8.52 min). A possible further
oxidation ketone product was labelled as $ at tR = 7.35 min. For clarity, the chromatograms were
offset along the x - and y-axes.
The enantioselectivity of both P450BM3 and P450cam mutants were assessed. To better
resolve any hydroxy cineole enantiomers via chiral GC analysis, the metabolites were
derivatised to their corresponding trifluoroacetate esters and the enantioselectivity was
analysed for each turnover (Figure 67 and 68).96,104
Mutants P450BM3-GVQ and RLYFGVQ produced the same major product (6-α-
hydroxy-1,8-cineole) as mutant P450cam-VFA. GC-chiral analysis of their derivitised
turnover extracts showed that the 6-α-hydroxy metabolite of the P450cam-VFA turnover
was resolved into one peak (Figure 67c). The two P450BM3 mutants resolved the same
metabolite into a smaller product peak alongside the major product (6-α, Figure 67a
and 67b, tR = 12.25 - 12.45 min)). This inferred that the product of the P450cam
mutant had higher e.e. than P450BM3 and therefore was more enantioselective. For
1,4-cineole oxidation, both P450BM3-RLYFFAIP and P450cam-WFA were selective for
the formation of 3-α-hydroxy-1,4-cineole (Figure 68, tR = 10.85 min). GC-chiral anal-
ysis showed the derivitised major product peak for both mutant enzymes resolved into
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one peak, this also suggests a high e.e. was possible for these mutants, though the peak
may not have been resolved by chiral GC. Further studies with comparisons to synthe-
sised racemic and chiral standards would be required to confirm the enantioselectivity
of these mutants with the cineoles.
(a) P450BM3-GVQ (b) P450BM3-RLYFGVQ
(c) P450cam-VFA (d) P450cam-WFAL
Figure 67: GC-chiral analysis of trifluoroacetate derivitised 1,8-cineole turnovers with (a) P450BM3-
GVQ and (b) P450BM3-RLYFGVQ, (c) P450cam-VFA and (d) P450cam-WFAL. Possible derivitised
enantiomers include 6-α-hydroxy-1,8-cineole (6-α, tR = 12.25 - 12.45 min) and 5-α-hydroxy-1,8-cineole
(5-α, tR = 12.5 - 12.7 min).
(a) P450BM3-RLYFFAIP (b) P450cam-WFA
Figure 68: GC-chiral analysis of trifluoroacetate derivitised 1,4-cineole turnovers with (a) P450BM3-
RLYFFAIP and (b) P450cam-WFA. Possible derivitised enantiomer include 3-α-hydroxy-1,4-cineole
(3-α, tR = 10.85 min).
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4.3 Discussion
Fenchone, fenchyl acetate, isophorone, and 1,8- and 1,4-cineole are molecules that
possess similar sizes and chemical functionalities to both camphor and pinene. The in
vivo screening of only a small library of P450cam mutants, designed primarily to oxidise
pinene, allowed for selective transformations of these substrates to produce their oxy-
metabolites in improved yield relative to the WT.46 Several of the oxidations have also
been shown to be enantioselective when this was determined.
Fenchone and fenchyl acetate oxidation by mutants Y96F and Y96A was selective for
the C5-C6-C7 face of both molecules. The carbonyl and acetate groups likely acted
as an anchor within the enzyme active site to bias this face towards the heme centre.
The introduction of alanine and phenylalanine mutations to the Tyrosine96 residue of
P450cam seem to have increased the product yield over the WT. A possible explanation
is that the less bulky residues provided more active site volume to accommodate the
larger fenchyl acetate and the different shape of fenchone compared to camphor.
There was greater selectivity with the Y96A variant in oxidising fenchyl acetate. This
mutant selectively hydroxylated the exo face of fenchyl acetate. Both exo and endo
hydroylation products were observed with fenchone oxidation by Y96F. Fenchone has
been oxidised to form the 6-endo, 6-exo, 10-hydroxy and 5-exo hydroxy products by
various organisms, including the bacterial organism, Salmonella typhimurium and the
common cutworm, Spodoptera litura.101,149,150 It has also been metabolised by human
microsomal CYP2A6 to form 6-endo, 6-exo and 10-hydroxyfenchone.140 Fenchyl acetate
oxidation has only been reported with CYP101B1 and forms the 5-exo hydroxy product.
For both substrates, the formation of the 7-hydroxy product via biotransformation
using a P450 enzyme or otherwise has not previously been reported.
The enantioselective production of (R)-4-hydroxyisophorone in high yield was achieved
using two P450cam mutants, WFL and WFAL, with the latter displaying the highest
yield of the desired product. Isophorone differs from the other substrates tested here
in that it lacks a bicyclic structure and possesses an alkene moiety. The oxidation of
isophorone by the WFAL mutant has also been studied concurrently in a separate in-
vestigation by Turner et al. and our results agree with their findings.142 Their docking
studies with the WFAL mutant and isophorone have suggested that the L244A muta-
tion introduces additional space to accomodate the dimethyl groups, while the longer
side chain of the V247L residue might push the bound isophorone closer to the heme
centre.142
4-Hydroxyisophorone is of considerable commercial value as a flavouring agent and an
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intermediate for the synthesis of natural dye pigments.133,134 The ability to produce
this compound via whole-cell biocatalysis would enable it to be generated on a large
scale.130–133 A study by Kaluzna and colleagues has already successfully scaled up a
turnover of WT-P450BM3 with isophorone in a fermentor system.
129 They successfully
produced 10 g L−1 of 4-hydroxyisophorone with cell densities 30 times than those used
in our experiments and space-time product yields of 1.5 g L−1 h−1. However, the in
vivo reaction of isophorone and WT-P450BM3 has been observed to give low yields and
activity,135 and the availability of more efficient and high yielding P450 systems such
as those reported here is encouraging for the scale up of this reaction.
The P450cam mutant library has also exhibited a diverse array of predominantly re-
gioselective oxidations of 1,8- and 1,4-cineole. These were also enantioselective in some
cases and this provides a significant development towards new enantio- and regiose-
lective hydroxylation pathways for cineoles. This circumvents the need for reactive
chemical reagents to functionalise the inherently chemically inert bonds of both com-
pounds.96 The selective formation of one cineole oxidation product in higher yield will
also aid in the isolation and purification of said product.
P450cin from Citrobacter braakii selectively produces (1R)-6-β-hydroxy-1,8-cineole from
1,8-cineole.104 The same reaction has also been reported with a Rhodcoccus bac-
terium.20,96 1,4-Cineole oxidation by P450cin (Figure 62) was not as selective as its
1,8 analogue. The preference for 1,8-cineole by P450cin despite their similar structures
indicates P450cin has evolved specifically to oxidise 1,8-cineole to form the hydroxy
metabolite. This is unsurprising, as the hydroxylation of its substrate is the first step
of 1,8-cineole metabolism within C.braakii.151 The complementary (1R)-6-α-hydroxy
metabolite was reported to be a biotransformation product of 1,8-cineole by Bacil-
lus cereus.96 Oxidation products at the C2, C3, C4, C7 and C8 positions have also
been produced from the metabolism of various organims such as rabbits and human
microsomes, though in an unselective manner.96,152,153
A number of P450cam mutants within the library were able to hydroxylate 1,4-cineole
with high selectivity at either the C3 and C8 positions. 1,8-Cineole was hydroxylated
at the C5 and C6 positions. These metabolites have been produced previously in other
organisms, though mostly in a less selective manner as minor products.101,104,144–146
The selective nature of the P450cam mutant oxidations greatly expands the range of
metabolites that can be generated from 1,8- and 1,4-cineole. The P450cam mutants also
seem to favour the endo (α) face of the cineoles that would be sterically less hindered
than the exo (β) face. P450cin showed a very strong preference for the exo face. The
orientation of 1,8-cineole within P450cin is biased through a hydrogen bonding interac-
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tion between Asparagine242 (N242) and the cineole’s ether oxygen that orientates the
5-exo hydrogen above the heme for hydroxylation (Figure 69).154 An alanine mutation
introduced at N242 (N242A) was able to decrease the product selectivity and oxidation
from the endo face was significantly increased.104,154
Figure 69: Active site of Cytochrome P450cin with bound 1,8-cineole (PDB ID: 1T2B). The Asn242
residue has a hydrogen bonding interaction with the ether oxygen of 1,8-cineole.154
WT-P450cam was previously reported to be selective for (1S )-6-α-hydroxy-1,8-cineole
and this metabolite was also produced by mutant VFA when oxidising 1,8-cineole.104
The mutant formed one enantiomer of the 6-α metabolite with high e.e. based on
the single peak resolved via GC-chiral analysis of the trifluoroacetate ester derivative
as according to previous methods (Figure 67c).104 The identity of this enantiomer
is likely to be in the (S ) configuration as the WT but comparison to known chiral
standards would be needed to confirm this. The 3-α enantiomer formed by P450cam-
WFA oxidation of 1,4-cineole also appeared to be formed with high e.e. based on GC-
chiral analysis (Figure 68). It was crystallised by our colleagues with a (1S ) absolute
configuration.105
The 1,8-cineole hydroxy products were easily identified as they were already metabolites
generated by WT-P450cam. However, the mutant enzymes altered the selectivity of the
1,8-cineole oxidation and this was exemplified by the WFA and VFA mutants which
catalysed the selective production of the 5α and 6α isomers respectively (≥ 90 %).
The production of the desaturated alkene metabolite of 1,4-cineole was greatest for
the LF mutant and this could be potentially used to investigate this unusual P450
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transformation.
Comparisons of the whole-cell systems between P450cam and P450BM3 displayed con-
trasting behaviours for isophorone and cineole oxidations. The cell wet weights per
litre for P450 systems used were largely consistent across all mutant P450cam and
P450BM3 systems but the enzyme concentrations detected were lower for P450cam sys-
tems. P450BM3 is a single species fused to its electron transfer partner. However,
P450cam must be produced with its two electron transfer partners which could decrease
the yield.
Despite the low P450 concentration, P450cam systems displayed greater product yields
for isophorone oxidations over a longer period of time. However, the P450BM3 mutants
gave greater product yields with cineoles using similar conditions. This could suggest
that the cineoles were better substrates for P450BM3 systems and isophorone was more
suited for the P450cam systems instead. However, direct comparison between two P450s
from widely different electron transfer systems, i.e. three component Class I versus
fused Class VIII systems respectively is not trivial. This is because P450BM3 may
also require different cellular NADPH concentrations and possess different co-factor
regeneration rates against that of the NADH used by P450cam.
155–158 In vitro studies
would be needed to confirm the preference of each system for these substrates.
Regardless, it has been shown that functional whole-cell oxidation systems for both
P450cam and P450BM3 mutants are capable of oxidising a variety of monoterpenoids
in good yield. These systems were scaled up for product isolation in a non-optimised
manner in shake flasks and it is likely these oxidations can be made more efficient
with further study. The oxidations here were found to be regioselective through the
use of mutant enzymes. Therefore it is possible that further protein engineering of
these enzymes could increase the activity of these or other P450 enzymes towards the
biotransformation of monoterpenoids and other related compounds.
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5 Oxidation of Fragrance Compounds by P450s
5.1 Introduction
The potential of developing new aroma compounds from the biocatalytic oxidation of
existing fragrances makes P450 enzymes especially valuable. P450 enzymes such as
CYP101B1 are capable of hydroxylating compounds that include ionones and dam-
ascones with high efficiency.61,62 Monoterpenoid acetates have also been hydroxylated
with high activity by CYP101B1. The presence of the acetate moiety in these sub-
strates is hypothesised to mimic the butenone side chain in norisoprenoids.101
Mutant variants of P450BM3 have also been observed to oxidise ionones and terpenes in
a selective manner.74 For example, P450BM3 mutant variant GVQ has been developed
for α-pinene oxidation and mutant R47L/Y51F/F87V can oxidise β-ionone with high
selectivity.74,159
A selection of fragrance compounds will be screened for selective and high yield genera-
tion of metabolites with CYP101B1 and P450BM3-GVQ (Figure 70) . These compounds
possess molecular architectures similar to the above mentioned substrates that can be
efficiently oxidised by these enzymes.
Figure 70: Fragrance compounds with norisoprenoid and acetate structures.
The norisoprenoid compounds, α-damascone, δ-damascone, dynascone and α-iso-
methylionone have similar structures to β-ionone (Figure 70). All four of these com-
pounds possess pleasant floral and fruity aromas that have considerable commercial
value.160 The damascones are known to possess potent odour blocking properties and
are important components in deodorants and perfumes.161,162 The key structural dif-
ferences between these compounds compared to β-ionone is the differing alkene and
carbonyl positions on the side chain. Dynascone and α-iso-methylionone also pos-
sess longer alkyl side chains. The alkene position on the ring also differs between the
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four compounds and this alongside the altered side chains could have an effect on the
binding to and oxidation by P450 enzymes.
Monoterpenoid acetate esters have also been oxidised with high yield and efficiency
by CYP101B1.101 Therefore a selection of acetate and ester compounds with ring and
side chain moieties similar to ionones and monoterpenoids will also be screened with
the aforementioned P450 enzymes. These substrates include cuminyl acetate, verdyl
acetate, dihydroflorate and ethyl safranate. They all possess a 6-membered ring and
a carbonyl moiety within their structure. For example, ethyl safranate possesses an
ethyl formate group attached to a ring structure with two ring alkenes and methyl
substitutions in the same positions as the norisoprenoids (Figure 70). As with the
norisoprenoids, these acetate compounds also possess pleasant aromas and the oxidised
derivatives of these compounds may also provide new sensory properties.
In vitro and in vivo screening of these substrates with CYP101B1 and P450BM3-GVQ
will be carried out. Whole-cell turnovers that displayed selective oxidation profiles and
high conversion/yield will be scaled up as before. The products of these high yielding
turnovers will be isolated and characterised.
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5.2 Results
Initial in vitro binding studies of CYP101B1 were first carried out on the chosen sub-
strates (Figure 70). Amongst the substrates tested, the norisoprenoid derivatives, δ-
and α-damascone, dynascone and α-iso-methylionone induced the highest changes in
spin-state with CYP101B1 (65 - 95 %, Table 12, Figure 71). The similarity in structure
between these substrates and β-ionone would be expected to enable them to bind to
the active site pocket of CYP101B1 with high complementarity.
Table 12: Spin-state shift data for CYP101B1 and P450BM3 with different substrates.










aNo spin-state shift observed.
(a) (b)
(c) (d)
Figure 71: Spin-state shift studies of WT-CYP101B1 with (a) δ-damascone, (b) α-damascone, (c)
dynascone, (d) α-iso-methylionone.
78
Addition of ester compounds, ethyl safranate and dihydroflorate to CYP101B1 also
generated a significant spin-state shift (60 - 90 % HS, Figure 72).
The remaining ester compounds, cuminyl and verdyl acetate showed minor changes in
the spin-state when added to CYP101B1 (Table 12). Ethyl safranate and dihydroflorate
both possess an ethyl formate side chain that is comparable in length to the butenone
moiety in the norisoprenoids. They also contain ring structures which are similar to the
norisoprenoids. Ethyl safranate has an additional ring alkene while dihydroflorate has a
saturated ring system. The similar ring structure and side chains of these substrates are
likely to contribute to the greater spin-state shift observed with CYP101B1 compared
to cuminyl and verdyl acetate.
(a) (b)
Figure 72: Spin-state shift study for (a) ethyl safranate and (b) dihydroflorate with WT-CYP101B1.
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Next, the turnover of the compounds by the complete CYP101B1 system were assessed
to determine the catalytic activity and production formation, where oxidation products
were identified using GC-MS analysis based on the change in mass (∆m/z ) compared
to the substrate. The NADH oxidation rate of CYP101B1 with dihydroflorate (1235
min−1) was comparable with the oxidation of β-ionone61 (1600 min−1) but resulted in
low levels of product formation (Figure 74). This is reflected in a low coupling efficiency
(24 %).
GC-MS analysis of the dihydroflorate turnover showed the formation of three products
that all show MS spectra consistent with substrate oxidation (m/z = 200, ∆m/z = +16,
Appendix C.1). The three products formed are presumed to correlate with the three
substrate peaks (D1, D2, D3) observed by GC-MS (Figure 74). The dihydroflorate
sample supplied displayed three peaks by GC-MS analysis. All three peaks in the
supplied dihydroflorate possessed similar mass spectra (Appendix C.1). Dihydroflorate
possesses three chiral centres and the sample could contain different diastereomers
(Figure 73).
Figure 73: Structure of dihydroflorate where chiral centres are marked with *.
Figure 74: GC-MS analysis of the in vitro turnover of dihydroflorate (m/z = 184) with WT-CYP101B1
(black) with substrate control (red). Products at tR = 7.75, 7.85 and 8.08 min had mass spectra
consistent with an addition of an oxygen atom (m/z = 200, ∆m/z = +16). Dihydroflorate has three
chiral centres and could be composed of different diastereomers as evidenced by the 3 peaks (D1, D2
and D3). These had similar mass spectra which were consistent with isomers of dihydroflorate.
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Addition of ethyl safranate also induced a high NADH oxidation rate in the CYP101B1
system (837 min−1). Higher levels of product formation compared to the dihydroflorate
turnover were observed and were reflected in the coupling efficiency of the turnover
(32 %). The supplied ethyl safranate also possessed three peaks that had similar
mass spectra (Appendix C.2). Ethyl safranate is known to be produced commercially
as a mixture of its α, β and γ-isomers, where the ratio between them depends on
the reaction conditions used to generate the sample (Figure 75).163,164 At least six
metabolites (Figure 76) could be assigned as oxidation products (m/z = 200, ∆m/z
= +16) based on their mass spectra detailed in Appendix C.2. The presence of two
alkenes within the ethyl safranate ring structure would likely favour epoxidation by
CYP101B1 (see δ-damascone in Chapter 5.2.1.1) and the multiple products formed
could be diastereomers of these epoxides.
Figure 75: Different isomers of ethyl safranate.
Figure 76: GC-MS analysis of the in vitro turnover of ethyl safranate (m/z = 184) with WT-
CYP101B1 (black) with substrate control (red). Products at tR = 7.7, 7.8, 8.1, 8.15, 8.22 and
8.43 min had mass spectra consistent with an addition of an oxygen atom (∆m/z = +16). Substrate
possessed 3 peaks (E1, E2 and E3) that had similar mass spectra that are likely to be the α, β and
γ-isomers of this substrate.163,164
The norisoprenoid compounds, α-damascone, δ-damascone, dynascone and α-iso-
methylionone all displayed high rates of NADH oxidation (495 - 850 min−1). These
high rates are in good agreement with the high spin-state shifts observed for these sub-
strates. This further indicates the high complementarity between these substrates and
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CYP101B1. The coupling efficiency and levels of product formation were the highest
for the damascones (50 - 60 %, Figure 77).
(a) (b)
Figure 77: GC-MS analysis of the in vitro turnovers of CYP101B1 (black) with (a) δ-damascone (m/z
= 192) where products were identified at tR = 8.9, 9.0, 9.14, 9.4 min and (b) α-damascone (m/z =
192) with products at tR = 9.0, 9.25, 9.3, 9.55 min and 9.8 min. Mass spectra for the products of
both substrates were consistent with either oxidation (m/z = 208, ∆m/z= +16) or further oxidation
(m/z = 206, ∆m/z = +14) (Appendix C.3 and C.4). The α-damascone may have shown a possible
desaturation product at tR = 7.5 min (∆m/z = -2). Substrate controls are shown in red. Impurities
are labelled as *. For clarity, chromatograms were offset along the x axis for (b).
δ-Damascone oxidation by CYP101B1 formed four metabolites with one metabolite at
tR = 9.4 min being produced nearly 10-fold higher over the other metabolites (Figure
77a). α-Damascone formed five products upon oxidation by CYP101B1 and was less
selective overall compared to the turnover of the δ-derivative, though there were two
major metabolites at tR = 9.3 and 9.55 min (Figure 77b).
The two damascone turnovers contained mainly monooxygenase products (m/z = 208,
∆m/z = +16). There was also evidence for products, that were present in lower
amounts, with m/z = 206 (∆m/z = +14), the change in mass by two units compared to
the oxidation product would indicate that an oxygen has been added to the compound
with an additional abstraction of hydrogen to generate a ketone further oxidation
product (Appendix C.3 and C.4). Additionally, it could also arise from epoxidation
of a desaturated metabolite. A desaturated metabolite was also present within the
α-damascone turnover (m/z= 190, ∆m/z = -2) at tR = 7.5 min.
Compared to the damascones, α-iso-methylionone and dynascone formed lower
amounts of product with CYP101B1. This is reflected in their lower coupling effi-
ciency (32 - 39 %, Table 13). Based on MS analysis, the α-iso-methylionone (m/z =
206) turnover formed two oxidation metabolites (m/z = 222, ∆m/z = +16) as the ma-
jor products while four other further oxidation products were also observed in smaller
amounts (m/z = 220, ∆m/z = +14) (Figure 78a).
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The dynascone (m/z = 192) turnovers formed 3 products (m/z = 208, ∆m/z = +16)
(Figure 78b). One of these at tR = 9.82 min was formed in significantly higher yield
based on its peak area (75 %) than the remaining two products. Mass spectra of the
oxidation products for both substrates were detailed in Appendix C.5 and C.6.
These two substrates were also supplied as multiple isomers which were detected via
GC-MS analysis and their isomers possessed similar mass spectra (Appendix C.5 and
C.6). Dynascone is known to be produced commercially as both its α and β iso-
mers.165 α-iso-Methylionone is also produced alongside a mixture of isomers and the
composition depends on the manufacturing route.163 The two isomers present for these
two substrates were likely both oxidised by CYP101B1 to form the multiple products
observed.
(a) (b)
Figure 78: GC-MS analysis of the in vitro turnovers of CYP101B1 (black) with (a) α-isomethylionone
where products were identified at tR = 10.1, 10.3, 10.4, 10.5, 10.6 and 10.65 min. (b) Dynascone
turnover with products at tR = 9.82, 9.88 and 10.1 min. Mass spectra for the products of both
substrates were consistent with either oxidation (∆m/z= +16) or further oxidation (∆m/z = +14).
Substrate controls are shown in red. The substrate controls exhibited two peaks with similar mass
spectra. Impurities are labelled as *. For clarity, chromatograms were offset in either the x - or y-axes.
CYP101B1 mediated oxidation of cuminyl acetate resulted in no product formation
when analysed by GC-MS, this was despite a moderate NADH oxidation rate of 365
min−1 (Table 13). The GVQ mutant of P450BM3 is a highly active variant that is
capable of oxidising a range of non-natural substrates including alkanes, arenes and
branched fatty acids.166,167 We wished to investigate whether this variant was capable
of oxidising the fragrance compounds used here, especially the ones that CYP101B1
could not.
P450BM3-GVQ catalysed oxidation of cuminyl acetate (m/z = 192) formed two metabo-
lites (Figure 79) with an NADH oxidation rate of 465 min−1. The major metabolite
formed at tR = 9.3 min had a mass (m/z = 208.1) consistent with oxidation activity
(∆m/z = +16) (Appendix C.7). The minor metabolite formed (tR = 8.48 min, m/z
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= 190.1) had a mass two units (∆m/z = -2) lower than the substrate that agrees with
the presence of a desaturation product.
Figure 79: GC-MS analysis of the in vitro turnover of cuminyl acetate with P450BM3-GVQ (blue) and
CYP101B1 (black) with substrate controls (red). Products at tR= 8.48 and 9.3 min. Mass spectra of
the products indicated a desaturation (m/z = 190, ∆m/z = -2) and oxidation (m/z = 208, ∆m/z =
+16) products.
CYP10B1 and P450BM3-GVQ were both capable of oxidising verdyl acetate (m/z =
192). The NADH oxidation rate (Table 13) was faster for CYP101B1 (664 min−1)
than it was for P450BM3-GVQ (111 min
−1). CYP101B1 was selective for the formation
of a single product but the P450BM3 variant formed two metabolites (Figure 80). All
products had mass spectra indicative of a monooxygenase reaction (m/z = 208, ∆m/z
= +16, Figure 81). Despite the similar retention times, the different mass spectra of
all three products suggests there were no metabolites formed in common between the
CYP101B1 and the P450BM3-GVQ systems (Figure 81). Impurities were also present
within the verdyl acetate sample that were not identified.
Figure 80: In vitro turnover of verdyl acetate with P450BM3-GVQ (blue) and CYP101B1 (black).
Products at tR = 9.75 and 9.8 min were identified as oxidation products (∆m/z = +16) based on
their mass spectra. Impurities are labelled with *.
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(a) Mass Spectrum of in vitro verdyl acetate oxidation product with with m/z = 208.1 formed
with P450BM3-GVQ, tR = 9.75.
(b) Mass Spectrum of verdyl acetate in vitro oxidation product with m/z = 208.1 and tR =
9.8 min formed with P450BM3-GVQ. Product was identified as 6-hydroxy-verdyl acetate.
(c) Mass Spectrum of verdyl acetate oxidation product with m/z = 207.8, tR = 9.85 min
formed with CYP101B1.
Figure 81: Mass Spectrum of verdyl acetate oxidation products formed in vitro with different P450
systems.
Table 13: Substrate binding and in vitro turnover data for CYP101B1 and P450BM3 with different
substrates. The data are given as mean ± S.D. with n ≥ 3. Rates are given as nmol.nmolP450−1.min−1.
Enzyme Substrate NADH PFR Coupling Efficiency (%)
CYP101B1
δ-Damascone 705 ± 32 417 ± 35 59 ± 3
α-Damascone 890 ± 10 457 ± 33 52 ± 3
Dynascone 495 ± 94 66 ± 20 13 ± 3
α-Methylionone 850 ± 38 325 ± 9 39 ± 3
Ethyl Safranate 837 ± 49 264 ± 41 32 ± 4
Verdyl Acetate 664 ± 100 190 ± 10 29 ± 3
Dihydroflorate 1235 ± 300 296 ± 70 24 ± 0.01
Cuminyl acetate 365 ± 25 -b -b
P450BM3-GVQ
c
Cuminyl acetate 465 ± 36 76 ± 16 11 ± 2
Verdyl acetate 111 ± 11 11 ± 2 10 ± 1
aNo product formation. bNot measured. cWhole-cell oxidations of P450BM3-GVQ with the
remaining fragrance compounds tested had low product yield.
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5.2.1 Scale up of Product Formation using CYP101 and CYP102 Whole-
Cell Oxidation Systems
In vivo whole-cell oxidation systems enable large scale and facile biocatalytic produc-
tion of metabolites. In order to generate the products from the turnovers in large
enough quantities for isolation and identification, enzyme systems of CYP101B1 and
P450BM3 were used with the fragrance compounds. They were chosen based on the in
vitro turnovers reported above, whereby δ- and α-damascone, cuminyl acetate, verdyl
acetate, α-iso-methylionone, ethyl safranate and dihydroflorate had turnovers that
gave high levels of metabolite formation with either CYP101B1 or P450BM3-GVQ.
These were scaled up accordingly with the aim of identifying the metabolites.
The turnovers with α-iso-methylionone, ethyl safranate and dihydroflorate displayed
multiple product and substrate peaks that caused purification and product isolation
to be difficult (Figure 74, 76, 78a). Further study would be needed to isolate these
turnovers for characterisation and HPLC separation is likely required to isolate the
substrate isomers in a pure form before metabolite formation and identification.
5.2.1.1 Whole-Cell Turnovers of δ-Damascone and α-Damascone
Whole-cell oxidation of δ-damascone showed metabolite formation for CYP101B1 (Fig-
ure 82), while the P450BM3-GVQ variant did not show any formation of product. One
major metabolite was produced in excess at tR = 9.4 min as per the in vitro turnover.
Two other minor metabolites were formed at tR = 8.9 and 9.0 min that were also
present in the in vitro turnover as seen in Figure 77a.
Figure 82: The oxidation of δ-damascone by CYP101B1 alongside the GC-MS analysis of the
CYP101B1 whole-cell turnover. Major metabolite produced was 3,4-epoxy-δ-damascone at tR =
9.4 min. Possible minor oxidation metabolites (∆m/z = +16) were formed at tR = 8.9 and 9.0 min.
Impurities were labelled as *.
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The major metabolite was extracted from the whole-cell turnover of CYP101B1. This
metabolite was purified by preparative HPLC, analysed by NMR and identified to
be 3,4-epoxy-δ-damascone (16 mg isolated yield, Appendix C20). That the metabolite
arose from epoxidation was determined via 1H and 13C NMR (Figure 83). The 1H NMR
spectrum showed only two alkene hydrogen signals and the presence of two signals with
high chemical shifts consistent with epoxide hydrogens (2.87 and 3.19 ppm).168 This
would indicate that alkene oxidation occurred and is confirmed by the loss of two sp2
carbons in the 13C NMR spectrum.
(a)
(b)
Figure 83: NMR data for 3,4-epoxy-δ-damascone that shows (a) an expansion of the 1H NMR data,
(b) 13C NMR data showing the alkene and epoxide signals for 3,4-epoxy-δ-damascone. Full data in
Appendix C20.
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HMBC analysis showed the epoxide signals were correlated with signals within the ring
structure (C1, C5, C2, C13) indicating that the C3/C4 ring alkene of δ-damascone was
oxidised. In addition, the alkene hydrogen signals correlated to the carbonyl group
(C7) and the butenone methyl (H10) group (Figure 84), which shows that the alkene
retained is located on the butenone side chain.
(a)
(b)
Figure 84: 1H-13C HMBC NMR data of (a) epoxide and (b) alkene signals for 3,4-epoxy-δ-damascone.
Epoxide signals show correlation to ring carbon signals (C1, C2, C5, C6) while the alkene signals show
correlation with the carbonyl (C7) and methyl hydrogens (H10) on the butenone side chain. Full data
in Appendix C22.
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ROESY NMR studies of the purified metabolite showed no through-space correlation
between the epoxide hydrogen signals (H3 and H4) and the butenone side chain. There-
fore, the epoxidation face cannot be definitively confirmed through the ROESY analysis
and further study would be needed to confirm the stereochemistry of the epoxide.
It is also worth noting that the selectivity of CYP101B1 for δ-damascone epoxidation is
in agreement with the hydroxylation of β-ionone at C3 or C4 and α-ionone at C3 by this
enzyme. The formation of the epoxide was not surprising as P450 alkene epoxidation
is an energetically feasible reaction. However, we note that epoxidation in α-ionone is
not observed after oxidation by CYP101B1 in any detectable quantity.
Figure 85: ROESY NMR data of epoxide signals for 3,4-epoxy-δ-damascone.
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The whole cell CYP101B1 turnover of α-damascone also generated high levels of prod-




Figure 86: (a) The oxidation of α-damascone by CYP101B1. (b) GC-MS analysis of the whole-cell
turnover of CYP101B1 with α-damascone. Metabolites produced include cis-3-hydroxy-α-damascone
(tR = 9.3 min), trans-3-hydroxy-α-damascone (tR = 9.55 min), and 3-oxo-α-damascone (tR = 9.80
min).
Products were purified using preparative HPLC from a larger scale turnover of
CYP101B1 and were characterised via NMR to be cis-3-hydroxy-α-damascone (12 mg
isolated yield, Appendix C23), trans-3-hydroxy-α-damascone (14 mg isolated yield,
Appendix C26) and 3-oxo-α-damascone (2 mg isolated yield, Appendix C29). The
NMR data for all 3 products matched data in the literature (Appendix C23, C26,
C29).169
ROESY NMR analysis further confirmed the relative orientation of the two diastere-
omers via through-space correlations between the H6 and H3 signals. For the cis
isomer, the H6 and H3 signal were correlated to the same H12 ring methyl group, in-
dicating they were cis to each other (Figure 87). The trans isomer instead had the H3
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and H6 signals correlated with H11 and H12 signals respectively (Figure 88), therefore
these two hydrogens are trans to each other on the ring.
(a)
(b) (c)
Figure 87: ROESY NMR data for (a) cis-3-hydroxy-α-damascone that shows correlations of the (b)




Figure 88: ROESY NMR data for (a) trans-3-hydroxy-α-damascone that shows correlations of the (b)
H6 and (c) H3 hydrogen signal. H6 is correlated through-space to the H11 methyl hydrogens while
H3 is correlated to the H12 signals instead.
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The regioselectivity of CYP101B1 for α-damascone was exclusively at the C3 posi-
tion. This was in agreement with the oxidation of α-ionone by both CYP101B1 and
CYP101C1, which also form the cis-, trans-3-hydroxy and 3-oxo derivatives.61,62 In
contrast to δ-damascone, no epoxidation products were formed from the oxidation of
α-damascone by CYP101B1.
5.2.1.2 Whole-Cell Turnovers of Cuminyl Acetate and Verdyl Acetate
Cuminyl acetate and verdyl acetate contain acetate groups attached to cyclic struc-
tures. Functionalisation of monoterpenes with acetate groups have enabled CYP101B1
to oxidise monoterpenoid derivatives more efficiently.101 With cuminyl acetate, we
wished to assess whether the acetate group can allow efficient oxidation of aromatic
compounds by P450 enzymes. CYP101B1 did not show any product formation with
cuminyl acetate which was in agreement with the in vitro turnover. P450BM3-GVQ
gave two products with cuminyl acetate (Figure 89).
(a)
(b)
Figure 89: (a) Oxidation of cuminyl acetate by P450BM3-GVQ. (b) GC-MS analysis of the P450BM3-
GVQ turnover with cuminyl acetate. Major metabolite formed was 4-(2-hydroxypropan-2-yl)benzyl
acetate (tR = 9.3 min). Possible desaturation product with the cuminyl acetate turnover is labelled
as # at tR = 8.30 min (m/z = 190, ∆m/z = -2).
A larger scale turnover of P450BM3-GVQ was carried out with cuminyl acetate and the
major product formed was extracted. The product was purified by preparative HPLC
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and identified by NMR to be 4-(2-hydroxypropan-2-yl)benzyl acetate (10 mg isolated
yield, Appendix C17). The oxidation site was confirmed by the loss of the septuplet
signal in the alkyl region within the 1H NMR spectrum (Figure 90). Therefore, the C8
benzylic hydrogen was abstracted by the P450 and this was the site of hydroxylation.
The NMR spectrum also indicated that symmetry of the initial substrate was preserved
within the oxidation product.
(a)
(b)
Figure 90: 1H NMR data of cuminyl acetate that shows the (a) aromatic region and (b) alkyl/benzylic
region. Symmetry is present on the molecule and the absence of a septuplet signal indicates the tertiary
isopropyl hydrogen on cuminyl acetate was the site of hydroxylation.
A secondary metabolite in the whole-cell turnover (# in Figure 89) that was also
present within the in vitro turnover was not isolated. This was likely a desaturation
product as identified via its mass spectrum (Appendix C.7), whereby compared to the
substrate (m/z = 192), the desaturation showed ∆m/z = -2. The hydroxylation of
cuminyl acetate at the isopropyl group by P450BM3-GVQ supports the formation of a
desaturated metabolite and it is likely that the alkene double bond would be located
between the C8 and C9 carbon on the substrate (Figure 91). A similar desaturation
activity was observed with the oxidation of 1,4-cineole by P450cam mutants (Chapter
4.2.3.2). The mechanism for desaturation is discussed in Figure 96.
Figure 91: Structure of the possible desaturation product formed by CYP101B1 with cuminyl acetate.
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Verdyl acetate is tricyclic compound with a structure similar to fenchyl acetate (Chap-
ter 4.2.1) but possesses an additional 5-membered ring which introduces additional
steric bulk. CYP101B1 showed metabolite formation in vitro with this substrate, it
did not produce significant levels of the metabolite with the whole-cell turnovers. The
turnover with P450BM3-GVQ displayed product formation of a single major product (tR
= 9.8 min) alongside two other minor metabolites (Figure 92). The three metabolites
formed were oxidation products based on their MS spectra (Appendix C.8).
(a)
(b)
Figure 92: (a) Oxidation of verdyl acetate by P450BM3-GVQ. (b) GC-MS analysis of P450BM3-GVQ
turnover with verdyl acetate. Major metabolite formed was 6-hydroxy-verdyl acetate (tR = 9.8 min).
Minor metabolites with ∆m/z = +16 at tR = 9.75 and 9.85 min.
Extraction and purification of the major product with preparative HPLC from a large
scale turnover of the GVQ variant with verdyl acetate was successful. The product
was characterised via NMR (4 mg isolated yield, Appendix C32). The hydroxylation
site was identified from an additional high chemical shift signal (δH = 4.34 ppm) with
an integration of 1H (Figure 93a). This suggests that a CH2 group of the substrate
was oxidised. There are therefore only three potential oxidation sites (C6, C11, C12)
(Figure 92a).
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HMBC NMR analysis of the product showed a correlation between the two remaining
CH2 groups (Figure 93b). It is most likely that oxidation at the C6 site results in the
CH2 hydrogens at C11 correlating with the C12 carbon as seen in the HMBC spectrum
(Figure 93b). The oxidation at the C6 would be expected as the carbonyl of the ester
group would anchor the substrate within the active site and allow it to oxidise regions
remote from the acetate group.
(a)
(b)
Figure 93: (a) Expansion of the 1H NMR data for 6-hydroxy verdyl acetate showing the alkene and
C-H-O signals. (b) HMBC NMR data of the CH2 signals for 6-hydroxy verdyl acetate, whereby a
correlation can be seen between the CH2 hydrogen of the C11 and the C12 carbon.
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To further assess which of the CH2 groups was hydroxylated, the
1H NMR spectrum
of the initial verdyl acetate starting material was measured (Figure 94a) and the CH2
groups were identified via 1H - 13C HSQC analysis (Figure 94b).
(a)
(b)
Figure 94: (a) Expansion of the 1H NMR data of verdyl acetate that shows the CH2 groups (C6, C11,
C12). (b) 1H - 13C HSQC NMR data showing the CH2 groups of verdyl acetate. Blue cross-peaks are
the CH2 groups. Note there is a contamination in the supplied sample which complicates the analyses.
The allylic CH2 signals for the substrate were identified at δH = 2.58 ppm and 1.91 ppm
and equivalent signals were not present within the 1H NMR spectrum of the hydroxy
product (Figure 93a). The other two CH2 signals were at similar chemical shifts. This




The screening of a selection of fragrance compounds with the enzymes CYP101B1
and the GVQ variant of P450BM3 generated a number of metabolites in good yield.
These enzymes have all shown the ability to selectively oxidise fragrance and flavouring
compounds.61,62,79,101 In particular, CYP101B1 can oxidise norisoprenoids selectively
and it is unsurprising that this enzyme has oxidation activity and binding affinity with
norisoprenoid derivatives such as α-damascone, δ-damascone, dynascone and α-iso-
methylionone (Table 13). The GVQ variant was able to oxidise cuminyl acetate, which
CYP101B1 showed no oxidation activity for.
CYP101B1 exhibited contrasting oxidation activity with α-iso-methylionone and dy-
nascone. α-iso-Methylionone gave higher product formation in vitro compared to the
dynascone turnovers. This is likely caused by the higher degree of structural similarity
between α-iso-methylionone and α-ionone, whereby the ring substituents are identical
between the two but the butenone group has been replaced with a longer pentenone
in α-iso-methylionone. Dynasone showed lower product formation and induced lower
spin-state shifts with CYP101B1 likely because its structure was more dissimilar to
the ionones by possessing a pentenone side chain with a terminal alkene and lacks an
additional ring methyl group.
Ethyl safranate, dihydroflorate and verdyl acetate were among the formate/acetate
ester functionalised compounds tested that had moderate to fast NADH oxidation by
CYP101B1, though only ethyl safranate exhibited high coupling efficiency and therefore
product formation. Ethyl safranate possesses a similar pattern of ring substituents to
the ionones but has an additional ring alkene. Its formate ester side chain could mimic
the butenone group of the norisoprenoids. These two factors are likely to contribute
to its increased activity and greater spin-state shift. The other formate ester tested,
dihydroflorate, had poor coupling efficiency despite its fast NADH oxidation rate with
CYP101B1. This is most likely due to competing uncoupling pathways. Uncoupling
events occur when the electron or proton transfer step occurs too slowly in the P450
catalytic cycle (Chapter 1.2, Figure 1).13
P450BM3-GVQ displayed moderate product formation rates and coupling efficiencies
with cuminyl and verdyl acetate. The whole-cell turnovers of these two substrates
with this mutant variant generated product in good yield that would indicate that the
oxidation of these substrates was feasible. When compared to the P450BM3 variant,
CYP101B1 had a higher coupling efficiency with its in vitro turnover of verdyl acetate
but showed no product formation in the whole-cell turnover. Cuminyl acetate also
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displayed no product formation with CYP101B1. This inferred that mere functionali-
sation of aromatic compounds with a butenone mimicking group is not a viable method
to increase the affinity of these compounds to CYP101B1. There are likely additional
secondary interactions between the norisoprenoid ring structure and the CYP101B1
active site that play a role in substrate binding. The greater flexibility of the ionone
ring and its smaller size when compared to cuminyl and verdyl acetate respectively
may be important for its binding to CYP101B1.
The oxidation of α-damascone by CYP101B1 was regioselective for the C3 position
forming the cis and trans-hydroxy metabolites and the further oxidation keto product.
This product distribution was similar to that of α-ionone oxidation by CYP101B1.
A similar trend in the product distribution was also observed with the oxidation of
β-ionone and β-damascone by the same enzyme.61 The formation of a keto product is
indicative of further oxidation of the hydroxy metabolite and was also present in the
reaction with α-ionone. It is believed that further oxidation occurs when the amount
of initial substrate is limited compared to the hydroxylated products.61
The preference for the C3 position despite the changing positions of the ketone and
alkene moiety on the butenone side chain suggests their positions has little control
on the regioselectivity of CYP101B1. In contrast, the oxidation of β-damascone by
CYP260B1 from Sorangium cellulosum was exclusively at the C4 site but the regiose-
lectivity was altered slightly with β-ionone, where the C5/C6 alkene underwent epoxi-
dation alongside C4 hydroxylation. This suggests other P450 enzymes are affected by
the positions of the alkene and ketone on the butenone side chain.160 Crystal structure
data of the CYP101B1 enzyme with substrate bound could confirm these hypotheses.
The major diastereomer formed by the oxidation of α-ionone by CYP101B1 was the
trans isomer,61 while α-damascone oxidation by this enzyme favoured the cis isomer
instead (Figure 86b). Free-energy related calculations on the stereoselective hydroxy-
lation of α-ionone with P450BM3 mutants were carried out by Beer and co-workers to
determine the thermodynamic stability of products bound to the enzyme upon oxida-
tion.170 It was found that trans-isomers have the most favourable binding free energies
and thus the more favoured isomer. The formation of the cis-isomer by CYP101B1
when oxidising α-damascone was nearly 3-fold higher than the trans isomer. The chang-
ing diastereomer preference between α-ionone and α-damascone oxidation by CYP101
enzymes suggests the positions of the butenone substituents have an effect on the di-
astereoselectivity of the enzyme. This may arise from the enzyme having a different
preference for the enantiomers of each substrate.
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Preliminary studies of CYP101B1 mutants, H85F and H85G with α-damascone showed
a change in diastereoselectivity from the WT-enzyme by preferentially forming the
trans-isomer instead, suggesting changing the H85 residue alters the diastereoselectivity
(Figure 95).
Figure 95: GC-MS analysis of whole-cell turnovers of CYP101B1 mutants with α-damascone.
Turnovers include WT-CYP101B1 (black), H85F (pink) and H85G (blue). Metabolites produced
include cis-3-hydroxy-α-damascone (tR = 9.3 min), trans-3-hydroxy-α-damascone (tR = 9.4 min),
and 3-oxo-α-damascone (tR = 9.80 min).
The position of the alkene within the norisoprenoid ring plays an important role in
determining the type of oxidation reaction carried out by CYP101B1. α-Damascone
with its ring alkene at the C4/C5 position formed products that arose exclusively from
allylic C3 hydroxylation activity and also small quantities of the C3 keto-product.
Biotransformation of α-damascone using bacterial strains of Botrytis cinerea formed
the same products as CYP101B1, though a slew of other oxy-metabolites were also
generated.169
δ-Damascone underwent epoxidation at its C3/C4 alkene and has been previously
oxidised by CYP260B1 and CYP267B1 from S. cellulosum to form 2-hydroxy-δ-
damascone.160 The δ-damascone epoxide formed is therefore unique to CYP101B1.
This epoxide would be an ideal intermediate for further chemical or enzymatic ring-
opening chemistry that could lead to new flavouring and fragrance compounds with
unique sensory properties. For example, epoxidation of the sesquiterpene, ledene and
subsequent ring-opening gave ledene derivatives that include an ether, an enol and
a diol.171 These epoxide derived compounds have woody and floral scents.171 Noriso-
prenoids that have been hydroxylated at the C3 position have also exhibited allelo-
pathic properties that have garnered interest for possible antifungal and antimicrobial
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applications.172
Cuminyl and verdyl acetate are both fragrance compounds with woody and floral
notes.173 There does not appear to be any previous biotransformation studies carried
out with either of these substrates. The C-H bonds that were oxidised with cuminyl
acetate and verdyl acetate were benzylic and allylic C-H bonds respectively.
Cuminyl acetate also displayed the formation of a desaturated product. This is consis-
tent with the oxidation of the tertiary C-H bond within the isopropyl group of cuminyl
acetate, whereby an alkene has likely formed on the isopropyl group instead.174 The
GVQ variant produced the major hydroxy metabolite in high yield indicating it was a
viable enzyme for this biocatalytic reaction. This variant possesses mutations that are
designed to introduce more space and hydrophobicity to the active site of P450BM3.
The first step of the desaturation reaction catalysed by P450s is identical to the hy-
droxylation reaction, whereby hydrogen abstraction first occurs to give the carbon
radical.174 Instead of proceeding with a radical rebound for hydroxylation, desatura-
tion can occur either by (a) transfer of electron from the carbon radical to the iron
centre of Cpd I to generate a carbocation and immediate transfer of a proton from said
carbocation to the ferryl oxygen or (b) an additional hydrogen abstraction reaction at
the carbon radical site to generate the desaturated product (Figure 96).174,175
Figure 96: Two possible pathways of how the desaturation reaction can be catalysed by P450s.
The amount of hydroxy product formed was more than 2-fold higher than the desat-
urated product in the whole-cell turnover of P450BM3-GVQ (Figure 89). DFT and
QM/MM studies have found that the desaturation pathway has a higher energy bar-
rier that allows the hydroxylation reaction to proceed more favourably.175 The P450BM3
variant tested here may provide a suitable foundation for further mutagenesis studies to
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design P450 enzymes that will favour desaturation reactions and it has been suggested
that mutations introduced to the binding pocket could alter the binding orientation to
suppress the radical rebound pathway, which leads to hydroxylation.175 It is also pos-
sible that the desaturation product could arise from the elimination of water without
the involvement of the P450 enzyme.
The P450 catalysed oxidation reactions of the fragrance compounds screened were
largely regioselective and different types of reactions were observed including hydrox-
ylations, epoxidations and desaturations. A number of the products identified were
also new and expands the “toolbox” towards forming oxidised fragrance compounds
with new sensory properties. The engineering of CYP101B1, has not been explored
in detail, yet the mutation of a single residue has revealed changes in the diastere-
oselectivity of α-damascone oxidation. The CYP101B1 mutants may provide useful
diastereoselective biocatalytic pathways. The ability to form the desired stereoisomer
of a fragrance compound would be useful commercially as a way to tailor perfume for-
mulations with specific olfactory properties.125 Further studies of these P450 enzymes
would be needed to broaden the substrate range and enhance the activity and selectiv-
ity of these enzymes. In addition, future work could also involve establishing whether
the desaturation products were formed solely by P450 activity.
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6 Conclusions and Future Directions
CYP101B1 shows high affinity and oxidation activity for norisoprenoids such as β- and
α-ionone but was poor in oxidising hydrophobic substrates. Site-saturation mutage-
nesis of the CYP101B1 H85 residue was carried out to increase its affinity towards
hydrophobic substrates. A total of eleven mutants were made and cloned into pET22
and pRSFDUET vectors for in vitro and in vivo studies, respectively. Studies were
carried out with a selection of substrates that include norisoprenoids, terpenoids and
hydrophobic substrates of varying sizes. Whole-cell screening with the CYP101B1
mutants showed altered product selectivity or exhibited small increases in product for-
mation with the substrates tested. The oxidation of hydrophobic substrates by any
of the new variants were not significantly improved over the WT enzyme or the pre-
viously characterised H85F variant. In vitro studies of the H85A and H85G mutants
found that it had lower binding affinity and oxidation activity with phenylcyclohexane
when compared to the WT enzyme. A range of spin-state shifts measured for biphenyl
and naphthalene derivatives for these two variants were consistently lower than 50 %
HS. This is indicative of poor substrate to active site complementarity. It is evident
that simply changing this histidine residue does not significantly increase the affinity
of CYP101B1 towards larger hydrophobic substrates. New mutagenesis approaches
could be undertaken with CYP101B1 by altering other active site residues to increase
its activity towards non-natural substrates, such as residues Q234 and I237. However,
key information regarding how the active site residues interacts with the bound sub-
strate would be useful in rationally designing mutants for biocatalysis. As such, crystal
structure data of CYP101B1 could be crucial for further mutagenesis studies with this
enzyme.
Rationally designed mutants of P450cam developed for terpene oxidation were screened
whole-cell for selective oxidation with fenchone, fenchyl acetate, isophorone, 1,8- and
1,4-cineole. Fenchone and fenchyl acetate oxidation by WT-P450cam and two of its
mutants generated hydroxylated products at the C5, C6 and C7 position, with a pref-
erence for exo hydroxylation. This suggests the carbonyl and acetate within fenchone
and fenchyl acetate anchored these two substrates in the active site to favour oxi-
dation on the C5-C6-C7 face. Isophorone was selectively oxidised by mutants WFL
(F87W-Y96F-V247L) and WFAL (F87W-Y96F-L244A-V247L) to form two products.
The products identified were 4-hydroxyisophorone, as the major metabolite, and 7-
hydroxyisophorone as the minor. The C4 position was the preferred hydroxylation site
(> 90 %) and the (R)-enantiomer was predominantly formed by the P450cam mutants
(99 % e.e). 4-Hydroxyisophorone has considerable commercial value as a flavouring
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agent and selective biocatalytic processes to produce this compound would be highly
desirable.
A number of the P450cam mutants screened altered the regioselectivity of 1,8- and
1,4-cineole oxidations. The oxidation of 1,8-cineole by WT-P450cam formed 6-α-, 5-
α- and 5-β-hydroxy-1,8-cineole. Two P450cam mutants altered the selectivity to form
either the 5-α- (WFAL) and 6-α- (VFA) hydroxy products in significant excess (> 90
%). 1,4-Cineole oxidation by WT-P450cam unselectively formed 8-hydroxy- and 3α-
hydroxy-1,4-cineole in low yield. The 3α-hydroxy product was selectively formed by
mutants WFA and WFAL (> 90 %). The 8-hydroxy metabolite was preferentially
produced with mutant LF (F87L-Y96F, > 85 %). This metabolite was accompanied
by the formation of higher amounts of a desaturated product, whereby the alkene
is likely located between the C8 and C9 positions of the isopropyl group. This was
consistent with hydroxylation occurring on the same isopropyl group. The oxidation
of both cineoles by the P450cam mutants was also enantioselective when this could be
assessed. The screening of a small library of P450cam variants has therefore allowed
for an impressive range of selective oxidations at different C-H bonds with the two
cineoles. This could enable the production of specific cineole hydroxy metabolites that
could serve as chiral auxiliaries. This library of enzymes would be a good starting point
to develop mutants for other unique C-H bond hydroxylations.
Mutants of P450BM3 have also been identified that exhibit selective oxidation towards
isophorone and the two cineoles. Whole-cell oxidation of these three substrates were
carried out comparing both P450cam and P450BM3 enzyme systems to determine how
the product formation for both systems varied. Isophorone oxidation gave higher prod-
uct formation with the P450cam systems. However, the P450BM3 systems gave higher
metabolite yields for the cineole oxidations. Despite the poorer yield of the P450cam mu-
tants with cineole oxidations, the WT-P450cam whole-cell system converted a majority
of the 1,8-cineole added into product. These comparative experiments demonstrated
that these P450 whole-cell systems are capable of oxidising the three substrates in
higher yield. Scale-up of these systems could be carried out using fermentor systems
with higher cell yields and better control of oxygen, pH and substrate levels to generate
metabolites on a kilogram scale and may be the first step to using these P450 mutants
to produce useful hydroxy-metabolites in good yield.
A selection of fragrance compounds with different molecular architectures were screened
with CYP101B1 and a P450BM3 mutant, GVQ (A74G-F87V-L188Q). Norisoprenoid
compounds such as δ-damascone, α-damascone and α-iso-methylionone and an acetate
ester, ethyl safranate, induced high spin-state shifts with CYP101B1. The product
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formation rates for these four substrates with CYP101B1 were also the fastest and
the damascones gave the highest coupling efficiency and levels of product formation.
P450BM3-GVQ showed product formation with cuminyl acetate and verdyl acetate with
moderate product formation and coupling efficiency.
The oxidation of α-damascone by CYP101B1 occurred exclusively at the C3 position to
produce diastereomeric metabolites similar to α-ionone oxidation by the same enzyme.
This implied that the butenone carbonyl and alkene positions do not influence the re-
gioselectivity of oxidation. The conserved regioselectivity of CYP101B1 for ionones and
damascones, even when the butenone side chain is altered is an interesting insight to
how this enzyme interacts with different norisoprenoids. WT CYP101B1 preferentially
forms the cis diastereomer when oxidising α-damascone. Preliminary studies with the
mutants of CYP101B1 have shown that the H85F and H85G variants preferentially
formed the trans isomer rather than the cis. In principle, mutagenesis could be used to
control the diastereoselectivity of CYP101B1 oxidation. δ-Damascone was epoxidised
by CYP101B1 at the C3-C4 position which was in agreement with the regioselectivity
of this enzyme with α-damascone and β-damascone. This epoxide is a potential in-
termediate for ring-opening reactions to generate new norisoprenoid derivatives. The
mutant variant of P450BM3, GVQ, showed selective oxidations with both cuminyl and
verdyl acetate. The oxidation of these two substrates occurred at C-H bonds remote
from the acetate group. The oxidation of cuminyl acetate by P450BM3-GVQ produced
a desaturated metabolite that agreed with the hydroxylation of the isopropyl group
within this substrate. Desaturated metabolites were also formed from 1,4-cineole oxi-
dation by P450cam and P450BM3 mutants. The mutants tested here provide a suitable
starting point for future mutagenesis studies to generate new P450 variants to catalyse
and investigate these desaturation reactions.
Overall, the results of this work show that different P450s can be used to generate
selective oxidations with a range of substrates. The mutagenesis approach was not suc-
cessful in increasing the affinity of hydrophobic substrates towards CYP101B1, though
the H85F mutant did appear to change the diastereoselectivity of the enzyme when
oxidising α-damascone. A number of P450cam and P450BM3 mutants were also able to
oxidise terpenoid compounds not only with higher yield but also with good selectivity
towards different C-H bonds on the substrates tested. Desaturation reactions were also
observed with the mutants studied. These results could facilitate larger scale biocat-
alytic processes to produce specific metabolites. Future work could involve using the
enzymes to develop more selective oxidations using further mutagenesis approaches.
Additional optimisation of the whole-cell systems could also be carried out to further
scale-up the biocatalytic reactions studied here.
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Appendix A Data for Chapter 3
In Vitro Assays of CYP101B1 Mutants
(a) 1,8-Cineole (b) cis-Jasmone
(c) Fenchyl Acetate (d) Isobornyl Acetate
(e) (R)-nopol.
Figure A1: Spin-State Shift Studies of H85G-CYP101B1 with various terpenoids and norisoprenoids.
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(a) Cyclodecane. (b) Cyclododecane
Figure A2: Spin-State shift studies of H85G-CYP101B1 with cycloalkanes.
(a) Naphthalene. (b) 1-Methylnaphthalene.
(c) 2-Methylnaphthalene. (d) 1,2-Diethylnaphthalene.
(e) 3,6-Dimethylnaphthalene.
Figure A3: Spin-State Shift Studies of H85A-CYP101B1 with Napthalene Variants.
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(a) 3-phenyltoluene (b) 4-phenyltoluene
Figure A4: Spin-State Shift Studies of H85A-CYP101B1 with Toluene Variants.
(a) Naphthalene.
(b) 1-Methylnaphthalene.
(c) 1,5-Dimethylnaphthalene. (d) Sclareolide
(e) Valencene
Figure A5: Spin-State Shift Studies of H85G-CYP101B1 with various hydrophobic substrates.
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Appendix B Data for Chapter 4
Cell Biomass and P450 Concentrations.
Table B1: The concentration of P450 enzyme and cell wet weight (cell biomass) for enzymes used in
the whole-cell oidation of terpenoids. Cell biomass is given as given as mean ± S.D. with n = 2.
Enzyme P450 Concentration (nM) Cell Biomass (g/L)
P450BM3-WT 183 16± 0.3
P450BM3-GVQ 88 13± 0.3
P450BM3-RLYFFAIP 108 14± 0.3
P450BM3-RLYGVQ 86 14± 0.4
P450cam-WT 25 13± 0.3
P450cam-WFAL 54 13± 0.6
P450cam-WFL 15 17± 2
P450cam-VFL 10 17± 3
P450cam-LF 98 14± 0.4
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NMR Analysis of Fenchyl Acetate Oxidation Products
5-exo-hydroxyfenchyl acetate 1H NMR (500 MHz, CDCl3) δ 4.32 (d, J = 1.8 Hz,
1H, exo H2), 4.18 (d, J = 6.7 Hz, 1H, endo H5), 2.25 (ddd, J = 13.8, 6.7, 2.5 Hz, 1H,
endo H6), 2.06 (s, 3H, H12), 1.73 (s, 1H, H4), 1.62 (dd, J = 10.8, 1.5 Hz, 1H, H7a),
1.48 (d, J = 10.8 Hz, 1H, H7b), 1.14 (s, 3H, H9), 1.07 (s, 3H, H10), 1.00 (ddd, J =
13.8, 2.9, 1.6 Hz, 1H, exo H6), 0.76 (s, 3H, H8). 13C NMR (126 MHz, CDCl3) δ 171.4
(C11), 84.6 (C2), 71.3 (C5), 55.9 (C4), 47.6 (C3), 39.6 (C6), 39.0 (C1), 37.0 (C7), 29.7
(C9), 20.9 (C12), 19.3 (C8), 18.8 (C10).
(a)
(b)
Figure B1: 1H NMR (a) and 13C NMR (b) spectrum spectrum of 5-exo-hydroxyfenchyl acetate. Data
matched previously reported literature.101
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Table B2: Comparison of Experimental NMR data of 5-exo-hydroxyfenchyl acetate to the litera-
ture.101














(7S)-hydroxyfenchyl acetate 1H NMR (500 MHz, CDCl3) δ 4.39 (d, J = 1.2 Hz,
1H, H2), 3.86 (s, 1H, H7), 2.08 (s, 3H, H12), 1.87 – 1.57 (m, 4H, H4/H5/H6), 1.27 (m,
1H, H6), 1.12 (s, 3H, H9), 0.99 (s, 3H, H10), 0.80 (s, 3H, H8). 13C NMR (126 MHz,
CDCl3) δ 171.4 (C11), 83.7 (C2), 78.3 (C7), 53.2 (C4), 50.8 (C1), 37.2 (C3), 29.5 (C9),
23.5 (C6), 22.1 (C5), 20.8 (C12), 19.6 (C8), 16.1 (C10).
(a)
(b)




Figure B3: (a)1H-1H COSY and (b) 1H-13C HSQC NMR data for (7S )-hydroxyfenchyl acetate.
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Figure B4: 1H-13C HMBC for (7S )-hydroxyfenchyl acetate.
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Mass Spectra Analysis of Fenchyl Acetate Oxidation Products
(a) Mass spectra of 5-exo-hydroxyfenchyl acetate with m/z = 212.1 and tR = 6.55 min.
(b) Mass spectra of (7S )-hydroxyfenchyl acetate with m/z = 212.1 and tR = 6.72 min.
(c) Mass spectra of 5-exo-/6-exohydroxyfenchyl acetate with m/z = 212.1 and tR = 6.55 min.
Figure B5: Mass spectra of oxidation products of fenchyl acetate by P450cam-Y96A and WT-P450cam.
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NMR Analysis of Fenchone Oxidation Products
5-exo-hydroxyfenchone 1H NMR (500 MHz, CDCl3) δ 4.38 (d, J = 6.4 Hz, 1H,
endo-H5), 2.14 (s, 1H, H4), 2.07 (dd, J = 10.9, 1.9 Hz, 1H, H7b), 1.89 (ddd, J = 14.2,
6.5, 2.3 Hz, 1H, exo-H6), 1.74 (d, J = 10.8 Hz, 1H, H7a), 1.46 (d, J = 14.1 Hz, 1H,
endo-H6), 1.15 (s, 3H, H10), 1.06 (s, 3H, H8/H9), 1.03 (s, 3H, H8/H9). 13C NMR (126
MHz, CDCl3) δ 222.0 (C2), 70.7 (C5), 53.6 (C1), 53.2 (C4), 45.3 (C3), 43.2 (C6), 37.5
(C7), 23.7 (C8/C9), 21.3 (C8/C9), 14.2 (C10).
(a)
(b)
Figure B6: (a) 1H and (b) 13C NMR spectrum of 5-exo-hydroxyfenchone. Data matched previously
reported literature.101
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Figure B7: 1H NMR spectrum of the isolated mixture from the Y96F and (+)-Fenchone enzyme
turnover that contains 6-endo-, 6-exo- and (7S)-hydroxyfenchone.
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Table B3: Comparison of Experimental NMR data of 5-exo-hydroxyfenchone to the literature.101











Literature Data for Fenchone Oxidation Products
6-endo-hydroxyfenchone140 1H NMR (CDCl3) δ 1.10 (3H, s, H8), 1.12 (3H, s ,H9),
1.16 (3H, s, H10), 1.62 (1H, dd, J = 1.7, 11.0 Hz, H7b), 1.74 (1H, ddd, J = 2.6, 3.7,
13.8, endo-H5), 1.85 (1H, ddd, J = 1.7 , 2.6 , 11.0, H7a), 2.10 - 2.12 (1H, m, H4), 2.15
(1H, ddd, J = 4.3, 9.6, 13.8 Hz, exo-H5), 4.09 (1H, ddd, J = 1.7, 3.7, 9.6 Hz,exo-H6.)
EI-MS, m/z (rel. intensity): 168 [M]+ (2), 153 [M-CH3]
+ (1), 140 (1), 124 (8), 109 (4),
107 (5), 97 (9), 88 (35), 81 (100), 69 (21), 55 (7), 53 (6), 43 (6), 41 (19).
6-exo-hydroxyfenchone140 1H NMR (CDCl3) δ 0.96 (3H, s, H9), 1.06 (3H, s, H8),
1.14 (3H, s, H10), 1.55 (1H, ddd, J = 3.5, 4.5, 13.8 Hz, exo-H5), 1.76 (1H, dddd, J =
1.2, 1.5, 2.9 , 10.9 Hz, H7a), 1.90 (1H, dd, J = 1.7, 10.9 Hz, H7b), 2.18 - 2.20 (1H, m,
H4), 2.40 (1H, ddd, J = 2.9, 6.9, 13.8 Hz), endo-H5), 3.62 (1H, ddd, J = 1.5, 3.5, 6.9
Hz, emdo-H6).
EI-MS, m/z (rel. intensity): 168 [M]+ (18), 153 [M-CH3]
+ (3), 140 (3), 124 (41), 109
(16), 107 (11), 97 (55), 96 (35), 88 (34), 81 (100), 70 (37), 69 (30), 55 (12), 53 (10), 43
(12), 41 (33).
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Mass Spectra Analysis of Fenchone Oxidation Products
(a) Mass spectra of 5-exo-hydroxyfenchone with m/z = 168.05 and tR = 8.85 min.
(b) Mass spectra of 6-endo-hydroxyfenchone with m/z = 168.05 and tR = 8.53 min.
(c) Mass spectra of 6-exo-hydroxyfenchone with m/z = 168.05 and tR = 8.69 min.
(d) Mass spectra of (7S )-hydroxyfenchone with m/z = 168.05 and tR = 8.95 min.
Figure B8: Mass spectra of oxidation products of fenchone by P450cam-Y96F. Data for 5-exo-, 6-endo-,
6-exo-hydroxyfenchone is in good agreement with what was previously reported in the literature.101,140
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NMR Analysis of Isophorone Oxidation Products
4-hydroxyisophorone 1H NMR (500 MHz, CDCl3) δ 5.86 (s, 1H, H2), 4.03 (s, 1H,
H4), 2.41 (d, J = 16.3 Hz, 1H, H6), 2.21 (d, J = 16.3 Hz, 1H, H6), 2.06 (s, 3H, H7),
1.07 (s, 3H, H8/H9), 1.02 (s, 3H, H8/H9). 13C NMR (126 MHz, CDCl3) δ 202.12 (C1),
164.61 (C3), 128.64 (C2), 79.28 (C4), 51.62 (C6), 41.17 (C5), 29.57 (C8/C9), 24.24
(C8/C9), 24.01 (C7). [α]D
20 = +113.2 (c= 1.00, MeOH)
(a)
(b)




Figure B10: (a)1H-1H COSY and (b) 1H-13C HSQC NMR data for 4-hydroxyisophorone.
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Figure B11: 1H-13C HMBC for 4-hydroxyisophorone.
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7-hydroxyisophorone 1H NMR (500 MHz, CDCl3) δ 6.15 (s, 1H, H2), 4.22 (s, 2H,
H7), 2.27 (s, 3H, H6), 2.14 (s, 2H, H4), 1.05 (s, 6H, H8/H9). 13C NMR (126 MHz,
CDCl3) δ 200.09 (C1), 162.22 (C3), 122.11 (C2), 65.03 (C7), 51.56 (C6), 40.26 (C4),
33.66 (C5), 28.23 (C8/C9).
(a)
(b)




Figure B13: (a)1H-1H COSY and (b) 1H-13C HSQC NMR data for 7-hydroxyisophorone.
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Figure B14: 1H-13C HMBC for 7-hydroxyisophorone.
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Mass Spectra Analysis of Isophorone Oxidation Products
(a) Mass spectra of 4-hydroxyisophorone with m/z = 154.05 with tR = 9.15 min.
(b) Mass spectra of 7-hydroxyisophorone with m/z = 154.05 with tR = 10.6 min.
Figure B15: Mass spectra of (a) 4-hydroxyisophorone and (b) 7-hydroxyisophorone.
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Mass Spectra Analysis of 1,8-Cineole Oxidation Products
(a) Mass spectra of 6α-hydroxy-1,8-cineole with m/z = 170.05 and tR = 7.7 min.
(b) Mass spectra of 5-α-hydroxy-1,8-cineole with m/z = 170.05 and tR = 8.5 min.
(c) Mass spectra of 5-β-hydroxy-1,8-cineole with m/z = 168.05 and tR = 8.2 min.
(d) Mass spectra of 6-β-hydroxy-1,8-cineole with m/z = 170.15 and tR = 7.5 min.
Figure B16: Mass spectra of (a) 6-α-hydroxy-1,8-cineole, (b) 5-α-hydroxy-1,8-cineole and (c) 5-β-
hydroxy-1,8-cineole and (d) 6-β-hydroxy-1,8-cineole
142
Literature Data for 1,4-Cineole Oxidation Products
8-hydroxy-1,4-cineole145 1H NMR (CDCl3, 400 MHz) δ 1.25 (s, 6H, CH3, H9 and
H10), 1.43 (s, 3H, CH3, H7).
13C NMR (CDCl3, 100 MHz) δ 21.1, 25.3 (2 Ö CH3),
31.9 (2 Ö CH2), 37.5 (2 Ö CH2), 71.6, 83.9, 91.7. GC-MS (m/z ): 170 (M+, 7), 155
(4), 137 (7), 112 (13), 111 (39), 110 (18), 109 (12), 97 (10), 95 (9), 93 (15), 85 (13), 83
(8), 79 (9), 69 (17), 67 (12), 59 (100), 55 (19), 43 (96).
2-β-hydroxy-1,4-cineole145 1H NMR (CDCl3, 400 MHz) δ 0.94 and 0.95 (2 Ö d, J
= 6.9 Hz, 2 Ö 3H, CH3, H9 and H10), 1.40 (s, 3H, CH3, H7), 2.04 (m, 2H), 3.73 (t,
J = 7.5 Hz, 1H). 13C NMR (CDCl3, 100 MHz) δ 16.4, 18.18, 18.21, 32.60, 32.63, 32.9,
45.2, 76.9, 85.6, 88.8. GC-MS (m/z ): 170 (M+, 4), 153 (4), 137 (2), 127 (6), 125 (9),
112 (17), 109 (10), 97 (13), 95 (10), 86 (10), 83 (19), 71 (23), 43 (100).
3-β-hydroxy-1,4-cineole145 1H NMR (CDCl3, 400 MHz) δ 0.91 and 1.00 (2 Ö dd, J
= 6.9 and 0.7 Hz, 2 Ö 3H, H9 and H10), 1.45 (s, 3H, CH3, H7), 1.70 (td, J = 12.2 and
3.4 Hz, 1H), 2.18 (dd, J = 13.3 and 6.9 Hz, 1H), 2.36 (septet, J = 6.9 Hz, 1H), 3.89
(ddd, J = 9.3, 6.8 and 2.0 Hz, 1H). GC-MS (m/z ): 170 (M+, 7), 155 (1), 139 (1), 137
(3), 127 (8), 125 (6), 111 (8), 109 (8), 86 (54), 84 (43), 71 (58), 43 (100).
3-α-hydroxy-1,4-cineole147 1H NMR (CDCl3, 500 MHz) δ 0.98 and 0.99 (2 Ö d, J
= 6.9 Hz, 2 Ö 3H, CH3, H9 and H10), 1.34 (s, 3H, CH3, H7), 1.38 (dd, J = 12.5 and
3.1 Hz, 1H, H2), 1.46 – 1.59 (m, 3H, OH, 2 Ö 1H, H5 and H6), 1.75 (m, 1H, H6), 1.98
– 2.06 (m, 2H, H8 and H2), 2.25 (ddd, J = 11.8, 9.4 and 4.3 Hz, 1H, H5), 4.17 (dddd,
J = 9.6, 4.6, 3.1 and 1.6 Hz, 1H, H3). 13C NMR (CDCl3, 125 MHz) δ 17.9, 18.3, 21.7,
25.3, 32.3, 37.3, 47.9, 74.9, 83.0, 90.4. GC-MS (m/z ): 170 (M+, 8), 137 (2), 128 (1),
127 (8), 125 (9), 111 (9), 109 (7), 97 (6), 95 (4), 87 (22), 86 (55), 71 (55), 43 (100).
9-hydroxy-1,4-cineole145 1H NMR (CDCl3, 400 MHz) δ 0.83 (d, J = 7.0 Hz, 3H,
CH3, H10), 1.43 (s, 3H, 3H, CH3, H7), 3.48 (dd, J = 11.2 and 4.2 Hz, 1H), 3.70 (dd,
J = 11.1 and 9.6 Hz, 1H). GC-MS (m/z ): 170 (M+, 14), 155 (1), 141 (11), 139 (12),
137 (3), 123 (13), 111 (38), 97 (10), 95 (18), 93 (17), 91 (7), 87 (35), 83 (15), 81 (13),
79 (19), 69 (29), 67 (28), 55 (52), 43 (100).
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Mass Spectra Analysis of 1,4-Cineole Oxidation Products
(a) Mass spectra of 8-hydroxy-1,4-cineole with m/z = 170.05 and tR = 6.0 min.
(b) Mass spectra of 2-β-hydroxy-1,4-cineole with m/z = 170.05 and tR = 7.15 min.
(c) Mass spectra of 3-β-hydroxy-1,4-cineole with m/z = 170.05 and tR = 6.85 min.
(d) Mass spectra of 2-α-hydroxy-1,4-cineole with m/z = 170.05 and tR = 7.65 min.
(e) Mass spectra of 3-α-hydroxy-1,4-cineole with m/z = 170.05 and tR = 7.3 min.
(f) Mass spectra of 9-hydroxy-1,4-cineole with m/z = 170.05 and tR = 8.25 min.
(g) Mass spectra of Desaturation Product A with m/z = 152.05 and tR = 4.15 min.
Figure B17: Mass spectra of (a) 8-hydroxy-1,4-cineole, (b) 2β-hydroxy-1,4-cineole and (c) 3β-hydroxy-
1,4-cineole, (d) 2α-hydroxy-1,4-cineole, (e) 3α-hydroxy-1,4-cineole, (f) 9-hydroxy-1,4-cineole and (g)
Desaturation product A.
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(a) Mass spectra of unknown 1,4-cineole further oxidation product (#) with m/z = 168.15
and tR = 7.49 min.
(b) Mass spectra of unknown 1,4-cineole oxidation product ($) and m/z = 170.15 with tR =
7.23 min.
Figure B18: Mass spectra of unknown oxidation products of 1,4-cineole by P450cam and P450BM3
mutants.
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Appendix C Data for Chapter 5
C.1 Mass Spectra Analysis: Dihydroflorate
(a) Mass spectra of dihydroflorate isomer, D1, with m/z = 184.2 and tR = 5.60 min)
(b) Mass spectra of dihydroflorate isomer, D2 with m/z = 184.2 and tR = 5.95 min)
(c) Mass spectra of dihydroflorate isomer, D3 with m/z = 184.1 and tR = 6.23 min)
Figure C1: Mass spectra of dihydroflorate isomers.
(a) Mass spectrum of dihydroflorate oxidation product with m/z = 200 and tR = 7.75 min.
(b) Mass spectrum of dihydroflorate oxidation product with m/z = 200.1 and tR = 7.85 min.
(c) Mass spectrum of dihydroflorate oxidation product with m/z = 199.9 and tR = 8.08 min.
Figure C2: Mass spectra of dihydroflorate oxidation products.
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C.2 Mass Spectra Analysis: Ethyl Safranate
(a) Mass spectrum of ethyl safranate isomer, E1 with m/z = 194.15 and tR = 5.60 min.
(b) Mass spectrum of ethyl safranate isomer, E2 with m/z = 194.15 and tR = 5.95 min.
(c) Mass spectrum of ethyl safranate isomer, E3 with m/z = 194.15 and tR = 6.23 min.
Figure C3: Mass spectra of ethyl safranate isomers.
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Mass Spectra Analysis: Ethyl Safranate (continued)
(a) Mass spectrum of ethyl safranate oxidation product with m/z = 210.3, tR = 7.7 min.
(b) Mass spectrum of ethyl safranate oxidation product with m/z = 210.15, tR = 7.8 min.
(c) Mass spectrum of ethyl safranate oxidation product with m/z = 210.15, tR = 8.1 min.
(d) Mass spectrum of ethyl safranate oxidation product with m/z = 210.15, tR = 8.15 min.
(e) Mass spectrum of ethyl safranate oxidation product with m/z = 210.2, tR = 8.22 min.
(f) Mass spectrum of ethyl safranate oxidation product with m/z = 210.15, tR = 8.43 min.
Figure C4: Mass spectra of ethyl safranate oxidation products.
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C.3 Mass Spectra Analysis: δ-Damascone
Figure C5: Mass Spectrum of δ-damascone with m/z = 192.15, tR= 7.34 min.
(a) Mass spectra of δ-damascone oxidation product formed in vivo and in vitro with m/z =
208.3, tR= 8.9 min.
(b) Mass spectra of δ-damascone oxidation product formed in vivo and in vitro with m/z =
208.3, tR= 9.0 min.
(c) Mass spectra of δ-damascone oxidation product formed in vitro with m/z = 208.3, tR=
9.14 min. This product was not observed in the whole-cell turnover.
(d) Mass spectra of δ-damascone oxidation product formed both in vivo and in vitro with
m/z = 208.15, tR= 9.4 min. Product is identified as 3,4-epoxy-δ-damascone.
Figure C6: Mass spectra of δ-damascone oxidation products.
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C.4 Mass Spectra Analysis: α-Damascone
Figure C7: Mass Spectrum of α-damascone with m/z = 192, tR= 7.51 min.
(a) Mass spectra of α-damascone oxidation product with m/z = 207.9, tR = 9.0 min. This
product was only observed in the in vitro turnover.
(b) Mass spectra of α-damascone oxidation product with m/z = 208, tR = 9.25 min. This
product was only observed in the in vitro turnover.
(c) Mass spectra of α-damascone oxidation product with m/z = 208.05, tR = 9.3 min. Prod-
uct was identified as cis-3-hydroxy-α-damascone.
(d) Mass spectra of α-damascone oxidation product with m/z = 208.05, tR = 9.4 min.
Product was identified as trans-3-hydroxy-α-damascone.
(e) Mass spectra of α-damascone oxidation product with m/z = 206.1, tR = 9.8 min. Product
was identified as 3-oxo-α-damascone.
Figure C8: Mass spectra of α-damascone oxidation products.
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C.5 Mass Spectra Analysis: α-iso-methylionone
(a) Mass spectra of α-iso-methylionone isomer 1 with m/z =206.25, tR= 8.40 min.
(b) Mass spectra of α-iso-methylionone isomer 2 with m/z =206.15, tR= 8.77 min.
Figure C9: Mass spectra of α-iso-methylionone isomers.
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Mass Spectra Analysis: α-iso-methylionone (continued)
(a) Mass spectra of α-iso-methylionone oxidation product with m/z = 221.9, tR = 10.13 min.
(b) Mass spectra of α-iso-methylionone oxidation product with m/z = 222.3, tR = 10.3 min.
(c) Mass spectra of α-iso-methylionone oxidation product with m/z = 220, tR = 10.4 min.
(d) Mass spectra of α-iso-methylionone oxidation product with m/z = 220, tR = 10.5 min.
(e) Mass spectra of α-iso-methylionone oxidation product with m/z = 219.9, tR = 10.6 min.
(f) Mass spectra of α-iso-methylionone oxidation product with m/z = 220.1, tR = 10.65 min.
Figure C10: Mass spectra of α-iso-methylionone oxidation products.
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C.6 Mass Spectra Analysis: Dynascone
(a) Mass spectra of dynascone isomer 1 with m/z = 192.1, tR = 7.9 min.
(b) Mass spectra of dynascone isomer 1 with m/z = 192.15, tR = 8.23 min.
Figure C11: Mass spectra of dynascone isomers.
(a) Mass spectra of dynascone oxidation product with m/z = 208.2, tR = 9.82 min.
(b) Mass spectra of dynascone oxidation product with m/z = 208.2, tR = 9.88 min.
(c) Mass spectra of dynascone oxidation product with m/z = 208, tR = 10.1 min.
Figure C12: Mass spectra of dynascone oxidation products.
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C.7 Mass Spectra Analysis: Cuminyl Acetate
Figure C13: Mass Spectrum of cuminyl acetate with m/z = 192.1 and tR= 7.81 min.
(a) Mass spectra of cuminyl acetate desaturation product with m/z = 190.05, tR = 8.48 min.
(b) Mass spectra of cuminyl acetate oxidation product with m/z = 208.1, tR = 9.3 min.
Product identified as 4-(2-hydroxypropan-2-yl)benzyl acetate.
Figure C14: Mass spectra of cuminyl cetate turnover products.
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C.8 Mass Spectra Analysis: Verdyl Acetate
Figure C15: Mass Spectrum of verdyl acetate with m/z = 192.15 and tR= 7.84 min.
In Vivo Products
(a) Mass Spectrum of in vitro verdyl acetate oxidation product with with m/z = 208.1 and
tR = 9.75 formed with P450BM3-GVQ.
(b) Mass Spectrum of verdyl acetate in vitro oxidation product with m/z = 208.1 and tR =
9.8 min formed with P450BM3-GVQ. Product was identified as 6-hydroxy-verdyl acetate.
(c) Mass Spectrum of verdyl acetate oxidation product with m/z = 208.1, tR = 9.82 min
formed with P450BM3-GVQ.
Figure C16: Mass Spectrum of verdyl acetate oxidation products formed in vivo with P450BM3-GVQ.
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NMR Analysis
4-(2-hydroxypropan-2-yl)benzyl acetate 1H NMR (500 MHz, CDCl3) δ 7.49 (d,
J = 8.2 Hz, 1H, H6), 7.34 (d, J = 8.1 Hz, 1H, H5), 5.10 (s, 1H, H3), 2.10 (s, 1H, H1),
1.58 (s, 6H, H9). 13C NMR (126 MHz, CDCl3) δ 170.93 (C2), 149.28 (C7), 134.31
(C4), 128.27 (C7), 124.67 (C6), 72.46 (C8), 66.06 (C3), 31.77 (C9), 21.04 (C1).
(a)
(b)





Figure C18: (a)1H-1H COSY and (b) 1H-13C HSQC NMR data for 4-(2-hydroxypropan-2-yl)benzyl
acetate.
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Figure C19: 1H-13C HMBC for 4-(2-hydroxypropan-2-yl)benzyl acetate.
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3,4-epoxy-δ-damascone 1H NMR (500 MHz, CDCl3) δ 6.83 (dq, J = 13.8, 6.9 Hz,
1H, H9), 6.20 (dd, J = 15.5, 1.6 Hz, 1H, H8), 3.21 – 3.18 (m, 1H, H3), 2.88 (d, J =
4.0 Hz, 1H, H4), 2.48 (dq, J = 11.6, 7.2 Hz, 1H, H5), 2.20 (d, J = 11.5 Hz, 1H, H6),
1.93 (dd, J = 15.2, 1.3 Hz, 1H, H2), 1.90 (dd, J = 6.9, 1.6 Hz, 3H, H10), 1.59 (d, J
= 1.6 Hz, 1H, H2), 0.98 (s, 3H, H11/H12), 0.96 (d, J = 7.2 Hz, 3H, H13), 0.86 (s,
3H, H11/H12). 13C NMR (126 MHz, CDCl3) δ 203.0 (C7), 142.1 (C9), 134.0 (C8),
60.2 (C6), 56.6 (C4), 53.2 (C3), 39.9 (C2), 33.4 (C1), 32.1 (C11/C12), 29.3 (C5), 23.4
(C11/C12), 19.0 (C13), 18.3 (C10).
(a)
(b)




Figure C21: (a)1H-1H COSY and (b) 1H-13C HSQC NMR data for 3,4-epoxy-δ-damascone.
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Figure C22: 1H-13C HMBC for 3,4-epoxy-δ-damascone.
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cis-3-hydroxy-α-damascone 1H NMR (500 MHz, CDCl3) δ 6.91 (dq, J = 13.8, 6.9
Hz, 1H, H9), 6.32 (dd, J = 15.5, 1.4 Hz, 1H, H8), 5.69 (s, 1H, H4), 4.20 (s, 1H, H3),
2.94 (s, 1H, H6), 1.92 (dd, J = 6.8, 1.4 Hz, 3H, H10), 1.66 (d, 1H, H2), 1.65 (d, 1H,
H2), 1.60 (s, 3H, H13), 0.98 (s, 3H, H12), 0.89 (s, 3H, H11). 13C NMR (126 MHz,
CDCl3) δ 201.2 (C7), 143.3 (C9), 133.5 (C5), 132.4 (C8), 127.6 (C4), 66.2 (C3), 60.8
(C6), 40.9 (C2), 34.9 (C1), 28.6 (C11), 28.3 (C12), 23.0 (C13), 18.3 (C10).
(a)
(b)




Figure C24: (a)1H-1H COSY and (b) 1H-13C HSQC NMR data for cis-3-hydroxy-α-damascone.
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Figure C25: 1H-13C HMBC for cis-3-hydroxy-α-damascone.
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trans-3-hydroxy-α-damascone 1H NMR (500 MHz, CDCl3) δ 6.89 (dq, J = 13.8,
6.9 Hz, 1H, H9), 6.23 (dd, J = 15.5, 1.6 Hz, 1H, H8), 5.90 – 5.60 (m, 1H, H4), 4.34 (s,
1H, H3), 3.13 (s, 1H, H6), 1.95 (dd, J = 13.6, 5.9 Hz, 1H, H2), 1.91 (dd, J = 6.9, 1.6
Hz, 2H, H10), 1.63 (s, 2H, H13), 1.42 (d, J = 5.4 Hz, 1H, H2), 1.39 (d, J = 5.4 Hz, 1H,
H2), 1.13 (s, 3H, H11), 0.88 (s, 3H, H12). 13C NMR (126 MHz, CDCl3) δ 200.43 (C7),
142.83 (C9), 134.21 (C5), 132.64 (C8), 126.69 (C4), 65.49 (C3), 61.04 (C6), 43.63 (C2),
33.33 (C1), 30.54 (C11), 25.87 (C12), 22.73 (C13), 18.28 (C10).
(a)
(b)




Figure C27: (a)1H-1H COSY and (b) 1H-13C HSQC NMR data for trans-3-hydroxy-α-damascone.
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Figure C28: 1H-13C HMBC for trans-3-hydroxy-α-damascone.
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3-oxo-α-damascone 1H NMR (500 MHz, CDCl3) δ 6.99 (dq, J = 13.8, 6.9 Hz, 1H,
H9), 6.30 (dd, J = 15.5, 1.7 Hz, 1H, H8), 6.01 (s, 1H, H4), 3.37 (s, 1H, H6), 2.68 (d,
J = 16.6 Hz, 1H, H2), 2.03 (d, J = 16.6 Hz, 1H, H2), 1.96 (dd, J = 6.9, 1.7 Hz, 3H,
H10), 1.86 (d, J = 1.0 Hz, 3H, H13), 1.09 (s, 3H, H11/H12), 1.00 (s, 3H, H11/H12).
13C NMR (126 MHz, CDCl3) δ 199.17 (C3), 197.73 (C7), 156.07 (C5), 144.89 (C9),
132.35 (C8), 127.62 (C4), 61.77 (C6), 47.02 (C2), 36.66 (C1), 29.17 (C11/C12), 27.56
(C11/C12), 23.97 (C13), 18.46 (C10).
(a)
(b)




Figure C30: (a)1H-1H COSY and (b) 1H-13C HSQC NMR data for 3-oxo-α-damascone.
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Figure C31: 1H-13C HMBC for 3-oxo-α-damascone.
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6-hydroxy-verdyl acetate 1H NMR (500 MHz, CDCl3) δ 5.84 (d, J = 5.5 Hz, 1H),
5.74 (d, J = 5.4 Hz, 1H), 4.66 (d, J = 6.7 Hz, 1H), 4.34 (d, J = 3.8 Hz, 1H), 2.75 (d,
J = 6.5 Hz, 1H), 2.25 (d, J = 3.9 Hz, 1H), 2.12 (s, 1H), 2.01 (s, 3H), 1.82 (d, J = 6.7
Hz, 1H), 1.77 (ddd, J = 13.5, 7.0, 2.1 Hz, 1H), 1.46 (s, 1H), 1.31 (d, J = 10.5 Hz, 1H),
1.03 (d, J = 10.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 170.84 (C2), 136.07 (C8),
135.17 (C7), 82.69 (C6), 77.18 (C3), 54.34 (C10), 50.29 (C4), 43.97 (C9), 39.41 (C5),
38.73 (C11), 29.11 (C12), 21.35 (C1).
(a)
(b)




Figure C33: (a)1H-1H COSY and (b) 1H-13C HSQC NMR data for 6-hydroxy-verdyl acetate.
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Figure C34: 1H-13C HMBC for 6-hydroxy-verdyl acetate.
Table C2: HMBC correlation data for 6-hydroxy verdyl acetate.
Position δC (ppm) δH (ppm) HMBC Correlation Positions
11 38.73 (CH2) 1.77 (ddd), 1.46 (m) 12, 10, 4
12 29.11 (CH2) 1.31 (d), 1.03 (d) 11, 10
10 54.34 (CH) 1.81 (d) 9, 11, 12
9 43.94 (CH) 2.12 (s) 5, 10
5 39.41 (CH) 2.25 (d) 9
4 50.29 (CH) 2.75 (d) 11
1 21.35 (CH3 2.01 (s) 2
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